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Summary 
Summary 
Measles is an extremely contagious vaccine-preventable disease responsible 
for more than 90000 deaths worldwide annually. The number of deaths has 
declined from 8 million in the pre-vaccination era to few thousands every year due 
to the highly efficacious vaccine. However, this effective vaccine is still unreachable 
in many developing countries due to lack of infrastructure, while in developed 
countries too many people refuse vaccination. Specific antiviral compounds are not 
yet available. In the current situation, only an extensive vaccination approach 
along with effective antivirals could help to have a measles-free future. To develop 
an effective antiviral, detailed knowledge of viral-host interaction is required.  
This study was undertaken to understand the interaction between MV and 
the innate host restriction factor APOBEC3G (A3G), which is well-known for its 
activity against human immunodeficiency virus (HIV). Restriction of MV 
replication was not attributed to the cytidine deaminase function of A3G, instead, 
we identified a novel role of A3G in regulating cellular gene functions. Among two 
of the A3G regulated host factors, we found that REDD1 reduced MV replication, 
whereas, KDELR2 hampered MV haemagglutinin (H) surface transport thereby 
affecting viral release. REDD1, a negative regulator of mTORC1 signalling 
impaired MV replication by inhibiting mTORC1. A3G regulated REDD1 
expression was demonstrated to inversely correlate with MV replication. siRNA 
mediated silencing of A3G in primary human blood lymphocytes (PBL) reduced 
REDD1 levels and simultaneously increased MV titres. Also, direct depletion of 
REDD1 improved MV replication in PBL, indicating its role in A3G mediated 
restriction of MV. Based on these finding, a new role of rapamycin, a 
pharmacological inhibitor of mTORC1, was uncovered in successfully diminishing 
MV replication in Vero as well as in human PBL. The ER and Golgi resident 
receptor KDELR2 indirectly affected MV by competing with MV-H for cellular 
chaperones. Due to the sequestering of chaperones by KDELR2, they can no longer 
assist in MV-H folding and subsequent surface expression. Taken together, the two 
A3G-regulated host factors REDD1 and KDELR2 are mainly responsible for 
mediating its antiviral activity against MV. 
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Zusammenfassung 
Masern ist eine extrem ansteckende, durch Impfung verhinderbare 
Infektionskrankheit, die für mehr als 90000 Todesfälle jährlich weltweit 
verantwortlich ist. Die Zahl der Todesfälle nahm von ca. 8 Millionen in der Prä-
Impf-Ära auf wenige Tausend pro Jahr aufgrund dieses effizienten Impfstoffs ab. 
Dieser ist jedoch aufgrund mangelnder Infrastruktur in vielen 
Entwicklungsländern nicht ausreichend verfügbar, oder die Impfung wird – vor 
allem in entwickelten Ländern – verweigert. Spezifische antivirale Substanzen 
sind noch nicht verfügbar. So könnte nur eine extensive Impfkampagne zu einer 
Masern-freien Zukunft führen. Um antivirale Substanzen zu generieren wird 
detailiertes Wissen über Virus-Wirt-Interaktionen benötigt. 
Diese Studie wurde unternommen um Interaktionen zwischen Masernviren 
(MV) und dem zellulären Restriktionsfaktor APOBEC3G (A3G), der allgemein 
bekannt für seine antivirale Wirkung gegen das humane Immundefizienzvirus 
(HIV) ist, zu charakterisieren. A3G hemmt die MV-Replikation nicht aufgrund 
seiner Cytidin-Desaminase-Funktion, sondern wir entdeckten eine neue Funktion 
des A3G, nämlich dass es die Expression zellulärer Faktoren reguliert. Wir fanden, 
dass unter den A3G-regulierten Wirtszellfaktoren REDD1 die MV-Replikation 
reduzierte, während KDELR2 den Transport des MV-Hämagglutinins (H) zur 
Zelloberfläche, und somit die Virusfreisetzung, inhibierte. REDD1, ein negativer 
Regulator des mTORC1-Signalübertragungswegs, reduzierte die MV-Replikation 
indem es mTORC1 inhibiert. Die Expression des durch A3G regulierten REDD1 
korrelierte umgekehrt mit der MV Replikation. SiRNA-vermittelte Reduktion des 
A3G in primären humanen Lymphozyten des Bluts (PBL) führte zu einer 
Abnahme des REDD1 und gleichzeitig zu einer Zunahme des MV-Titers. Ebenso 
führte direktes Silencing des REDD1 zu einer verstärkten MV-Replikation in PBL, 
was seine Rolle bei der A3G-vermittelten Restriktion der MV-Replikation 
unterstreicht. Aufgrund dieser Befunde wurde auch eine neue Funktion des 
mTORC1-Inhibitors Rapamycin als Inhibitor der MV-Replikation in Vero-Zellen 
und primären PBL aufgedeckt. Der ER- und Golgi-residente Rezeptor KDELR2 
wirkte sich indirekt auf die MV-Replikation aus, indem er mit dem MV-H um die 
Interaktion mit Chaperonen kompetiert. KDELR2 bindet Chaperone und 
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verhindert so deren Interaktion mit MV-H und den Transport zur Zelloberfläche. 
Zusammenfassend lässt sich sagen, dass die beiden A3G-regulierten 
Wirtszellfaktoren REDD1 und KDELR2 hauptsächlich für die antivirale Aktivität 
des A3G gegen MV verantwortlich sind. 
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1. Introduction 
1.1. Measles virus 
More than 100 million viruses are estimated to colonize planet earth and 
significantly shaping past, present and future of evolution of life. Out of this 
colossal numbers, 320000 different viruses infect mammals [1]. Adolf Mayer 
pioneered the research on viruses in 1882 followed by Martinus Beijerinck who 
conceived the term ‘Virus’ in 1898. Baltimore classification categorized these 
viruses in seven different groups which was further developed by ICTV 
(International Committee on Taxonomy of Viruses).  
The family of Paramyxoviridae comprises some unique and classical viruses 
such as measles virus (MV). Paramyxoviruses are known not only for their 
extensive disease burden on animal husbandry such as NDV (Newcastle disease 
Virus) but also for the recently identified deadly viruses such as Nipah and 
Hendra. MV is a highly infectious virus and assumed to have evolved from 
rinderpest virus (RPV) during early livestock farming and diverged around 11th 
century [2]. Antigenically and genetically it is closely related to RPV, a causative 
agent of a devastating cattle plague. Phylogenetic analysis of MV shows a genetic 
link to animal viruses such as RPV, peste des petits ruminants virus (PPRV), 
canine distemper virus (CDV) (Figure 1.1). 
=
Figure 1.1. Genetic relationship between MV and other morbilliviruses (source [3]).  
Measles virus phylogenetic tree based on N protein sequence.  
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Historic evidence dated back in the 9th century by Abu Becr who gave a 
scientific description of measles-like symptoms whereas, the earliest repeated 
epidemics were reported in the 11th and 12th centuries. In 1757, Scottish physician 
Francis Home shown that measles disease is caused by an infectious agent. It took 
around 200 years for isolation of MV in tissue culture. In 1954 Enders and Peebles 
isolated MV from the blood of  David Edmonston, whereas, the measles-associated 
complications such as encephalomyelitis was described in 1790 by James Lucas 
and subacute sclerosing pan encephalitis (SSPE) by Dawson in 1933 [4]. 
MV cause acute infection resulting in a cough, fever, Kolpik’s spots inside 
the mouth and flat skin rash. In 30% of cases complications such as diarrhoea, 
pneumonia and encephalitis appear. Although an effective vaccine is available, MV 
is still accountable as a major cause of child mortality and morbidity.  
 
1.1.1. Taxonomy  
Various morphological features define viruses in a subfamily of 
Paramyxovirinae such as an enveloped virus with negative stranded non-
segmented RNA genome. The term ‘myxovirus’ implies an affinity for mucin and 
originally denoted to a large group of enveloped viruses that are able to attach to 
glycoprotein cell surface receptors.  A detailed classification of MV is summarized 
in Table 1.1. The name Measles is derived from a word masel (Middle Dutch) or 
maselen (middle low German), which means blisters or sick skin spots.  
=
=
=
=
=
=
=
=
=
=
Table 1.1: ICTV taxonomic classification of Measles virus 
Domain Virus 
Group Group V (-) ssRNA 
Order Mononegavirales 
Family Paramyxoviridae 
Subfamily Paramyxovirinae 
Genus Morbillivirus 
Species Measles morbillivirus 
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1.1.2. Morphology 
MV is a pleomorphic virus of 100-900 nm in size (Figure 1.2). The viral 
genome is a negative ss RNA of 16 kb, encoding eight viral proteins. The outermost 
lipid envelope is derived from the plasma membrane of the host cell. The viral 
genome is encapsidated by ribonucleoprotein (RNP) complex consisting of 
Nucleoprotein (N), phosphoprotein (P) and large protein (L) [5]. Two viral non-
structural proteins V and C are expressed from P genes by RNA editing and 
alternative translational initiation respectively [6]. The viral RNP is packaged into 
a lipid envelope. Matrix protein (M) lines the interior of the envelope, whereas, the 
viral transmembrane glycoproteins hemagglutinin (H) and fusion (F) line the 
exterior of the envelope [7]. 
=
Figure 1.2. Schematic representation of MV virion (source: adapted from [8]). 
=
1.1.3. Genome and Viral proteins 
MV negative-stranded RNA genome length is 15,894 bp. Viral RNA is 
enclosed in nucleoprotein forming helical RNPs (ribonucleoprotein) to which 
Phosphoprotein (P protein) and Large polymerase proteins (L protein) are 
attached. The MV genome encodes for eight proteins (Figure 1.3 and Table 1.2) 
Conserved gene-end and gene-start transcriptional control sequences are located 
at both ends of each gene. The entire sequence is flanked with 52 nt non-coding 3’ 
leader region and 37 nt non-coding trailer region which are essential for viral 
transcription and replication [9]. 
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Figure 1.3. Genomic organization of MV (adapted from [10])  
(UTR: untranslated regions, PNT: P protein N-terminal, PCT: P protein C-terminal) 
=
=
=
=
=
=
=
=
=
=
=
Out of eight viral proteins, only six are part of the virion. The RNP is the 
template for transcription and replication. N protein is the first to be transcribed 
from the genome and a central player in replication of MV. The N-terminal domain 
of 400 amino acids forms a core region (NCORE) which is important for self-assembly 
and RNA binding. It also contains a nuclear localization signal which is important 
for inhibition of IFN-a/b and g signalling [11]. The C-terminal domain (NTAIL) of 
100 amino acids is intrinsically disordered and binds to M and P protein [12]. Apart 
from its interaction with viral proteins, NTAIL interacts with various cellular 
proteins.  It is also required for flexibility of viral nucleic acid [13].  
The second gene transcribed from the genome encodes for the P protein. The 
P protein upon phosphorylation acts as a co-factor to form a replicase complex by 
linking L protein to N protein. A less conserved N-terminal domain (PNT) plays an 
important role in replication by preventing binding on N0 to cellular RNAs and 
nuclear translocation. Whereas, the C terminal domain (PCT) is crucial for 
transcription as it helps for binding of polymerase L to its template [14].  
Table 1.2: MV genome encoded transcripts and viral proteins (adapted from [9]) 
Nucleotide number mRNA Proteins 
1-52 Leader - 
56-1744 N Nucleocapsid 
1748–3402 P/V/C Phosphoprotein/ V and C protein 
3406–4872 M Matrix protein 
4876–7247 F Fusion glycoprotein 
7251–9208 H Hemagglutinin glycoprotein 
9212–15,854 L Large protein 
15,858–15,894 Trailer - 
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Two more non-structural proteins V and C are transcribed from the P gene 
which is not detected in fully mature virion released from the cell [15]. The C 
protein affects interferon signalling and prevents cell death by regulation of viral 
RNA synthesis [16]. V and C are not required for MV replication in Vero cells, but 
it has been shown that the C protein is crucial for in vivo pathogenesis of measles 
[17][18].  
Matrix (M) protein is the third protein translated. This hydrophobic protein 
lines the inner leaflet of the viral envelope thus playing a central role in viral 
assembly and pathogenesis [19]. Interaction of M protein with a cytoplasmic region 
of H and F glycoproteins regulates the fusogenic capacity of F protein and viral 
release from infected cells [20]. It also interacts with N protein to regulate viral 
RNA production [21]. Mutations in the M protein enhance cell to cell fusion and 
contribute to the establishment of persistent infection [22].  
The next two genes encode for hemagglutinin (H) and fusion (F) protein 
(Figure 1.4). Together with M protein, they form the viral fusion machinery. These 
highly conserved proteins are embedded in the viral envelope and bind to cellular 
receptors, and thus are responsible for MV infectivity.  
The F protein is a type I transmembrane glycoprotein. It is glycosylated and 
oligomerized in Endoplasmic Reticulum (ER). F protein is synthesized as 60 kDa 
inactive precursor (F0) which is cleaved by cellular furin in trans-Golgi network. 
The cleavage results in fusion competent mature F protein trimer composed of 
three monomers linked by disulphide bonds [6].==
 
Figure 1.4. Schematic representation of MV glycoproteins.  
CT: cytoplasmic tail; TM: Trans-membrane domain; FP: Fusion peptide; HRA: Heptad repeat A; HRB: Heptad 
repeat B (adapted from [23]). 
 
H is a tetrameric type II transmembrane glycoprotein expressed on mature 
virions and the infected cell surface. The attachment protein H of MV is different 
than other Paramyxoviruses as it does not have neuraminidase activity. Instead of 
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sialic acid H uses CD46, SLAM and Nectin-4 as cellular receptors to determine the 
cellular tropism [24][25][26][27][28]. Upon binding to cellular receptors 
conformational changes are triggered in H and F proteins. The so-called fusion 
peptide of the F protein is inserted into the target cell membrane and fusion pore 
complex is formed which results in viral entry, or cell to cell fusion [29].  Similar 
to F protein, H is glycosylated and is oligomerized in the ER and crucial for particle 
assembly [30]. These glycoproteins are transported to the plasma membrane by 
cellular secretory pathway and expressed on the infected cell surface for particle 
assembly or cell to cell fusion [31]. 
The last gene encodes for a Large protein (L), a highly conserved 250 kDa 
viral protein which is present in small amounts in infected cells and in virions.  
Along with P protein L acts as RNA-dependent RNA polymerase (RdRp) and viral 
RNA is the template for transcription and replication [4][32]. L proteins carry out 
all essential functions of RNA synthesis such as polymerization, mRNA binding, 
polyadenylation and methylation [33]. 
 
1.1.4. Cellular Receptors 
Binding of viral antigens to cellular receptors is a prerequisite for initiating 
infection in cells, thus, governing susceptibility of cells to a virus. As mentioned 
above, binding of H on cellular receptors triggers conformational changes in F and 
this facilitates pH-independent fusion of the viral envelope with the cellular 
plasma membrane.  
Over the period of last 30 years, various groups identified three main 
cellular receptors for MV. CD46 was the first MV receptor identified in 1993 [24] 
followed by identification of SLAM/CD150 in 2000 [26] and recently Nectin-4 has 
been identified as an epithelial cell receptor [27][34]. All three important receptors 
are shown in Figure 1.5. 
CD46 (Cluster of differentiation-46) or MCP (membrane cofactor protein) 
was the first receptor identified for Edmonston vaccine and lab adapted MV 
strains. It is an inhibitory complement regulatory receptor and expressed on all 
nucleated cells to protect from damage by complement system [35]. A tyrosine and 
glycine at position 481 and 546 determine the affinity of H to CD46 [36]. Although 
identified first, CD46 is less relevant pathologically since no wild-type MV uses 
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this receptor as efficiently as vaccine strains [9]. Clinical isolates of MV  have been 
shown to prefer SLAM as a cellular receptor [37]thus, indicating that CD46 usage 
as a receptor reflects in vitro adaptation of  MV rather than it’s in vivo ability.  
 
=
=
Figure 1.5. Structure of cellular surface receptors for MV (Source: adapted from [38]) 
(A) CD46 a type I glycoprotein with four SCRs (short consensus repeats), STP domain (Serine-Threonine-Proline), 
a transmembrane domain and a cytoplasmic domain. (B) CD150/SLAM (signalling lymphocyte-activation molecule) 
a membrane glycoprotein with a variable Ig-like V-type domain (V) and a constant Ig-like C-type domain (C2) 
domain, transmembrane domain and cytoplasmic domain with tyrosine phosphorylation site (C) Nectin-4/PVRL-4 
(Polio virus receptor-like protein-4) is member of nectin family and contain one Ig-like V-type domain and two 
constant Ig-like C-type domain (C2) domain. 
 
A second receptor, CD150 (Cluster of differentiation-150) or SLAM 
(signalling lymphocyte-activation molecule) is expressed on immune cells such as 
activated T and B-cells, thymocytes, macrophages and mature Dendritic cells. The 
distribution of SLAM on immune cells supports lymphotrophism of MV. Wildtype 
MV as well as Edmonston strains, use SLAM as a receptor but with fivefold higher 
affinity to SLAM than CD46 [39] [40] [41]. All MV strains ever reported have been 
shown to use SLAM as a receptor with exception of recombinant SLAM-blind 
viruses.  It is also reported that three residues (Isoleucine 60, Histidine 61 and 
Valine 63) are critical for SLAM to function as a cellular receptor for MV [42]. 
However, the absence of SLAM on epithelial and neuronal cells indicated a 
requirement of another important ‘receptor X’ for MV entry.  
In 2011 this ‘receptor X’ was identified to be Nectin-4/PVRL-4 (Polio virus 
receptor-like protein-4)  [27][34] thus solved the mystery of MV infection of a 
respiratory epithelial cell. Nectin-4 is a 55 kDa transmembrane protein belonging 
to immunoglobulin superfamily [43]. Nectin-4 is expressed the basolateral side of 
(A) (B) (C) 
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primary airway epithelial cells and many carcinoma cell lines. This receptor is 
responsible for mediating infection in respiratory epithelial cells and followed by 
subsequent amplification of MV and release from apical surfaces of epithelial cells 
[44].  
However, identification of these receptors does not explain the ability of MV 
to infect neuronal and endothelial cells [45][46] indicating possible use of another 
unknown receptor by MV. 
 
1.1.5. Viral replication 
Viral replication is a biological process in which the virus enters the host 
cell and forms progeny virus. It is an indispensable step for viruses to establish 
infection and continuation of infection in the new host. Viruses are dependent on 
host cells for energy and cellular machinery to synthesize progeny virus, and 
therefore, can multiply only in living cells.  
Viruses of different families have different replication strategies and 
different intracellular locations to replicate. MV like other members of the 
Paramyxoviridae family replicate entirely in the cytoplasm. The life cycle of MV in 
a cell is depicted in Figure 1.6.  
=
Figure 1.6. Schematic representation of replication of Measles virus (Source: [47] © G.D. Parks and R.A. 
Lamb 2006)  
MV enters the cells by attachment of H on the cellular receptor and viral nucleic acid is released in the cytoplasm. 
(Solid line: transcription and replication; Dotted line: viral egress). The newly synthesised virus is assembled near 
the plasma membrane and then released by budding. (N: Nucleocapsid, P: Phosphoprotein, L: Large protein, F: 
Fusion protein, H: Hemagglutinin, ER: Endoplasmic Reticulum). 
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Tetrameric H proteins bind to the cellular receptors CD46, SLAM and 
nectin-4 and trigger conformational changes in H stalk carrying F triggering 
activity [48] [6][49]. Thus, initiating a series of spontaneous conformational 
changes in F protein eventually leading to insertion of the fusion peptide into the 
target membrane. Various models have been proposed to show F activation by H 
[6]. These structural rearrangements finally result in fusion pore formation via 
merging of viral and cell membranes. The viral nucleocapsid is then released into 
the cell cytoplasm for subsequent steps of viral replication.   
Viral RdRp uses the negative-stranded non-segmented viral RNA as a 
template for both transcription to generate mRNA and for replication to generate 
progeny RNA. Obligatory sequential transcription begins at the 3’ end and 
requires termination of each upstream gene to initiate transcription of the next 
downstream gene [50]. Thus, MV genes are transcribed sequentially. Each of six 
viral genes are flanked with 3’ short leader sequences and 5’ trailer sequences 
containing start and stop codons. Newly synthesized (+) mRNA is translated into 
viral proteins by cellular machinery. N protein is synthesized first and in highest 
amounts of the viral gene products and forms tight complexes with progeny RNA 
which serves as a functional template for subsequent viral transcription and 
replication [51][52].  
After translation, the H and F proteins undergo post-translational 
modifications and oligomerization in the ER using cellular chaperones. Impaired 
ER retention of H and F  has been shown to affect the cell to cell fusion ability of 
MV [30][31].  
Newly synthesised viral proteins, the viral genomic RNA, and cellular 
membrane assemble to form infectious progeny virions which exit host cells by 
budding in order to infect other susceptible cells. The matrix protein is crucial in 
MV assembly and the budding process [53][54]. The location of M proteins at the 
inner leaflet of the viral envelope allows a close interaction not only with the viral 
RNP complex but also with cytoplasmic tails of H and F glycoproteins. This 
interaction aggregates them at the plasma membrane for viral assembly and 
release [55][21]. The M protein interacts with the C-terminal domain of the N 
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protein. Two leucines at position L523 and L524 of the N protein are important 
for this interaction.  This interaction results in the retention of RNP at the plasma 
membrane and shifts the equilibrium from viral replication to virus assembly and 
release [21]. In addition, M proteins at inner leaflet regulate the fusogenic activity 
of the envelope proteins [56][57]. Taken together, the M protein orchestrates MV 
budding in an ESCRT (endosomal sorting complexes required for transport) 
independent manner [58].  
1.1.6. Measles virus Pathogenesis 
Although MV diverged relatively recently from a common ancestor with 
RPV [2], humans are the only natural host. Measles is a highly contagious disease 
with a secondary attack rate of more than 90% [59].  
1.1.6.1. Entry into a susceptible host 
MV enters a host by respiratory route via infectious droplets and aerosols.  
The primary site of virus replication was initially believed to be respiratory 
epithelial cells. However, recent evidence suggest that epithelial cells are infected 
from basolateral surface and not from apical surfaces [60], hence epithelial cells 
may get infected in later stages of infection. In non-human primate infection 
model, lung CD150+ immune cells such as alveolar macrophages and DCs are the 
first cells reported to be infected by MV followed by significant viral multiplication 
in BALT (bronchus-associated lymphoid tissue) [61]. These cells then transport 
MV to local lymphatic tissue and in draining lymph node. Subsequent analysis of 
MV-infected blood cells and lymphoid tissue have shown a massive replication of 
MV in CD150+ T and B cells [4][62][63]. Thus, measles is an acute viral infection 
resulting in the systemic spread of the virus in the host. 
Measles has an incubation period of 10-14 days. The prodromal phase of 2-
4 days is characterized by classical MV symptoms such as fever followed by 
running nose (coryza), cough and conjunctivitis.  Two to three days later blue-white 
spots on red background appear inside the mouth which are known as Koplik’s 
spots. Three to five days after onset of initial symptoms measles rash appears 
throughout the skin starting from hairline to face and neck (Figure 1.7B). Then 
proceed to arms, legs and feet in the next 3-4 days [64]. The appearance of 
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symptoms coincides with a viral spread in lymphatic tissue, CD4+ /CD8+ immune 
response and with cytokine production (Figure 1.7A).    
 
 
Figure 1.7. Measles virus Pathogenesis  
(A) MV enters from the respiratory tract and gradually spread to other organs. Rash appears when MV-specific CD4 
and CD8 T cells are activated and antibody response is triggered (adapted from [4]) (B) Classical MV rash. (source: 
CDC/ Heinz F. Eichenwald, MD). 
 
1.1.6.2. Viral dissemination and transmission 
Within 4-7 days the virus is detected in blood. Virus dissemination from the 
primary site of infection is shown in Figure 1.8.  The viremia is often associated 
with leukopenia due to significant infection in T and B cells or due to the migration 
of T and B cells out of the blood vessels into organs. MV replicates in primary, 
secondary and tertiary lymphoid tissues and forms multinucleated giant cells 
(syncytia) known as Warthin-Finkeldey cells [4]. Increased LFA-1 (Leucocyte 
function-associated antigen-1) in MV-infected monocytes and lymphocytes leads to 
enhanced adherence and virus dissemination to endothelial cells via cell to cell 
transmission of the virus [65] [66]. MV then spreads systemically via blood to other 
organs such as kidney, liver, gastrointestinal tract, respiratory tract, genital 
mucosa, conjunctiva and skin. 
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Figure 1.8. Measles virus dissemination cycle (Source: [67]) 
Epithelial cells of the respiratory tract are highly susceptible for MV 
infection. The virus is delivered to the basolateral side by infected myeloid cells 
[68]  and then is spread as well as released from the apical surface of the cell [34] 
in mucus lining of the respiratory tract. These cell-free particles are then released 
as infectious droplets by coughing.  
1.1.7. Immune response 
Current knowledge of the immune response to MV is progressively 
increasing with new aspects of viral-host protein interactions being uncovered. 
Measles is a typical childhood disease conferring lifelong immunity. Along with 
the acute infection, MV is known to cause severe immunosuppression and may 
lead to persistent infections.  
1.1.7.1. Innate immune response 
The primary defence against all viral infections is mediated by interferons 
(IFNs). These potent pro-inflammatory cytokines not only play an important role 
in inhibiting viral replication but also govern host immunity. IFN response is 
triggered by recognition of viral proteins by cell surface or cytoplasmic PPRs 
(pattern recognition receptors). Subsequent signalling eventually activates the 
transcription factors IRF-3 (IFN regulatory factor-3) and NFkB (nuclear factor 
kappa-light chain enhancer of activated B cells). NFkB regulates different aspects 
of the innate and adaptive immune response leading to the induction of various 
proinflammatory cytokines, interferons and ISGs (Interferon-stimulated genes) 
which can suppress MV replication [69].  
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TLR (toll-like receptor) 7 and 9 mediated IFNa/b production is aptly shut 
down by MV [70].  The V protein inhibits IFN production by blocking intracellular 
sensing molecules such as RIG-I (retinoic acid-inducible gene I) and MDA-5 
(melanoma differentiation associated gene 5) [71][72]. Several groups have 
reported inhibition of IFN and downstream JAK/STAT signalling pathway by P,C 
and V proteins [73][74][75][76] [77]. As a result, viral replication is not sufficiently 
suppressed by the innate immune response leading to the systemic spread of MV 
(reviewed in [78][79][80]). 
1.1.7.2. Cellular immune response  
Normally, acute MV infection is brief and the virus is cleared within months 
of onset of disease. Cellular immunity has been shown to be more critical in MV 
clearance than humoral immunity. Studies on immunodeficient or 
immunocompromised individuals have proven the importance of the cellular 
immune response. Individuals with deficient cellular immunity had prolonged 
infectious period and often died due to MV associated complications [81] [82] while 
children with agammaglobulinemia cleared the MV infection [83]. In-vivo, CD8+ T 
cell depleted Rhesus monkeys have shown uncontrolled viremia for a prolonged 
period, higher viral load and severe rash [84], whereas B cell depleted Rhesus 
monkeys cleared the virus effectively [85]. Similarly, in-vitro CD8+ T cells instead 
of CD4+ T cells controlled MV [86]. Fever and rash slowly resolve as CD8+ and 
CD4+ T cells infiltrate to infection sites. Follow-up studies on PBMC after recovery 
period have shown effective IFN-g production and CD8+ T cell memory response 
[87].  
Before the onset of the rash, effective early TH1 response is engaged leading 
to the production of IFN-g and IL-2, followed by increased IL-2, soluble CD4 and 
CD8 levels. During convalescence as rash fades, type II cytokines IL-4, IL-5, IL-10 
and IL-13 are produced in high levels [88][89].  
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1.1.7.3. Humoral immune response 
MV-specific neutralizing antibodies protect from the disease at the time of 
exposure, whereas antibody-mediated clearance of MV after the onset of disease 
has a minor role. Maternal antibodies have been shown to confer protection in 
infants [90]. Poor prognosis of MV has been shown to be associated with the 
absence of robust antibody response [91]. Therefore, the induction of neutralizing 
antibodies by vaccination certainly plays a significant role in the control of MV 
disease and spread.  
Along with the initial onset of rash antibodies are detected in blood. MV- 
specific IgM dominates the early phase of infection followed by class switching to 
low avidity IgG2 and IgG3 isotypes. As infection progress the avidity of IgGs 
increase gradually. These antibodies are then also detected in mucosal secretions 
[92].  Antibodies are detected for all viral proteins and anti-N antibodies are most 
prevalent [93]. Antibodies targeting viral envelop glycoprotein H and F result in 
neutralization of viral infectivity by preventing fusion of viral envelop and cell 
membrane [94] and downregulate intracellular viral replication[95][96].  
1.1.7.4. Immunosuppression 
Immunosuppressive effects of MV are known to increase the susceptibility 
to other diseases and result in deaths due to complications such as pneumonia and 
diarrhoea [97].Several mechanisms have defined MV-induced immunosuppression 
such as, 1) short-term lymphopenia: in which due to lymphotrophism of MV, the T 
and B cells are primarily infected and result in CD95 mediated apoptosis 
[98][99][100]. Spontaneous apoptosis of uninfected T cells also has been observed 
[101]. 2) diminished Akt phosphorylation upon MV contact shown to affect T cell 
activation during immunosuppression [102]. 3) Type-2 cytokine response: during 
acute measles impaired IL-12 production leads to TH2 response with increased IL-
4, IL-10 and IL-13 production, however, this TH2 cytokine dominance favours the 
establishment of humoral immunity during recovery [103][104].  
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1.1.7.5. ADME 
ADME (acute disseminated encephalomyelitis) is an inflammatory 
demyelinating condition affecting white matter of CNS [105], a frequent 
complication (in more than 0.1% cases after natural infection) of MV which develop 
within 2-4 weeks after infection without the presence of virus in the brain [106]. 
The precise mechanisms of ADME progression are still poorly understood. 
Structural homology of myelin proteins with foreign epitopes or CNS damage due 
to direct infection leaking autoantigens in systemic circulation have been thought 
to trigger autoimmunity [107]. 
1.1.7.6. Persistent infection 
MV virus often persists and slowly spreads from cell to cell without 
production of detectable amounts of infectious virus [108]. Some of the 
characteristic features of persistent infection include accumulation of 
nucleocapsids in the cytoplasm, decreased virus-induced cytopathic effect, limited 
expression of viral proteins on the infected cell surface and defects in viral proteins. 
Persistent MV infections of the CNS (central nervous system) can have early or 
late occurrence after acute onset of MV.  
The MIBE (measles inclusion body encephalitis) occurs 1-9 months after 
acute infection. The frequency of occurrence is rare.  MIBE is exclusively seen in 
immunocompromised individuals especially those with HIV and patients receiving 
immunosuppressive drugs [109][110]. It is characterized by giant inclusion bodies 
in neurons and glia [111]. Although the virus can be directly isolated from brain, 
MIBE differs from SSPE due to the absence of a strong humoral response. 
Subacute sclerosing panencephalitis (SSPE) is a fatally progressive 
neurological disorder which occurs within months to years after the initial onset of 
measles [112]. Children below the age of two with acute measles infection are at 
great risk of developing SSPE later in life [113] [114]. Grey and white matter are 
affected in SSPE and loss of cognitive functions, motor loss, seizures and eventual 
organ failure are seen in all affected patients (reviewed in [115]). Severe 
demyelination and wide spread infection of neurons is observed. Oligodendrocytes, 
astrocytes and endothelial cells are also infected [116]. Abnormally high titres of 
neutralizing antibodies in serum and CSF (cerebrospinal fluid) are observed in 
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SSPE patients [112]. Taken together, MV and its protein along with the host’s 
immune response contribute to MV persistence, though the exact role of each and 
underlying mechanisms yet remain to be elucidated [117]. 
 
1.1.8. Epidemiology 
1.1.8.1. Strain variation 
MV genomes have exceptional stability, a property that is shared among 
other members of Paramyxovirinae. A stable genome, absence of animal reservoir 
and absence of latency resulted in maintenance of MV only in susceptible human 
population. Till date, 8 clades and 24 distinct genotypes A, B1-B3, C1-C3, D1-D11, 
E, F, G1-G3 and H1-H2 of MV have been reported [118]. Association between MV 
and SSPE was found only with wild-type stains and not with vaccine strains [119]. 
Despite a number of genotypes MV has only one serotype which is marked by high 
genetic constrains on H, F, N and M protein. These constrains contributed to the 
absence of antigenic drift, one serotype and life-long immunity [10]. 
1.1.8.2. Vaccines 
Measles is a vaccine-preventable disease. Herd immunity through active 
vaccination reduces MV disease burden. Antibody-mediated neutralization of viral 
glycoprotein have been shown to be sufficient for passive protection against MV 
[94]. Adaptation by serial passaging of Edmonston strain in chick embryo and 
chick embryo cells resulted in Edmonston B strain, a first live attenuated vaccine 
strain [120]. Various efficacious and successful vaccine stains such as Zagreb, AIK-
C, CAM, Leningrad-16, Shanghai 191 were derived in subsequent years [4]. Two -
dose vaccination at the age of six months and 12 months has shown more than 95% 
protection during an outbreak [121]. 
The lyophilized vaccine is a stable vaccine at lower temperatures but lose 
potency rapidly within one day after reconstitution [122] thus, hamper availability 
of effective vaccine in undeveloped regions of the world. To improve the delivery 
method of current vaccine various vaccination strategies are being developed such 
as inhalation of aerosols or dry powder form [123][124].  
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1.1.8.3. Global disease burden 
Despite availability of an effective vaccine, MV remains a leading cause of 
mortality and morbidity in young children. In the pre-vaccine era, the outbreaks 
were frequent, and more than 90 % of the children acquired measles by age of 15. 
The absence of animal reservoir and latency results in maintenance of MV in the 
human population only when the stable supply of susceptible individuals is 
available. Due to high R0 ( basic reproduction number), a 95% level of herd 
immunity is required to discontinue measles transmission [125][4]. The 
introduction of mass vaccination in 1963 has reduced the incidence rate, however, 
it still remains a significant disease burden in children. In 2016, according to 
WHO 132,129 cases and 89780 deaths were reported worldwide[126] [127].==
MV due to its vaccine preventability was targeted for eradication by World 
health assembly in 2010 [125]. Although MV is eliminated from the North 
American continent, the remaining five regions yet have to achieve the 
eradication target. The current incidence rate of MV worldwide is shown in Figure 
1.9. More than 95% coverage of vaccination is still an unreached target in many 
parts of the world. In developing countries, poor infrastructure, lack of cold chain, 
financial burden and availability of trained medical personnel have hampered the 
coverage of vaccine [128].  
 
Figure 1.9. Current MV incidence rate worldwide (source WHO 2018)=
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In developed countries, despite the existing infrastructure and access to the 
vaccine, hesitancy about vaccination and exemption have led to serious and large 
outbreaks [129][130]. According to ECDC (European Centre for Disease 
Prevention and Control) in 2017 Europe itself has seen a fourfold increase in MV 
incidences [131]. Therefore, sustained efforts and adequate epidemiological 
surveillance to improve vaccine coverage are required to achieve the goal of global 
measles elimination. 
1.1.9. Treatment 
Measles was often reported to re-appear in developed countries when 
vaccination rates have declined [132]. Currently, there is no specific anti-viral 
treatment available for measles. An effective therapeutic approach along with 
broader vaccination coverage could help to promote measles eradication.  
Oral supplementation of a high dose of Vitamin A during measles has been 
observed with a decrease in mortality and morbidity. According to WHO, Vitamin 
A is recommended for all children with measles [133][134].  IFNa has been used 
as therapeutics in SSPE patients with partially beneficial and partially relapsing 
results [135][136]. Treatment with Ribavirin and/or IFNa have shown more 
promising results than the use of IFNa alone [137][138]. Thus, administration of 
antivirals after the initial onset of disease might reduce measles complications. 
Debated reports of MV antiviral efficacy, limitations of IFN and ribavirin and Ig 
therapies mark requirement of safe, novel and efficacious antiviral against MV 
[117].   
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1.2. Innate restriction factors 
Recognition of pathogens by several sensing mechanisms and the innate 
immune response act as the first line of defence.  PPRs (Pattern recognition 
receptors) mediate innate microbial sensing that detects PAMPs (Pathogen -
associated molecular patterns). PPRs such as RLRs (RIG-I like receptors), NLRs 
(NOD-like receptors) are cytoplasmic autonomous viral sensing molecules 
recognizing viral 5’ tri-phosphorylated ss RNA or regions of double-stranded RNA. 
Whereas TLRs (Toll like receptors) are PPRs that recognize extracellular, 
endosomal, or membrane-bound structures of pathogens. These different innate 
sensing mechanisms converge to induce innate and adaptive immune responses 
[139] [140]. 
========
=
Figure 1.10. Antiviral restriction factors (adapted from [141]) 
Various restriction factors target various viral components and active against various viral families. Overview 
above show these restriction factors (in the orange box) target various stages of viral life cycle (in the green box). 
(IFITIM: interferon-induced transmembrane protein, SAMHD: SAM domain and HD domain-containing protein 1, 
MxB: myxovirus resistance gene B, TRIM5: tripartite motif-containing protein 5, KAP1: KRAB-associated protein 
1, ZAP: zinc-finger antiviral protein, PKR: (ds)RNA-dependent protein kinase R;, APOBEC3: apolipoprotein B 
mRNA-editing enzyme, catalytic polypeptide-like 3, SERNIC5: serine incorporator; CH25H, cholesterol 25-
hydroxylase). 
 
Anti-viral restriction factors are germline encoded proteins that target 
almost every stage of viral replication (Figure 1.10). Several of these restriction 
factors are ISGs (interferon-inducible genes) or constitutively present in cells 
(Table. 1.3). The term ‘Restriction Factors’ was coined in 1970 by the laboratories 
working on retroviruses. Although, now it is applicable to a wide range of gene 
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products targeting different viruses. For qualification of a host gene as a restriction 
factor, it requires to have certain features such as, antiviral activity, induction by 
IFN or virus, antagonized by viral proteins and signatures of positive selection. It 
is also possible that these factors may have unidentified cellular functions. These 
potent cellular blocks are in a constant evolutionary battle with rapidly mutating 
antagonizing viral proteins. Thus, have an important role in shaping innate 
immunity.  
  Table 1.3: List of various well studied restriction factors (adapted from [140])=
(Fv1: Friend virus susceptibility-1, TRIM5: tripartite motif-containing protein 5, APOBEC3: apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3, SAMHD1: SAM domain and HD domain-
containing protein 1, ZAP: zinc-finger antiviral protein, MxA: myxovirus resistance gene A/B, PKR: (ds)RNA-dependent protein kinase R.)=
Various viral proteins antagonize these restriction factors by various 
mechanisms. For example, by targeting restriction factors to cellular protein 
degradation pathway, down-regulating their expression, mimicking a substrate, or 
sequestering them. Constant selection pressure on the virus by restriction factors 
and vice-versa can be seen in the genetic footprint of such proteins.  Therefore, the 
study of these restriction factors is important to enhance our current 
understanding of immune response against viral infections. 
1.3. APOBEC3G 
APOBEC3G/A3G (Apolipoprotein B mRNA-editing enzyme catalytic 
polypeptide-like 3G) belongs to a family of cytidine deaminases and was the first 
restriction factor identified against HIV-1. HIV-1 Vif (virion infectivity factor) 
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phosphoprotein deficient virus produced non-infectious virus in “non-permissive” 
cells such as CD4+ T cells and macrophages whereas, this virus replicated 
efficiently in lab adapted “permissive” cell line. The non-permissive cells expressed 
antiviral factor which was antagonized by Vif. In 2002, this factor was identified 
to be APOBEC3G (A3G) [142]. 
1.3.1. Evolution 
The origin of APOBEC family has been proposed to be in AID (activation-
induced cytidine deaminase) ancestral genes found in lymphocytes of jawless fish 
such as lamprey that lived more than 500 million years ago. These proteins were 
potent inducers of mutagenesis in various infectious agents of lamprey [143]. 
Complex gene duplication and positive gene selection in the past have resulted in 
the generation of current members of the APOBEC family (Figure 1.11A) [144]. 
Currently, the APOBEC family consists of 11 primary gene products that include, 
AID, APOBEC2 (A2), APOBEC3A (A3A-H) and APOBEC4 (A4) proteins. As shown 
in  Figure 1.11B cytidine deaminase motifs are a hallmark of these family  [145].  
=
===== ======== =
Figure 1.11. A3G evolution and family members 
(A) Phylogenetic tree of the evolution of APOBEC family from Jawless fish which contained single deaminase 
domain to recent single and double deaminase domain containing APOBECs in rodents, primates and human. (B) 
ZDD (Zinc-dependent deaminase domain) organization in each member of APOBEC family is shown schematically. 
The uniform amino acid sequence is shown below.  
 
AID hyper-mutational activity is responsible for the generation of enormous 
diversity during V(D)J recombination by three distinct gene diversification 
processes: class-switching recombination, somatic hypermutation and gene 
conversion [146]. Along with A3G, other members of APOBEC family such as A3B 
and A3F have been shown to restrict HIV-1 in absence of Vif [147][148][149]. Not 
(B) (A) 
 =
 
23 
NK=fåíêçÇìÅíáçå=
much information is available about A2 and A4 proteins. Some studies have 
reported a link of A2 with liver cancer and muscle development (reviewed in [150]). 
APOBEC proteins of non-human primates have been shown to inhibit HIV-1 which 
explains the extent of these proteins as restriction factors [151][152].  
 
 
1.3.2. APOBEC3G structure and function  
As mentioned above, APOBEC family members consist of one or two ZDD 
domains. The C-terminal motif (CD2) is catalytically active, whereas, the N-
terminal motif (CD1) is not (Figure 1.12). CD1 mediates RNA binding and 
encapsidation in HIV virions along with that it is also a target site of Vif. CD2 is 
responsible for cytidine deaminase activity [153]. The A3G core contains 5 b-
sheets and 6 a-helices with loops in their secondary structures which play a 
significant role in the overall function of this enzyme.  
 
=
=
Figure 1.12. Domain structure of A3G 
Putative interaction domains of A3G (A) Schematic and (B) Full-length model of significant domains of A3G 
(adapted from [154]).=
The antiviral activity of A3G is not only attributed to deamination but also 
to various deaminase independent functions as summarized in Figure 1.13. The 
(B) 
(A) 
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deamination by A3G prefers 5’-CCCA-3’ sequence and is not a random event. The 
chemical process (Figure 1.13B box) is initiated by hydrolytic deamination at the 
C4 position of cytosine (C). Briefly, a conserved glutamic acid in the catalytically 
active domain of A3G deprotonates water, whereas histidine and two cysteine 
residues coordinate Zn2+ ions. The resultant zinc-stabilized and reactive hydroxyl 
nucleophile attacks the C4 position and replaces the amine group (NH2) with a 
carbonyl group (=O) thereby deaminating cytidine (C) to uridine (U) [155][156]. 
The A3G enzyme preferentially targets viral ssDNA and not retroviral RNA. 
These mutations are responsible for alterations in the viral open reading frames 
and erroneous insertions of termination codons. Accumulated dU also results in 
reduced (-) DNA synthesis [157].  
=
Figure 1.13. HIV-1 restriction by A3G. 
(A) Through RNA binding capacity LLM (low molecular mass) complex of A3G interfere with reverse transcription 
in deaminase independent manner result in post-entry block. (B) The post reverse transcription functionally active 
HMM (high molecular mass) complex of A3G deaminate dC to dU in viral minus strand synthesis and the resultant 
virus is non-infectious. (C) In wild-type HIV-1 viral protein Vif direct A3G to ubiquitin-mediated degradation 
pathway. 
 
In absence of Vif protein (mode of targeting discussed in 1.3.3) the mutations 
are retained in pro-viral RNA and the extent of hypermutation is such that 
infectious progeny virus is not encoded by this erroneous pro-viral RNA. Mutated 
dU residues also target viral DNA to cellular DNA repair machinery and eventual 
degradation. 
(A) 
(B) 
(C) 
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The catalytic ability of A3G is not its only antiviral activity [158]. A 
significant amount of HIV-1 restriction by catalytically defective variants was 
reported by several groups [159][160][161]. These deamination defective mutants 
of A3G were efficiently packaged into virions and retained antiviral activity. A3G 
also affects the priming ability of tRNA lys3 to initiate reverse transcription (RT) 
[162]. Along with this mechanism, several other models have been proposed to 
show the ability of A3G to inhibit RT (reverse transcription) such as first strand 
and second strand transfer, minus strand stop synthesis, minus strand DNA 
synthesis, proviral DNA synthesis and integration (reviewed in [163]). 
Circulating resting CD4+ T cells are resistant to HIV-1, whereas lymphoid 
tissue resident resting CD4+ T cells are susceptible. Though, A3G is found in both 
types of cells, it is present in two distinct forms. The LMM (low molecular mass) 
A3G is the catalytically active form, whereas HHM (high molecular mass) A3G is 
catalytically inactive. A3G is found in LMM complexes in circulating resting CD4+ 
T cells. This enzymatically active complex functions as a potent post-entry 
restriction factor of HIV-1 [164]. However, in a complex lymphoid environment, 
the stimulation of resting  CD4+ T cells by mitogens and cytokines such as IL-2 
and IL-15 renders these cells susceptible to HIV-1 due to the recruitment of A3G 
into HMM complexes [165].   
Taken together these findings suggest that a second, editing-independent 
antiviral mechanism of A3G exists, which is not yet understood completely.  
1.3.3. HIV-1 Vif hinders antiviral activity of APOBEC3G 
Vif, a 23 kDa protein, is crucial for HIV-1 infectivity and replication [166] 
and Vif deleted HIV-1 (△vif ) could not replicate in non-permissive cells such as 
primary T cells and macrophages [167]. Expression of A3G in permissive cell lines 
resulted in a non-permissive phenotype for HIV-1 [142].  
An N-terminal A3G binding motif of Vif is responsible for its interaction 
with A3G. The C-terminal domain of Vif binds to ElonginC and the second zinc- 
binding motif binds to Cullin5. This binding results in the hijacking of an E3 
ubiquitin complex containing ElonginB, ElonginC, Cullin5 and Ring box-1. As a 
result, a suicidal polyubiquitinylation of Vif occurs and subsequent proteasomal 
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degradation of not only Vif but also of linked A3G is inevitable [168][169]. It has 
also been reported that Vif interferes with A3G packaging in virions and the 
antiviral activity of degradation resistant variants of A3G [170].  
1.3.4. Cellular expression of APOBEC3G 
A3G is located in an anthropoid-specific single cluster on chromosome 22 at 
q13.2 along with several other members of the APOBEC family [145]. As shown 
in Figure 1.14, A3G RNA is detected in a wide range of tissues. The A3G 
expression is inducible and stimulation with PHA and IL-2 has been shown to 
increase expression in PBL [164]. However, it is also present constitutively in 
some cells. Stimulation of cells with PMA was shown to increase the expression of 
A3G via activation of the MAPK (mitogen-activated protein kinase) signalling 
pathway [171]. How exactly A3G expression is induced in cells is still not clear. In 
some cells such as HepG2.2.15 cells, the A3G expression is induced upon IFN-a 
treatment [172], whereas in the T lymphocytic cell line H9, A3G expression 
remains unaffected after treatment with type I and II IFNs [171]. IL-2, IL-15, IL-
7 and IFN-g have been shown to induce A3G expression.  
 
Figure 1.14. RNA signature of A3G in different human organs (adapted from proteinatlas.org) 
 
At the transcriptional level human A3G expression is controlled by a 
constitutively active promotor with multiple transcription start sites. A GC-box 
plays an important role in the functioning of this promoter and has binding sites 
for nuclear transcription factor Sp1 (specificity protein 1) and Sp3 (specificity 
protein 3) [173]. Recently transcription factor USF1 (upstream regulatory factor 
1) has been shown to regulate A3G transcription in human hepatocytes [174]. 
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Similarly, another transcriptional cofactor CBF-b (Core-binding factor subunit 
beta) has been shown to regulate A3G expression. Interestingly, the lentiviral Vif 
protein has been evolved to hijack CBF-b to suppress antiviral defence of A3G 
[175].  
Due to the highly editing nature of A3G, it was assumed that this protein is 
located only in the cytoplasm. However, recently it was shown that A3G is 
cytoplasmic in resting CD4+ T cells and translocated to the nucleus in activated 
and proliferating CD4+ T cells [176]. These recent findings indicate that A3G may 
have a physiological role in cells.  
  
1.3.5. APOBEC3G oligomerization and interaction with RNA 
 The N-terminal domain (NTD) of A3G is a catalytically inactive domain 
but possesses the important function of interaction with RNA/DNA and 
incorporation of A3G into the virion. A3G monomers have been observed to form 
oligomers [177] [178] [179] and the exact role of this process is yet to be uncovered. 
However, alterations in NTD have been shown to affect oligomerization and thus 
hinder packaging of A3G into the budding virion [180].   
 A road-block model has been proposed to support this critical role of A3G 
oligomerization [181]. According to this model, A3G quickly deaminates viral 
ssDNA and then oligomerizes to present a road-block for reverse transcription. 
This may explain why the low number of A3G as found in virions can efficiently 
carry out antiviral function on large scale [181].  
 Apart from oligomerization, A3G was found in cellular ribonucleoprotein 
complexes (RNPs) containing more than 90 different cellular proteins. Many of 
these proteins were found to be RNA-interacting proteins having important roles 
in determining the fate of newly synthesized RNA as well as various other cellular 
RNA functions such as the Staufen containing RNA granules which are RNP 
complexes containing cellular RNA translation machinery and decay enzymes 
[182] [183][184][185]. Furthermore, the established sites of RNA metabolism and 
storage such as Stress granules and P-bodies contained substantial amounts of 
A3G [182]. Taken together these dynamic interactions between A3G and the RNA 
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processing machinery may play a crucial role in the regulation of the antiviral 
activity of A3G. 
1.3.6.  Restriction of other viruses by APOBEC3G 
As initially believed, HIV-1 is not the only target of APOBEC enzymes. After 
initial identification of A3G antiviral activity in the majority of research was 
focused on A3G-retroviral interaction. However, recent evidence suggests that 
many other viruses are targeted by APOBEC family of proteins especially by non-
enzymatic mechanisms.  
A3G is a well-known restriction factor of hepatitis B virus (HBV) 
independent of its cytidine deaminase activity. A3G shown to inhibit HBV DNA 
production in Huh7 cells [186] and recently HBV X protein has been identified to 
down-regulate A3G levels in a dose-dependent manner in Huh7 cells [187]. 
Extensive editing of human T-cell leukaemia virus type 1 genome by A3G, A3B, 
A3C and A3F was observed [188]. CTD of A3G was shown to directly bind to HCV 
non-structural protein NS3 and diminish helicase activity to inhibit HCV 
replication in Huh7.5 cells [189]. Catalytically active A3A effectively inhibited 
replication of a parvovirus, adeno-associated virus (AAV), and endogenous 
retroelements [190]. Similarly, A3G has been shown to provide partial protection 
in mice against mouse mammary tumour virus (MMTV) [191]. In addition, A3G 
mediated restriction of three RNA viruses, Measles, Mumps and Respiratory 
syncytial virus (RSV), was reported [192]. Another positive-stranded RNA virus, 
the human coronavirus, was restricted by A3C, A3F and A3H without causing 
hypermutations in the viral genome [193].  
Taken together, A3G antiviral potency is not just limited to cytidine 
deaminase activity but also extrapolate to various deaminase independent 
functions. Apart from protection from viral threat, APOBEC protein may also 
have pleiotropic effects on cellular functions and may contribute to malignant 
transformation. Only future research can help to completely understand the 
activities of this protein.  
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1.4. REDD1 
1.4.1.  Structure and function 
In our group, we investigated the basis of A3G-mediated inhibition of MV 
replication. Upon ectopic expression of A3G in Vero cells a significant reduction 
in MV titre was observed [192]. In these cells, the differential regulation of cellular 
genes was analysed by microarray. Two of the significantly upregulated 
genes/gene products were REDD1 and KDELR2, which are introduced below.  
REDD1 (Regulated in development and DNA damage response 1) or DDIT4 
(DNA-damage inducible transcript 4) or RTP801 or dig2 is a 24 kDa stress 
response protein. REDD1 is a highly conserved gene on human chromosome 10. 
REDD1 structure (Figure 1.15) is composed of two-layered sandwiches made of 
two anti-parallel a helices and mixed b sheet. No oligomerization of REDD1 has 
been reported in overexpressing cells [194].  
 
Figure 1.15. Crystal structure of REDD1 [194]. 
Ribbon model of REDD1 shows the sandwich arrangement of a and b helices.  
 
Ubiquitous expression of REDD1 was detected in many tissues. A diverse 
range of cellular stress has been shown to induce expression of REDD1 such as 
hypoxia and DNA damage [195][196], ER stress, serum depletion, energy-related 
stress and nutrient depletion [197] [198] [199]. Various stress condition related 
transcription factors such as HIF1 (hypoxia-inducible factor 1), p53, p63, ATF4 
(activating transcription factor 4), and Sp1 (specificity protein) control expression 
of REDD1 [195] [200][201]. The half-life of 5-7 minutes makes REDD1 a highly 
unstable protein with the tight transcriptional regulation [202].  
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Functionally, REDD1 is a negative regulator of mTORC1 (mammalian 
target of Rapamycin 1) specifically during hypoxic and stress condition and this 
effect is TSC2 (tuberous sclerosis complex) dependent [203] (Figure 1.16). TSC2 is 
a GTPase-activating protein that targets small Ras-related GTPase Rheb (Ras 
homolog enriched in brain) [204]. Rheb binds to the mTORC1 complex which 
results in activation of the TOR kinase via an unknown mechanism [205]. REDD1 
releases TSC2 from its growth factor-induced association with the inhibitory 14-3-
3 protein and blocks mTOCR1 signalling [206]. REDD1 expression alone results in 
significant down-regulation of S6K1 (Ribosomal protein S6 kinase beta-1) in a 
TSC2 dependent manner indicating that REDD1 acts upstream of mTOR1 [203].   
1.4.2. REDD1 and mTORC1    
Initially, after identification of REDD1, a Drosophila homolog ‘Scylla’ has 
been shown to repress TOR (a Drosophila ortholog of human mTORC) by targeting 
S6 kinase phosphorylation [207]. Later REDD1 was shown to negatively regulate 
mTOR in mammalian systems [208].  
mTOR consist of two distinct protein complexes, mTORC1 and mTORC2. 
Both complexes target different downstream molecules and therefore regulate 
different cellular functions. The mammalian target of rapamycin 1 (mTOR1) is the 
central regulator of cellular anabolic and catabolic processes. mTOR regulated 
downstream signalling governs the fate of extracellular and intracellular events 
that regulate cellular metabolism, growth, cytoskeleton rearrangement, 
transcription, protein synthesis and ribosomal biogenesis (Figure 1.16) (reviewed 
in [209][210]). mTOR has been shown to play a crucial role in determining the 
outcome of Ag recognition by regulating T cell activation and anergy [211]. In 
contrast, mTORC2 phosphorylates AKT (Protein kinase B) and PKC (Protein 
kinase C) to regulate cell survival and cytoskeletal organization [212] [213].  
mTOR is a highly conserved large protein of 289 kDa. As shown in Figure 
1.16 mTORC1 complex consist of five major components, mTOR, Raptor 
(regulatory associated protein of mTOR), PRAS40 (Proline-rich Akt substrate of 40 
kDa), Deptor (DEP domain containing mTOR-interacting protein) and mLST8 
(mammalian lethal with Sec13 protein 8). Two activating subunits of mTORC1 
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complex, Raptor assist in cellular localization of mTORC1 and help in substrate 
recruitment, whereas mLST8 stabilizes the catalytic domain. The two negative 
regulators PRAS40 and Deptor inhibit substrate binding (reviewed in [214]).  
 
 
 
 
Figure 1.16. mTOR1 signalling: role of REDD1 and Rapamycin 
(A) various upstream signalling events regulate the fate of mTORC1 either by activating or inhibiting signalling 
events. The green line represents positive signalling and red line represent negative signalling. (B) significant 
downstream signalling cascades are depicted here(4E-BP1: eukaryotic initiation factor 4E.binding protein 1, AKT: 
protein kinase B, Deptor: DEP domain containing mTOR-interacting protein, eEF2: eukaryotic translation elongation 
factor 2, eEF2K:eEF2 kinase, eIF: eukaryotic translation initiation factor, ERK1/2: extracellular signal-regulated 
kinase 1/2, FKBP12: FK506 binding protein of 12kDa, IKKb: IkB kinase-b, mLST8: mammalian lethal with Sec13 
protein 8, PKC: Protein kinase, Raptor: regulatory associated protein of mTOR, Rheb: Ras homolog enriched in 
brain, S6: ribosomal protein S6, S6K1: p70 ribosomal S6 kinase1, SREBP1: sterol regulatory element binding 
protein 1, TSC: tuberous sclerosis complex) (adapted from [214]) 
 
One of the significant downstream signalling events of mTORC1 activation 
is activation of S6 Kinase. Phosphorylation at Thr389 results in activation of S6K1, 
(A) 
(B) 
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which subsequently activates several downstream targets to promote mRNA 
translation initiation and ribosome biogenesis [215].  
In accordance with the crucial role of REDD1 on mTORC1 signalling, it has 
a very short life of 5-7 minutes. To restore mTOR signalling during the recovery 
phase, REDD1 degradation plays a crucial role. CUL4A-DDB1 (Cullin 4A-DNA 
damage-binding protein1) regulates the ubiquitin-mediated degradation of 
REDD1 (Figure 1.17) [216].   
 
Figure 1.17. Restoration of mTOR functions via degradation of REDD1 [216].  
REDD1 induced upon hypoxic condition inhibit mTORC1 signalling and during recovery phase phosphorylation of 
REDD1 recruit CUL4A E3 ligase-mediated ubiquitination of REDD1 and subsequent proteasomal degradation. (b-
TRCP: beta-transducin repeat-containing protein, CUL4A: cullin 4A, DDB1: DNA damage-binding protein 1, GSK3b: 
glycogen synthase kinase-3b, ROC1: regulator of cullins 1;)  
 
Interestingly, also a mTORC1-REDD1 feedback loop has been reported in 
which mTORC1 regulates REDD1 expression in a proteasome-dependent manner 
to exert some control over the inhibitory effects of REDD1 [217]. 
mTORC1 was defined by its sensitivity to a naturally occurring macrolide 
antibiotic Rapamycin or Sirolimus. Isolated from bacteria found on South Pacific 
island of Rapa Nui in 1964. This compound was acknowledged as an anti-fungal, 
immunosuppressive and anti-tumour agent. Rapamycin has been shown to 
specifically inhibit pathways involved in cell growth and proliferation by affecting 
p70S6K signalling [218]. Rapamycin binds to the intracellular receptor FKBP12 
(FK506 binding protein of 12kDa) and this complex binds to the FRB (FKBP12-
rapamycin binding) domain of the mTOR catalytic region at its C-terminus [219] 
[220]. This interaction occludes the binding of downstream substrates such as 
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S6K1 and 4E-BP1. S6K1 levels have been shown to be significantly down-regulated 
after Rapamycin treatment [203]. Interestingly, mTOR2 is insensitive to 
Rapamycin treatment [221].  
1.4.3. Antiviral activity 
As a metabolic regulator of the cell, a variety of factors that contribute to 
any kind of cellular stress converge to the mTOR pathway. Viral infection is one 
important mediator of cellular stress. Depending on the type of virus and the 
subcellular location of viral replication, activating or inhibiting signals for mTOR 
can be triggered. A number of viruses have been shown to target mTOR signalling 
for their own benefit (reviewed in [222]). Apart from the role of REDD1 in 
regulating mTORC1, recently REDD1 has been redefined as a cellular host 
defence factor and its regulation triggered an antiviral response against Influenza 
virus [223].  
These findings have highlighted a potent antiviral strategy against viruses 
that require mTOR signalling. Testing of synthetic and natural chemical 
compounds that can trigger REDD1 expression is certainly worth investigating to 
find new antivirals.  
1.5. KDELR2 
The fate of every newly translated protein is decided by its sequence 
(transmembrane domains, disulphide bonds, localization sequences etc) and post-
translational modifications (protein folding, glycosylation, acetylation, 
phosphorylation etc) which occur in the ER (endoplasmic reticulum). Subsequent 
membrane transport is a well-coordinated series of events in various cellular 
organelles to ensure correct delivery of proteins to their functional site. Various 
ER resident chaperones drive the correct folding of newly translated proteins. 
KDELR family receptors have been shown to play an important role in the 
retrieval of these ER-resident chaperones and also by triggering various cellular 
events.  
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1.5.1. KDELR2 structure and function 
In 1987, several ER-resident chaperones such as GRP78, GRP94 were 
shown to contain the C-terminal tetra peptide signal sequence KDEL (lys-asp-glu-
leu) [224] which is responsible for retention of these chaperones in the ER. The 
attempt to identify these retention signals first resulted in the identification of 
two genes ERD1 and ERD2  in yeast system [225][226], followed by identification 
of human homologue hERD2 (later referred as KDELR1 (ERD2.1)) [227]. 
Subsequently, the receptors KDELR2 (ERD2.2 or ELP1) and KDELR3 were 
identified (reviewed in [228]). Although KDEL receptors perform similar 
functions, the protein-encoding genes are located on different human 
chromosomes, namely KDELR1 on chromosome 19, KDELR2 on chromosome 7, 
and KDELR3 on chromosome 22. KDELRs are ubiquitously expressed. KDELR1 
was shown to regulate PP1 (protein phosphatase 1) in T cells, a key enzyme that 
regulates integrated stress response in naive T cells. Specific dysfunction of 
KDELR1 results in depletion of naive T cell population in mice [229]. 
Functionally, ER chaperones ensure the maturation of proteins before they 
are exported out of the ER or direct them for degradation, which is known as 
ERAD (ER-associated degradation) and thus prevent the excessive aggregation of 
proteins in the ER-Golgi network. Proteins destined to be exported out of the ER 
are packaged in COPII coated vesicles and transported to the Golgi via IC (pre-
Golgi intermediate compartments). The resultant membrane flow is sufficient to 
bulge the Golgi complex to a detrimental level making it necessary to have 
compensatory mechanisms. One of such mechanisms is retrograde transport back 
to the ER [230]. The ER resident soluble chaperones with KDEL motif (such as 
calnexin and GRP78) are recognized by KDELRs and then sorted out to COPI 
vesicles and retrograde transport. Thus, the KDELR family plays a decisive role 
in ER quality control.  
At homeostatic levels, KDELRs are located predominantly in the Golgi but 
redistributed to the ER upon ligand binding [231] or upon overexpression [232]. 
KDELR-ligand binding is efficient at acidic pH and at neutral or basic pH binding 
is weaker [233]. Therefore, the ligand bearing proteins bind to KDELRs in the 
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acidic environment of the Golgi and after retrieval to ER due to neutral pH the 
proteins are released in ER [234]. 
KDELRs contain seven transmembrane domains that span across the 
membrane. These domains are connected by three cytoplasmic loops and three 
luminal loops with cytoplasmic C-terminus and luminal N-terminus (Figure 
1.18A). KDELR2 has similarity to the family of PQ-loop proteins (Figure 1.18B). 
These proteins contain at least two conserved PQ-loop (Proline-glutamine) 
domains of 40-60 amino acids [235].  
       
Figure 1.18. Schematic representation of KDELR2 receptor 
(A) KDELR2 is membrane protein with cytoplasmic C terminal and luminal N terminal domain. KDEL motif 
containing peptide bind to KDELR2 to trigger transport of KDEL peptide-containing proteins (B) representation of 
PQ-loop protein topology which contain at least two PQ sequence [235] (ER: endoplasmic reticulum, C: C terminal 
of protein, N: N terminal of protein, H: Helices, P: Proline, Q: Glutamine)  
 
Interestingly, recent findings showed that KDELR structures are similar to 
GPCR (G-protein coupled receptors) superfamily proteins (Figure 1.19) with 
significant similarities within the transmembrane region of KDELRs [236]. GPCR 
family proteins are known to activate various signalling pathways upon binding 
to its ligands. Interestingly, KDELRs have been shown to bind to Ga proteins and 
to activate Gaq/11 which results in activation of Golgi SFKs (Src family kinases) 
and regulation of the secretory traffic [236]. KDELR-ligand binding also induces 
p38 MAP kinases which are known not only to regulate cell growth and 
differentiation but also immune and inflammatory responses [237].  
KDELR2 self oligomerizes and interacts with ARF1 (ADP ribosylation 
factor) and  GAP (GTPase-activating proteins) to regulate ARF1-mediated 
(A) 
(B) 
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vesicular transport. KDELR1 and KDELR2 also have been linked to the 
promotion of ECM (extra cellular matrix) degradation and invadopodia formation 
and may contribute to cancer cell dissemination [238].  
 
Figure 1.19. Schematic representation of KDELR2 receptor and comparison with GPCR 
Structural model of KDELRs showing seven helices with intracellular loops (Left) compared to classical GPCR 
(G protein coupled receptors) family proteins (right) ([236] [239]). 
 
Although identified in already 1990, KDELR receptor family functions are 
still poorly understood. Recent finding showed that the KDELR redistribution 
across the ER-Golgi network mediates signalling events and exerts effects on 
multiple levels which implies unidentified novel roles played by KDELRs. 
1.5.2. Role in viral egress 
Viral entry and replication processes occur in close interaction with various 
cellular proteins. During infection viral proteins must traffic across various 
cellular compartments to an exit site at the plasma membrane while avoiding 
transportation to degradative compartments. The ER is one of the crucial cellular 
organelles to regulate viral protein expression and assembly (reviewed in [240]).  
Membrane webs formed in the ER are important for HCV replication and 
assembly [241], whereas DENV (Dengue virus) form vesicle pockets for a similar 
purpose [242]. Since KDELR transport across ER to Golgi is pH a dependent 
process, it can be easily exploited by various viruses. In the case of DENV, 
excessive production of viral proteins in the ER requires equivalent transport via 
cellular cargo to the plasma membrane. DENV has been demonstrated to require 
assistance from KDELR1 and KDELR2 for vesicular transport. The DENV prM 
protein directly interacts with KDELRs for this process and sequestering of 
KDELRs in Golgi by depletion of Arf4 (ADP ribosylation factor 4) and Arf5 (ADP 
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ribosylation factor 5) resulted in the accumulation of DENV proteins in the ER 
[243].  
Interestingly another member of the Flavivirus family JEV (Japanese 
encephalitis virus) also was shown to be dependent on the KDELR1-mediated ER-
Golgi retrieval system for viral particle trafficking [244]. Similarly, KDELRs 
along with coatomer proteins deliver host cellular membranes to early forms of 
Vaccinia virus virions [245]. Moreover, FIPV (Feline infectious peritonitis 
coronavirus) glycoprotein 6b possesses the ER retention signal KTEL (similar to 
KDEL) for slow release of this protein from the ER [246].  
Taken together there is increasing evidence pointing out towards a critical 
role of KDELRs as host factors assisting viral egress.  
1.6. ER chaperones 
1.6.1. Calnexin and Calreticulin 
ER is the home of several chaperones of a distinct chaperone family. These 
chaperones are cellular sensors to detect and differentiate between native and non-
native protein conformations. They accurately interact with incorrectly folded 
protein and ensure correct processing or target incorrectly folded proteins for 
degradative pathways.  
Calnexin and Calreticulin (CRT) are unique ER chaperones which 
coordinate precise folding of newly synthesized monoglucosylated N-linked 
glycoproteins. Structurally they are type-I integral membrane lectins in the ER. 
Calnexin is membrane bound, whereas CRT is a luminal soluble protein. The 
luminal domain of calnexin immediately associates itself with newly synthesized 
peptides. The primary quality control of folding of glycoproteins is provided by the 
Calnexin-Calreticulin cycle. Cleavage of nascent protein chains by glucosidases I 
and II allows interaction of Calnexin/CRT with the polypeptide chain. Upon correct 
folding, glucosidase II releases these chaperones from the folded proteins so that 
they can exit ER. Otherwise, proteins are cycled back for re-folding. If they are 
permanently misfolded, they are targeted to ERAD [247].  
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1.6.2. GRP78 
GRP78 (Glucose-regulated protein 78) or BiP (binding immunoglobulin 
protein) is a 78 kDa chaperone located in the lumen of ER. GRP 78 is a crucial 
protein that assists in the maturation of proteins and regulates the UPR (unfolded 
protein response). In steady state, binding of GRP78 to luminal domains of  PERK 
(Protein kinase RNA-like endoplasmic reticulum kinase) and IRE1 (inositol-
requiring protein 1) (Figure 1.20) maintains them in a monomeric state thus 
prevents the UPR signalling cascade [248]. An increased amount of unfolded 
proteins results in depletion of all available luminal GRP78 molecules and 
dissociation of these proteins from PERK and IRE1 resulting in their 
oligomerization and initiation of UPR. Apart from the regulation of UPR, GRP78 
was also found at the cell surface playing roles in cell signalling and antigen 
presentation. Various malignancies, neoplastic conditions and viral infections 
result in increased surface expression of GRP78 (reviewed in [249]). 
 
Figure 1.20. The UPR stress sensors and downstream signalling [250] 
ER stress sensing molecules initiate downstream signalling from ER to cytosol and then to the nucleus.  
(IRE1a: inositol-requiring protein 1a, PERK: protein kinase RNA-like endoplasmic reticulum kinase, ATF6: 
activating transcription factor, XBP1: X-box binding protein 1, ERAD: ER-associated degradation, RIDD: IRE1 
dependent decay, JNK: JUN N-terminal kinase, NF-kB: nuclear factor kB, eIF2a: eukaryotic translation initiator 
factor 2a, NRF2: nuclear factor erythroid 2-related factor 2, COPII: coat protein II, S1P: site 1 protease, S2P: site 2 
protease, TRAF2: TNFR associated factor 2.) 
 
The UPR either results in ER recovery, or inability to handle the stress may 
lead to apoptosis. During a viral infection, the UPR either tries to control the 
infection or is used by the virus for its own benefit (reviewed in [251]). In figure 
1.20 the complex signalling network of UPR is summarized.  
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1.7. Aim of study 
It has been reported earlier in our group that measles, mumps and 
respiratory syncytial virus replication was reduced by more than 90% in A3G 
expressing Vero cells. A3G is a cytidine deaminase shown to hypermutate the HIV-
1 genome. However, no such hyper-mutational signatures were found in the MV 
genome [192]. Interestingly, it has also been shown that A3G is localized in various 
cytoplasmic structures such as P-bodies and stress granules. These structures 
function to regulate the cellular mRNA turnover. Therefore, we decided to 
investigate if A3G can alter the cellular RNA expression. On this line, preliminary 
work in our lab was done by analysing cellular gene expression in A3G expressing 
and non-expressing cells by using a microarray. This study revealed a differential 
regulation of several genes. The potential hits contained many interesting 
candidate genes. 
Therefore, this thesis aims to characterize the role of two top candidate 
genes (1) REDD1 and (2) KDELR2 in detail. Understanding the role of these 
proteins in MV replication will help to understand how these host factors influence 
and interact with MV to contribute to A3G mediated antiviral effects against MV.  
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2. ===Materials 
2.1.       Cell lines and Primary cells 
Table 2.1: List of Primary and established cell lines 
Name Origin Source 
Vero Adherent cell line derived from kidney epithelial 
cells of Cercopithecus aethiops (African Green 
Monkey) 
Lab of Dr. Jürgen Schneider-
Schaulies (Institute of Virology 
and Immunobiology) 
Vero hSLAM Vero cells expressing hSLAM (human CD150) Lab of Dr. Jürgen Schneider-
Schaulies (Institute of Virology 
and Immunobiology) 
Vero 023 Vero cells transduced with empty vector as a 
control 
A kind gift from Dr. Rebecca 
Holmes (King’s College London, 
United Kingdom) 
Vero 024-02 Vero cells transduced with human APOBEC3G A kind gift from Dr. Rebecca 
Holmes (King’s College London, 
United Kingdom) 
HEK 293T Adherent cell line derived by transforming 
human embryonic kidney cells with SV40 T-
antigen 
Lab of Dr. Jürgen Schneider-
Schaulies (University of 
Würzburg, Germany) 
CEM-SS 
pcMS 
Human T4-lymphoblastoid cell line transduced 
with an empty vector as a control 
A kind gift from Dr. Michael 
Malim (King’s College London, 
United Kingdom) 
CEM-SS A3G Human T4-lymphoblastoid cell line transduced 
with human APOBEC3G  
A kind gift from Dr. Michael 
Malim (King’s College London, 
United Kingdom) 
Hep2 Established epidermoid carcinoma of the larynx 
via HeLa cell contamination 
A kind gift from Dr. Benedikt 
Weissbrichk (Viral Diagnostic, 
University of Würzburg, 
Germany) 
 
2.2.   ==Virus 
=
2.3.     Bacteria 
Transformation of ligation reaction and amplification of plasmids was done in 
XL10-Gold® Ultracompetent cells from Stratagene, USA (200314). 
Table 2.2: List of Virus strains used and origin. 
Name Source 
rMVEdtag A kind gift from Dr. Paul Duprex (Boston University, USA) 
rMVEdtageGFP A kind gift from Dr. Paul Duprex (Boston University, USA) 
rMVIC323eGFP A kind gift from Dr. Yusuke Yanagi (Japan) 
HSV-1 GFP A kind gift from Dr. Beate Sodeik (Hannover Medical School, Germany) 
rgRSV GFP A kind gift from Dr. C Krempl (University of Würzburg, Germany) 
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2.4.     Plasmids and cDNA clones 
	
2.5.    DNA and Protein standards  
To analyse DNA on Agarose gel GeneRuler™ 50 bp DNA Ladder 
(#SM0371), GeneRuler™ 100 bp DNA Ladder (#SM0241) and GeneRuler™ 1 
kb Plus DNA Ladder (#SM1331) standards were used (Figure 2.1 A, B and C). 
To analyse proteins on SDS PAGE PageRuler™ Pre-stained Protein standard 
was used (Figure 2.1D). 
 
                                        
 
Figure 2.1: DNA and Protein standards pattern on agarose or polyacrylamide gels  
(A) GeneRuler™ 50 bp DNA Ladder (B) GeneRuler™ 100 bp DNA Ladder (C) GeneRuler™ 1 kb Plus DNA 
Ladder (D) PageRuler™ Pre-stained Protein Ladder bands on poly-acrylamide gel and subsequent bands on 
the blot. 
 
 
 
Table 2.3: List of plasmids and source. 
Name Source 
F6gW-dsRed2 A kind gift from Dr. Marco Herold (University of  Würzburg ) [252] 
pMD.G/VSV A kind gift from Dr. Marco Herold (University of  Würzburg ) [252] 
pRSV-rev A kind gift from Dr. Marco Herold (University of  Würzburg ) [252] 
pMDLg/pRRE A kind gift from Dr. Marco Herold (University of  Würzburg ) [252]  
pcMS28 A kind gift from Dr. Rebecca Holmes (King’s College London, United Kingdom) 
RC200007 KDELR2 Expression Plasmid, OriGene Technologies (USA) 
RC202847 REDD1 Expression Plasmid, OriGene Technologies (USA) 
(A) (B) (C) (D) 
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2.6. ====Primers and Oligonucleotides 
2.6.1.    Primers 
Table 2.4 summarize the list of primers used for cloning of cDNA, Semi- 
quantitative PCR, Real-time qPCR, PCR, colony PCR and sequencing. 
Table 2.4: List of primers. All primers in 5’ → 3’ direction. F: Forward primer and R: Reverse 
primer 
 Name Sequence 
Cloning KDEL cloning F GTCGACTGGATCCGGTACCGA 
 KDEL cloning R GTAGTGAATTCGGCCGGCCGTTTAAACCTT 
 REDD1 cloning F GTCGACTGGATCCGGTACCGA 
 REDD1 cloning R GTAGTGAATTCGGCCGGCCGTTTAAACCT 
Semi-Quantitative 
PCR KDELR2 F CTTCCGGCTGACTGGGGACCT 
 KDELR2 R GAGGCCTCCCACAGGGACCAC 
 REDD1 F GGTTTGACCGCTCCACGAGCC   
 REDD1 R CAGCTCTTGCCCTGCTCCACG 
Colony PCR F6gW F CAGTTTCTTTGGTCGGTTTTATGT    
 F6gW R ACAAAGGCATTAAAGCAGCGTATC     
 KDELR2_colonyPCR_new R CTGGCAAACTGAGCTTCTTTC 
 REDD1_colonyPCR_new R ACCTTATCGTCGTCATCCTTG 
Sequencing F6gW_Seq_F AGGCGTCAGTTTCTTTGGTCG 
 F6gW_REDD1_Seq F ACTTGTGTGCCAACCTGATGC 
 F6gW_KDELR2_Seq F TCTACCTTGCCTGCTCCTATG 
Real-Time qPCR KDELR2 F  CTCTTCCTCTGCTGCGAAGT 
 KDELR2 R  ATGGAAAGCAGCCAAAACTC 
 KDELR2 F Exon I TTCTCTCCTCTTGAGATCCTCTG 
 KDELR2 R Exon I AAACAGCTGCGGAAGGATAG  
 KDELR2 F Exon II ATGAACATTTTCCGGCTGAC 
 KDELR2 R Exon II GGCTTTTCCCAGAAATACCG  
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2.6.2.    shRNA oligonucleotide sequence 
 
2.6.3.    siRNAs 
Table 2.6: List of siRNAs 
siRNA Source Catalogue no 
siA3G siGENOME Human SMARTpool Human APOBEC3G (60489) M-013072-00-0005  
siREDD1 ON-TARGET plus Human REDD1 (54541) SMARTpool, 5 nmol L-010855-01-0005  
siNT siGENOME Non-Targeting siRNA pool #1, 5 nmol D-001206-13-05   
 
2.6.4. Other oligonucleotides, primers and peptides. 
Table 2.7: List of other oligonucleotides 
Name Source 
dNTP mix (10 mM) Thermo Scientific (R0191) 
Oligo (dT)18 primer Thermo Scientific (SO131) 
Random Hexamer Primer Thermo Scientific (SO142) 
Fusion inhibitory peptide (FIP) Z-D-Phe-Phe-Gly-OH BACHEM (H-9430) 		
Table 2.5: List of shRNA sequences. All oligonucleotides are in 5’ → 3’ direction. F: Forward and 
R: Reverse 
 Name Sequence 
KDELR2 
shRNA 1 KDELR2_sh1_378_F 
TGCCACAGTGTACCTGATCTACCGAAGTAGATCAGGTACA
CTGTGGCTTTTTTC 
 KDELR2_sh1_378_R TCGAGAAAAAAGCCACAGTGTACCTGATCTACTTCGGTAGATCAGGTACACTGTGGCA 
KDELR2 
shRNA 2 KDLER2_sh2_410_F 
TGGCAACCTACGATGGAAATCACGAATGATTTCCATCGTA
GGTTGCCTTTTTTC 
 KDLER2_sh2_410_R TCGAGAAAAAAGGCAACCTACGATGGAAATCATTCGTGATTTCCATCGTAGGTTGCCA 
KDELR2 
shRNA 3 KDELR2_sh3_529_F 
TGCTCAGTTTGCCAGCATAAGTCGAAACTTATGCTGGCAA
ACTGAGCTTTTTTC 
 KDLER2_sh3_529_R TCGAGAAAAAAGCTCAGTTTGCCAGCATAAGTCGAAACTTATGCTGGCAAACTGAGCA 
REDD1 
shRNA 1 REDD1_sh1_F 
T GCGGCAGGACGCACTTGTC 
CTGTGAAGCCACAGATGGG GACAAGTGCGTCCTGCCGC 
TTTTTTC 
 REDD1_sh1_R CGAGAAAAAA GCGGCAGGACGCACTTGTC CCCATCTGTGGCTTCACAG GACAAGTGCGTCCTGCCGCA 
REDD1 
shRNA 2 REDD1_sh2_F 
TCTCTCCCTTCCTCCCTGGC CTGTGAAGCCACAGATGGG 
GCCAGGGAGGAAGGGAGAG TTTTTTC 
 REDD1_sh2_R TCGAGAAAAAA CTCTCCCTTCCTCCCTGGC CCCATCTGTGGCTTCACAG GCCAGGGAGGAAGGGAGAG 
A 
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2.7.     Antibodies and Antiserum 
Table 2.8: List of antibodies 
Name Origin Source 
Anti-ACY1  Rabbit monoclonal (clone EPR8445) Epitomics 5879-1 
Anti-MOSC2 (C-term) Rabbit polyclonal Epitomics T3362 
Anti REDD1 Rabbit polyclonal Proteintech 10638-1-AP 
Anti-PRDX2  Rabbit polyclonal Sigma SAB2101878 
Anti-TXNIP Rabbit polyclonal Sigma SAB2102616 
Anti-PRDX1 Rabbit polyclonal Sigma HPA007730 
Anti-KDELR2  Rabbit polyclonal Sigma SAB1401554 
Anti- GAPDH  Rabbit polyclonal (FL-335) Santacruz sc-25778 
Anti-Calnexin  Rabbit polyclonal Pierce PA1-30197 
Anti-GRP78  Rabbit polyclonal Pierce, PA5-11418 
Anti- Calreticulin  Rabbit polyclonal Pierce PA3-900 
Anti-APOBEC3G Rabbit polyclonal  (a kind gift from Dr. Michael 
Malim) 
Anti MV-H Rabbit polyclonal (clone H45) Lab of Dr. Jürgen Schneider-
Schaulies 
Anti MV-H  Mouse monoclonal IgG1 (Clone L77) Lab of Dr. Jürgen Schneider-
Schaulies 
Anti MV-F Rabbit polyclonal (clone F42) Lab of Dr. Jürgen Schneider-
Schaulies 
Anti MV-F  Mouse monoclonal IgG1 (Clone 
A504) 
Lab of Dr. Jürgen Schneider-
Schaulies 
Anti-FLAG  Mouse monoclonal (clone M2) Sigma, F1804 
Anti-flag Alexa 488 Rabbit polyclonal Cell signaling 5407S 
Anti-mouse Alexa 488  Goat monoclonal IgG (H+L) Life technology A11001 
Anti-rabbit Alexa 594  Goat monoclonal IgG (H+L) Life technology, A11012 
Anti- mouse APC  Goat monoclonal IgG (poly4053) Biolegend 405308 
Anti-mouse Alexa 405 Goat monoclonal IgG (H+L) Life technologies A31553 
Anti-mouse Alexa 594 Goat anti-mouse igg (H+L)  Life technologies A11005 
Anti-rabbit Alexa 647 Donkey monoclonal IgG (clone poly 
4064) 
Biolegend, 406414 
Anti- mouse HRP  Horse monoclonal IgG (H#ampL) Cell signaling, #7076S 
Anti- rabbit HRP  Goat monoclonal IgG (H#ampL) Cell Signaling, #7074S 
PE anti-human CD3 Mouse IgG1, k (Clone: UCHT1) Biolegend, 300408 
APC anti human CD69 Mouse IgG1, k (Clone: FN50) Biolegend, 310910 
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P70 S6 Kinase Rabbit polyclonal  Cell signaling #9202 
Phospho-p70 S6 Kinase Rabbit polyclonal Cell signaling #9205 
Phospho-AKT Rabbit polyclonal Cell signalling #9271 
Cell proliferation dye 
ä670 
 
ebioscience, 65-0840-85 
 
 
2.8.     Enzymes  
Table 2.9: List enzymes and source 
Name Detail Source 
CAIP Calf intestine alkaline phosphate (#EF0341) Fermentas 
M-MLV RT M-MLV reverse transcriptase (M1701) Promega  
T4 DNA ligase T4 DNA ligase (EL0011) Thermo Scientific 
T4 PNK T4 Polynucleotide Kinase (#EK0031) Thermo Scientific 
Taq-Polymerase Taq DNA polymerase (#EP0402) Thermo Scientific 
Xho I Restriction enzyme (#ER0691) Thermo Scientific 
KspAI Restriction enzyme (#ER1031) Thermo Scientific 
EcoRI Restriction enzyme (#ER0271) Thermo Scientific 
BamHI Restriction enzyme (#ER0051) Thermo Scientific 
Protease inhibitor  Protease inhibitor cocktail (P8340) Sigma 
Phosphatase inhibitor Phosphatase inhibitor cocktail 2 (P5726) Sigma 
PCR Beads Illustra PuReTaq Ready-To-GoTM PCR Beads (27-9558-01) GE Healthcare 
 
2.9.     Media and Serum 
2.9.1.  Media and Serum for Cell culture. 
Table 2.10: List of Media and serum and source 
Name Detail Source 
MEM Minimum Essential Medium Gibco™ (31095029) 
DMEM DMEM (Dulbecco's Modified Eagle Medium) Gibco™ (41966029) 
RPMI 1640 Roswell Park Memorial Institute (RPMI) 1640 Gibco™ (21875059) 
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FCS Fetal Calf Serum (Heat inactivated at 56°C for 30 minutes) Biochrom (S0115) 
BSS Balanced Salt solution 
Institute of Virology 
and Immunology, 
Würzburg 
BSS + BSA Balanced Salt solution + 0.1%BSA 
Institute of Virology 
and Immunology, 
Würzburg 
 
For every 500 ml of MEM/DMEM/RPMI mixture of Penicillin and 
Streptomycin (100 IU/ml) was added with the required amount of heat- 
inactivated FCS.  
 
2.9.2. Media for Bacterial culture  
 
==================
=
=
=
=
Before preparing plates add 100µg/ml of Ampicillin or 30µg/ml of Kanamycin 
depending upon the antibiotic resistance of plasmid. 
 
2.10. ====Equipment and Instruments 
LB Medium (1 litre) 
Bacto Tryptone 10 g 
Bacto Yeast Extract 5 g 
NaCl 10 g 
Tris.HCl 1M 10 ml 
LB agar (1 litre) 
Bacto Tryptone 10 g 
Bacto Yeast Extract 5 g 
NaCl 10 g 
Tris.HCl 1M 10 ml 
Bacto Agar 15 g 
Table 2.11: List of equipment and instruments 
Equipment Detail Manufacturer 
Acrylamide gel Chamber NA Institute of Virology and Immunobiology 
Agarose gel chamber N/A Institute of Virology and Immunobiology 
Agarose gel electrophoresis unit N/A  
Institute of Virology and 
Immunobiology 
Analytical balance L 610-D  
Sartorius 
 
Analytical balance EW 3000-2M  
Kern 
 
Analytical balance AC210S MC 1  
Sartorius 
 
Bacterial shaker incubator Certomat®H  
B Braun 
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Biofuge Fresco 75005500  
Heraeus (Hanau) 
 
Blotting apparatus N/A  
Institute of Virology and 
Immunobiology 
 Cell counter 
 
Neubauer-improved 
 
Superior Marienfeld 
 
Cell sorter 
 
FACS Aria III 
 
Becton Dickinson  
 
Centrifuge 
 
Rotana 460R 
 
Hettich 
 
Confocal Microscope LSM 780 (Zeiss)  Zeiss 
Deep freezer -80°C NA Revco 
Flow cytometer FACScan Calibur Becton Dickinson  
Flow cytometer FACS LSR II Becton Dickinson  
Fluorescence Inverted Microscope Leica DMi8 Leica 
Fluorescence Inverted Microscope DMIRE2 Leica 
Ice machine AF30 Scotsman  
Incubator (Bacterial) B 60 30 Heraeus (hanau) 
Incubator (cell culture) HERACELL 240i Thermo Scientific 
Inverted Light Microscope 090-135-002 Leica 
Magnetic stirrer NA Ikamag RCT 
Microtitre pipettes Eppendorf Research® Eppendorf 
Microwave NA Panasonic 
Milifuge CT10 Millipore 
Nucleofector™ 2d device Amaxa 
pH meter Five Easy Mettler-Toledo 
Photometer BioPhotometer 6131 Eppendorf 
Pipette aid Accu Jet® Pro Brand 
Power supply (Agarose gel) E455 Consort 
Power supply (PAGE) EV243 Peqlab 
Real-time Thermal cycler LightCycler 2.0 real time PCR system Roche 
Refrigerator -20°C Sikafrost Comfort Siemens 
Refrigerator 4°C Sikafrost Comfort Siemens 
Rocker WS5 Edmund Bühler  
Safety cabinet/Laminar flow BSB 4A, Gelaire 
Sequencing apparatus ABI PRISM®310 Gennetic Analyzer Advanced Biolab Service 
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2.11.     Lab consumables 
Spectrophotometer Nanodrop Thermo Scientific 
Thermal block NA Liebisch 
Thermal block Thermostat 5320 Eppendorf 
Thermal Cycler Eppendorf Gradient Cycler Eppendorf 
Ultracentrifuge Sorvall® Discovery ™90SE Hitachi 
UV illuminator Gel Jet Imager Intas 
Vortex VTX-3000L A. Hartenstein 
Water-bath NA Superior Marienfeld 
Table 2.12: List of lab consumables and their source 
Article Article number Manufacturer 
12 well plate 665180 Greiner 
24 well plate 662160 Greiner 
48 well plate MU48 Greiner 
6 well plate 657160 Greiner 
Cell culture flask 550 ml 660160 Greiner 
Cell culture flask 250 ml with filter 658175 Greiner 
Cell culture flask 50 ml with filter 690175 Greiner 
Cell culture chamber slides 8 well OTC8 Hartenstein 
Cell culture dish 10cm GK03 Nunc 
Cell scraper ZS23 Hartenstein 
Centrifuge tubes 15 ml 188271 Greiner 
Centrifuge tubes 50 ml 227261 Greiner 
Cryo-vial 122277 Greiner 
Cuvettes Q-vettes Macro Ratiolab 
Dispenser tips 12.5 ml TD10 Hartenstein 
Electroporation Cuvettes 2mm 732-1136 VWR 
Eppis Safe lock 1.5 ml 296920086 Eppendorf 
FACS tubes (Falcon BD) FALC352052 Falcon 
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2.12.     Chemicals 
Corning™ Falcon™ Test Tube with Cell 
Strainer Snap Cap 
 
 352235 
 Corning™ 
Histopaqueâ 1077 10771 Sigma 
Filter tips NA Hartenstein 
Flat filter paper FF09 Hartenstein 
Gel blotting paper Whatman® 3MM Whatman 
Glass pipettes NA Institute of Virology and Immunobiology 
Mr. Frosty ™ Freezer 5100-0001 Thermofisher 
Nitrocellulose transfer membrane Amersham™ Protran™ 0.2 µm NC 10600001 GE healthcare 
Parafilm 701605 Parafilm 
PCR tubes RT08 PCR tubes 
Petri dish GBO (For Bacteria) 633180 Greiner 
Pipette tips Kristall (0.5-10µl) long 9260.1 Roth 
Pipette tips Yellow (1-200µl) 8156.1 Roth 
Pipettes tips Blue (100-1000µl) 732032 Brand 
Pipettes tips mikro (0.1-10µl) short K138.1 Roth 
Plastic pipettes 10 ml 607180 Greiner 
Plastic pipettes 5 ml 606180 Greiner 
Rnase-ExitusPlus™ A7153 Applichem 
Stepper HandyStep® Brand 
Sterile filter 0.22µM FI02 Sartorius 
Sterile filter 0.45 µM FI04 Sartorius 
UV microcuvettes KUVD Plastibrand® 
Table 2.13: List of chemicals 
Article Manufacturer 
Acetic acid AppliChem 
Acrylamide AppliChem 
Agarose AppliChem 
Albumin Bovine Fraction V SERVA 
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Aminohexanoic acid Sigma-Aldrich 
Ammonium persulfate AppliChem 
Ampicillin AppliChem 
Antibiotic Mix (penicillin and streptomycin) Institute of Virology and Immunobiology 
Acetic acid AppliChem 
ATV Institute of Virology and Immunobiology 
BCA (Bicinchoninic Acid) Sigma-Aldrich 
Beta-Mercaptoethanol Sigma-Aldrich 
Bromophenol blue AppliChem 
BSA AppliChem 
CaCl2 AppliChem 
CuSO4 solution Sigma-Aldrich 
DAPI Invitrogen 
Di-Sodium EDTA AppliChem 
Distilled water Institute of Virology and Immunobiology 
DMSO AppliChem 
DTT Sigma-Aldrich 
EDTA AppliChem 
Ethanol AppliChem 
Electroporation Solution Ingenio (MIR 50114) 
Fluoromount-G® Southern Biotech 
Gel red (10000X) Biotium 
Glycerin AppliChem 
Glycin AppliChem 
HCl AppliChem 
HEPES Roth 
HPLC water AppliChem 
Isopropanol AppliChem 
KCl AppliChem 
KH2PO4 AppliChem 
LE agarose Biozym 
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MgCl2 Applichem 
Methanol   AppliChem 
MOPS  
NaCl AppliChem 
NaF Ferak 
NaHPO4 AppliChem 
NaOH AppliChem 
Non-fat dry milk powder Sigma-Aldrich 
NP40 Sigma-Aldrich 
Paraformaldehyde Merck 
PEI Polyscience 
Phosphatase inhibitor cocktail Sigma-Aldrich 
Phytohemagglutinin (PHA-L) Roche 
Potassium acetate Applichem 
Propidium Iodide Biolegend 
Protease inhibitor cocktail  Sigma-Aldrich 
Puromycin AppliChem 
RIPA buffer Sigma-Aldrich 
RNase free water peqGOLD 
Rubidium Chloride Sigma Aldrich 
Rapamycin Sigma Aldrich 
Saccharose AppliChem 
SDS AppliChem 
Sodium azide AppliChem 
Sodium chloride AppliChem 
Sodium deoxycholate AppliChem 
TEMED Sigma-Aldrich 
Tris AppliChem 
Triton® X100 Sigma-Aldrich 
Trypan blue AppliChem 
Trypton Becton Dicknson 
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2.13.     Solutions and Reagents 
2.13.1. For Molecular Biology methods 
Oligo annealing Buffer   DNA loading Buffer   
0.5M EDTA 1 mM  Bromophenol Blue 0.03% (v/v) 
1M Tris.Cl pH 7.5 10 mM  Glycerol 60% (v/v) 
1M NaCl 0.1 M  Na2EDTA 60 mM 
Dissolve in DPEC H2O    Tris-HCl pH 8 10 mM 
   Xylen cyanol 0.03 % (v/v) 
   Dissolve in DPEC H2O pH 7.6  
     
Tris-Acetate-EDTA (TAE) buffer   PBS-T  
Tris Ultrapure base 24.2 % (w/v)  PBS 1 litre 
Acetic acid 5.71 % (v/v)  Tween 20 0.05% 
EDTA 0.5M pH 8.0 10 % (v/v)    
Dissolve in dH2O pH 8.5     
     
TE Buffer   Agarose gel (1%)  
EDTA pH 8 1 mM  TAE buffer 100 ml 
HCl 10 mM  LE Agarose 1% (w/v) 
Dissolve in dH2O pH 8   Gel red 0.005% (v/v) 
     
Transformation Buffer (TFB) I   Transformation Buffer (TFB) II  
Calcium Chloride 10 mM  MOPS 10 mM 
Glycerol 15% (v/v)  Rubidium Chloride 10 mM 
Potassium Acetate  30 mM  CaCl2 75 mM 
Rubidium Chloride 100 mM  Glycerol 15% (v/v) 
Manganese Chloride 50 mM  Adjust pH to 6.5 with KOH. Filter sterilizes before use.  
Adjust pH to 5.8 with 1M acetic acid. Filter sterilizes 
before use.    
Tween® 20 Sigma-Aldrich 
Xylene cyanol Ferak 
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Cathode buffer   Anode buffer 300 mM  
Tris base 0.025 M  Tris base 0.3 M 
Methanol 20% (v/v)  Methanol  20% (v/v) 
Hexanoic acid 0.04 M  Dissolve in dH2O, pH 10.4  
Dissolve in dH2O, pH 9.4     
     
Anode buffer 30 mM   Protein gel buffer 10X  
Tris base 0.025 M  Glycin 1.44 % (w/v) 
Methanol  20% (v/v)  Tris base 0.303% (w/v) 
Dissolve in dH2O, pH 10.4   SDS 0.1% (w/v) 
   Dissolve in dH2O pH 6.8  
     
Stripping buffer   Blocking buffer for NC membrane 
Tris. HCl, pH 6.8 90 ml  Non-fat dry milk powder 5% 
20% SDS 10 ml  Tween 20 0.05% 
Beta-Mercaptoethanol 700 µl  Dissolve in dH2O, Total volume 100 ml 
Dissolve in dH2O, Total volume 100 ml    
     
IP lysis buffer   Laemmli buffer  
Tris HCl pH 7.5 50mM  SDS 10% 
NaCl 150 mM  Tris.HCl pH 8.0 250 mM 
NaF 50 mM  Glycerol 50% 
EDTA 2 mM  Dithiothreitol (DTT) 500 mM 
Sodium deoxycholate 0.5%  Bromophenol Blue (BPB) 0.25% 
Nonodent-P40 (NP 40) 1%  Dissolve in dH2O  
Protease Inhibitor 1%    
Tris HCl pH 7.5 50mM    
Dissolve in dH2O     
     
Resolving SDS gel   Stacking SDS gel  
1.5 M Tris.Cl pH 8.7 37.5% (v/v)  1.5 M Tris.Cl pH 6.7 12.4% (v/v) 
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4K Bisacrylamid 30% (v/v)  4K Bisacrylamid 12.4% (v/v) 
Ammonium per sulphate (APS)  0.2% (v/v)  Ammonium per sulphate (APS)  0.2% (v/v) 
Sodium dodecyl sulphate (SDS)  1% (w/v)  Sodium dodecyl sulphate (SDS)  1% (w/v) 
TEMED 0.25% (v/v)  TEMED 0.25% (v/v) 
dH2O 22.25%(v/v)  dH2O 74.95%(v/v) 
     
PBS   IP lysis buffer  
CaCl2 1.5 mM  Tris-HCl pH 7.5 50mM 
KCl 2.7 mM  NaCl 150 mM 
KH2PO4 1.4 mM  NaF 50mM 
MgCl2 1 mM  EDTA 2mM 
NaCl 137 mM  Sodium deoxycholate 0.5% 
NaHPO4.7H2O 4.3 mM  Nonodent-P40 1% 
Dissolve in dH2O pH 7.4   Dissolve in dH2O pH 7.4  
 
=
=
2.13.2. For Immunological methods 
Permeabilization buffer   Fixation buffer  
Triton X-100 0.1% (v/v)  Paraformaldehyde 4% (v/v) 
Dissolve in PBS   Dissolve in PBS  
     
FACS buffer   PBS-T  
BSA 0.4% (w/v)  Tween 20 0.05% (v/v) 
Sodium azide 0.02% (w/v)  Dissolve in PBS  
Dissolve in PBS     
 
   
 
=
=
=
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2.13.3.  For Virological methods 
 
 
 
 
 
 
2.13.4. For Cell biological methods 
 
 
 
 
 
 
 
 
 	
=
===
2.14. Commercial Kits 
Table 2.14: List of equipment and instruments 
Name Detail Source 
cDNA synthesis kit RevertAid™ First-strand cDNA synthesis Kit Fermentas 
Gel extraction kit QIAquick® Gel Extraction Kit Qiagen 
Plasmid Miniprep QIAGEN Plasmid Mini Kit Qiagen 
Plasmid Maxiprep QIAGEN Plasmid Maxi Kit Qiagen 
DNA purification QIAquick PCR Purification Kit Qiagen 
DNA sequencing BigDye® Terminator v3.1 Cycle Sequencing Kit LifeTechnologies 
RNA Isolation GenElute™ Mammalian Total RNA Miniprep Kit Sigma-Aldrich 
25% Saccharose solution 
Sucrose 25% 
Dissolve in NTE buffer 
 
10 X NTE buffer 
Tris.HCl 0.1 M 
NaCl 1 M  
EDTA 0.01 M 
Dissolve in dH2O, pH 7.4 
ATV 
D-Glucose 5 mM 
NaCl 137 mM 
Na2EDTA 200 mg/L 
NaHCO3 70 mM 
KCl 5.4 mM 
Trypsin 500 mg/L 
Dissolve in dH2O   
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NC membrane development Chemiluminescent Femtomax™ Supersensitive HRP substrate Rockland  
Mycoplasma detection kit Venor®GeM Classic Mycoplasma Detection Kit Minerva Biolabs 
 
 
2.15. Software 
Table 2.14: List of software and programmes 
Name Source 
Flow cytometry analysis FlowJo Version 7.6 (Tree Star, USA) 
Acquisition of western blot Image studio (LI-COR) 
Quantification of western blots ImageJ (NIH, USA) 
Statistical analysis of data GraphPad Prism 6 (USA), Microsoft Excel (2013) 
Sequence analysis  Snapgene (GSL Biotech) 
siRNA sequences Block-iT RNAi designer (Invitrogen) 
Primer designing Primer Blast (NCBI) 
Literature management EndNote X8 
Co-localization analysis Zen 2012  
Electroporation Amaxa NucleofectorÒ Device AAD-1001 
 
 
  
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
                   METHODS 
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3. Methods 
3.1. Cell and Microbiological methods 
3.1.1. Cultivation of adherent cell lines 
Vero, HEK 293T, Hep 2 and other transduced cells are cultured and 
maintained in MEM with 10% FCS and antibiotic mix in sterile condition in CO2 
cell culture incubator at 37°C. 
Adherent cells are propagated by trypsinization with ATV to detach cells 
and washed with fresh media before passaging. Cells were passaged every 3-4 
days. 
For seeding cells in 6/12/24/48 well plates, cells were trypsinized and re-
suspended in media. The numbers of viable cells were determined by diluting cells 
in trypan blue and counting live cells in a Neubauer chamber. Cell density was 
determined using the following formula, 
Cell density (cells/ml) = average cell count x dilution factor x 104 
Following cell densities were used, 
Table 3.1: Cell seeding density used for different cell culture vessels 
Cell culture vessel Seeding density (cells/well) 
6 well plate 2 x 105 
12 well plate 1 x 105 
24 well plate 5 x 104 
48 well plate 1 x 104 
100 mm dish 8 x 106 
	
3.1.2. Cultivation of suspension cell lines 
CEM-SS cells and PBL were cultured and maintained in GIBCO®RPMI 
1640 with 10% FCS and antibiotic mix in sterile condition in CO2 cell culture 
incubator at 37°C unless otherwise specified. Suspension cells were propagated by 
centrifugation at 160 × g for 5 min at 20°C and then re-suspended in an appropriate 
volume of culture media. Cells were passaged every 3-4 days. 
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3.1.3. Revival and stock preparation of cell lines 
All adherent and suspension cells were revived from the frozen stock at -
140°C deep freezer. Cells were warmed quickly at 37°C and the cell suspension 
was transferred in a 50 ml falcon tube containing 30 ml of respective cold medium. 
Cells were then centrifuged at 160 × g for 5 min at 4°C. The supernatant was 
removed, and cells were re-suspended in fresh culture media. These cells were then 
transferred in appropriate tissue culture flask. 
Frozen stock of cells was prepared by harvesting cells in their logarithmic 
phase of growth. Briefly, cells were trypsinized and/or pelleted down by 
centrifugation at 160 × g for 5 min and re-suspended in the freezing mixture 
(MEM/RPMI + 10% FCS+10% DMSO). Cells were stored overnight in Mr. Frosty™ 
freezer at -80°C and then transferred in -140°C deep freezer. 
 
3.1.4. Preparation of competent bacterial cells 
A single colony of bacterial cells was inoculated into starter culture of 20 ml 
LB medium and incubated overnight in 37°C shaker at 220 rpm. 5 ml of this starter 
culture was inoculated in 500 ml of LB medium. Cells were incubated in 37°C 
shaker at 220 rpm till OD 600 reaches to 0.4 to 0.6. From this stage onwards, all 
steps were carried out on ice. Bacterial growth culture was collected and 
centrifuged at 3000× g for 15 minutes at 4°C. 
The supernatant was carefully removed, and the bacterial pellet was re-
suspended in 150 ml of TFB I. Bacteria were then incubated on ice for 15 minutes 
followed by centrifugation at 3000× g for 15 minutes at 4°C. Pellet was re-
suspended in 20 ml of TFB II. Competent bacteria were then aliquoted in pre-
chilled Eppendorf caps (Epi) and stored at -80°C. 
 
3.1.5. Transformation of bacteria 
Plasmids and ligated clones were amplified using E.coli XL10-Gold® 
ultracompetent cells. 0.1 µg of desired plasmid or 5µl of the ligation reaction was 
added on 50 µl of bacteria in precooled 1.5 ml Epi. The cells and plasmid were 
mixed by gentle swirling. The mixture was incubated on ice for 30 minutes followed 
by heat shock in a water bath for 2 minutes at 42°C. Bacteria were cooled down on 
ice for 5 minutes. 950 µl of LB medium without antibiotic was added on the 
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bacterial cells and incubated on a shaker at 200 rpm at 37°C for 1 hr. 200 µl of this 
bacterial culture was then surface spread on LB agar plate containing 100 µg/ml 
of Ampicillin or 30 µg/ml of Kanamycin. Plates were incubated at 37°C bacterial 
incubator for 24-48 hrs. Colonies were selected and further inoculated in LB 
medium for Miniprep plasmid isolation. 
 
3.1.6. Glycerol stock of transformed bacterial culture 
The stock of the selected transformed bacterial cells from a single colony was 
prepared in Glycerol. Briefly, 850 µl of bacterial culture was mixed gently with 
150µl of sterile Glycerol. The mix was then transferred in screw-capped epis and 
stored at -80°C. 
 
3.1.7. Transient transfection of cells 
For the transient expression of the desired plasmid in mammalian cells, PEI 
(1µg/µl) was used. For transfection, HEK 293T cells were seeded in 6 well plate at 
the density of 10 x 105 cells per well. Cells were incubated in cell culture incubator 
at 37°C for 24 hrs. 6-8 hrs prior to transfection the media was replaced with MEM 
10% FCS without antibiotic. Two separate mixtures were prepared in separate 
tubes. Mixture A: PEI + NaCl 100 µl (vortex for 1 min) and Mixture B: Plasmids + 
NaCl 100 µl (for 1 µg of total DNA add 3µl of PEI). Mixture A was added in Mixture 
B and mixed by gentle pipetting. The tubes were then incubated at room-
temperature for 30 minutes to build DNA-PEI complex and then distributed 
dropwise on the cells and incubated at 37°C. The medium was replaced after 6 hrs 
of transfection and cells were incubated further for 24-48 hrs for subsequent 
experiments. 
 
3.1.8. Generation of pseudo-typed Lentiviruses for stable transfection 
Long-term over expression or silencing of the target gene in mammalian 
cells was achieved using Lentiviral vector delivery method.  We used 3rd generation 
packaging plasmids for production of Lentiviruses [253].  
HEK 293T cells were seeded in 100 mm tissue culture dish at the density of 
5 x 106 cells per dish. Cells were incubated in cell culture incubator for 24 hrs. 6-8 
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hrs prior to transfection the medium was replaced with MEM + 10%FCS without 
antibiotic. The transfection mixture was prepared as shown in Table 3.2. 
=
Table 3.2: Amount of 3rd generation packaging plasmids and PEI used to generate pseudo-typed 
Lentivirus particles. 
Vector Amount Size (kb) 
 100 mm dish 6 well plate   
Mix I:      
    pMDLg/RRE 5 µg 0.8 µg 8.8 HIV-1 gag/pol 
    pRSV/REV 2.5 µg 0.4 µg 4.2 HIV-1 rev 
    pVSV-G 2.5 µg 0.4 µg 4.8 VSV glycoprotein 
Transfer vector 10 µg 1.5 µg 8-12  
NaCl 200 µl 100 µl   
Mix II:     
PEI (1mg/ml) 60 µl 10 µl   
NaCl (150 mM) 200 µl 100 µl   	
Two separate mixtures were prepared in separate tubes. Mixture A: PEI + 
NaCl (vortex for 1 min) and Mixture B: Plasmids + NaCl. Mixture A was added in 
Mixture B and mixed by gentle pipetting. The tubes were then incubated at room-
temperature for 30 minutes to build DNA-PEI complex and then distributed 
dropwise on the cells. The medium was replaced after 6-8 hrs of transfection and 
cells were incubated further for 30-48 hrs. The supernatant containing viral 
particles was harvested and used directly for transduction of mammalian cells or 
concentrated.  
For concentration of viral particles, the supernatant was transferred in 15 
ml Falcon and centrifuged at 160 × g  for 5 minutes at 4°C.  The viral supernatant 
was transferred in another falcon containing cold PEG-it (1 volume of PEG-it for 4 
volumes of supernatant) and mixed by gently inverting tubes 4-5 times. The tubes 
were incubated overnight or at least 12 hrs at 4°C. After incubation, the tubes were 
centrifuged at 1500 × g for 30 minutes at 4°C. the supernatant was discarded and 
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the pellet was re-suspended in 1/100th of the original volume of sterile cold PBS. 
Aliquots were pipetted in cryo-vials and stored at -80°C till further use. 
 
3.1.9. Transduction of cells  
Target cells for transduction were seeded in 48 well plate at the density of 4 
x 104 cells per well and incubated in cell culture incubator at 37°C for 24 hrs. Cell 
culture media were removed and cell monolayers were washed once with serum- 
free MEM. Lentiviral supernatants or concentrated virus (MOI: 2-3) were then 
added on the cells. To increase the efficiency of transduction and obtain maximum 
expression of target genes, the plates were centrifuged at 400 x g for 2 hrs at 37°C 
and then incubated at 37°C for 48 hrs. Transduced cells were propagated for 3-4 
days to achieve sufficient confluency.  These cells were sorted by expression of 
DsRed2 or transduced again to achieve more than 95% transduction efficiency. 
 
3.1.10. Cell sorting 
To achieve the maximum expression of shRNA, cells were sorted in BD 
FACS Aria III based on the DsRed2 fluorescence. Adherent cells were trypsinized 
with ATV and washed. Cells were centrifuged at 160 × g for 5 min at 18°C and re-
suspended in 500 µl of the medium. Cells were then passed through cell strainer 
tube to prepare a single cell suspension. Cells were then sorted based on the 
DsRed2 expression. After sorting cells were washed twice and re-suspended in 2 
ml of respective media containing double the concentration of antibiotics as in the 
normal medium. Cells were then transferred into 6 well plates and observed daily 
for confluency.  
 
3.1.11. Cell proliferation assay 
3 x 105 adherent or suspension cells were seeded in 6 or 24 well plates 
respectively. These cells were serum starved overnight. Cells were washed twice 
with cold BSS w/o BSA to remove any traces of growth factors.  5 µM of eFluor670 
was prepared in BSS w/o BSA and added on the cells with gentle agitation every 5 
min during the incubation for 15 min at 37°C. Cells were then washed three times 
with BSS + BSA and further incubated in medium containing serum. 24, 48 and 
72 hr later, cells were collected in FACS tubes. Cells were washed once with FACS 
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buffer and fixed with 4% paraformaldehyde for 20 minutes at 4°C and washed 
again with FACS buffer. Cells were then acquired in APC channel of FACS LSRII. 
The percentage of proliferated cells was calculated based on the efluor670 signal 
at each time point. 
 
3.1.12. Cell viability by Propidium Iodide staining 
The viability of cells upon treatment with Rapamycin was determined by 
staining Rapamycin treated cells with Propidium Iodide (PI). 3 x 105 adherent or 
suspension cells were seeded in 6 or 24 well plates respectively. These cells were 
treated with increasing concentration of Rapamycin (100, 200, 400, 800, 1000, 2000 
nm), and 100 % DMSO treated cells were used as positive control (dead cells), and 
untreated cells were used as negative control for PI staining. 48 hrs after 
Rapamycin treatment cells were collected in FACS tubes. All the subsequent steps 
were carried out on ice. Cells were stained with 2.5 µl of PI per tube and incubated 
in the dark for 15 minutes. Samples were then acquired immediately in FL-3 
channel of FACSCalibur. The percentage of PI-positive cells (dead cells) was 
determined and the percentage of viable cells was calculated. 
 
3.1.13. Isolation of Peripheral Blood Lymphocytes (PBL) 
																															 																					 	
Figure 3.1: Schematic figure of Histopaque density gradient centrifugation. (A) Layers of blood and 
Histopaque before centrifugation (B) layers of blood cells after centrifugation 
 
PBL were obtained with permission of the ethics committee of the medical 
faculty from leukapheresis filter devices from the department of transfusion 
(A) (B) 
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medicine of the Universitätsklinikum Würzburg, kindly provided by Lab group of 
Dr. Sibylle Schneider-Schaulies. Briefly, peripheral blood mononuclear cells 
(PBMC) were isolated from fresh blood samples collected from healthy donors by 
the following procedure: 25 ml of heparinized blood was carefully layered on 9 ml 
of Histopaque in a 50 ml falcon tube and centrifuged at 160 × g without any brakes 
for 30 minutes at 20°C. the upper layer (Figure 3.1) containing serum and platelets 
was removed carefully and discarded. The buffy coat containing PBMC was 
carefully removed and transferred in a 50 ml falcon tube. Cells were then washed 
with sterile PBS thrice by centrifugation at 280 × g for 5 minutes at RT. Cells were 
then re-suspended in 25 ml of RPMI with 10% FCS, plated on 175 cm2 flask and 
incubated for 2 hrs at 37°C. Non-adherent cells (PBL) were separated and counted 
before using. 
 
3.1.14. Stimulation of PBL  
To measure the response from isolated PBL, they were stimulated with 
PHA, IL-2 and IFN-a. For analysing differential gene regulation in stimulated 
PBL, 1x107 PBL in 3 ml per well were seeded in 12-well plates in RPMI with 10% 
FCS. Stimulation was done by 2.5µg/ml of PHA, 25ng/ml of Proleukine (human IL-
2) and 105 units/ml of IFN-a either individually or in combination. 48 hrs post 
stimulation cells were lysed for western blot analysis.  
For stimulation of PBL after electroporation of siRNA (in 3.2.6.1) the same 
concentrations of PHA and IL-2 were used.  
 
3.2. Molecular biology methods 
3.2.1. Gene cloning 
3.2.1.1. Restriction digestion of Vector plasmids and inserts 
Desired DNA fragments from plasmids for cloning were prepared by 
restriction digestion. These enzymes recognize specific palindromic sequences of 6-
8 bases. The selection of enzymes is done on the basis of the desired insert and 
vector size. All the enzymes used were from Thermo Scientific. The following 
digestion reaction was set up for Vector and insert. The digested products were 
analysed on agarose gel for verifying the size of the digested product. 
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Table 3.3: Restriction digestion reaction of F6gW-dsRed2 plasmid to generate Vector for shRNA cloning 
 
 Reagent For gel extraction 
Plasmid  15 µg 
XhoI 5 µl 
KspAI 5 µl 
10x Buffer G 10 µl 
Total volume 100 µl 
Make desired total volume using DPEC H2O 
 
 
Table 3.4: Restriction digestion reaction of F6gW-dsRed2 plasmid and KDELR2/REDD1 cDNA clone to 
generate Vector and insert fragment 
 
Reagent For analysis  Reagent For gel extraction 
Plasmid  1µg  cDNA clone  15 µg 
EcoRI 1 µl  EcoRI 5 µl 
BamHI 1 µl  BamHI 5 µl 
10x Buffer R 2 µl  10x Buffer R 10 µl 
Total volume 25 µl  Total volume 100 µl 
Make desired total volume using DPEC H2O 
 
3.2.1.2. Gel extraction of nucleic acid 
Required DNA fragments were purified from Agarose gel using QIAquick® 
Gel Extraction Kit according to Manufacturer’s instructions. The DNA was eluted 
in 50µl of elution buffer. 
 
3.2.1.3. De-phosphorylation of Vector 
The linearized and purified vectors were de-phosphorylated. De-phosphorylation 
prevents re-ligation of linearized vectors thus prevents background activity during 
cloning. The following De-phosphorylation reaction was according to the 
manufacturer’s protocol (Table 3.5). The reaction was then incubated for 1 hr at 
37°C for de-phosphorylation and 10 min at 72°C to inactivate the enzyme. 
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Table 3.5: De-phosphorylation of linearized F6gW-dsRed2 plasmid 
Reagent Volume 
Plasmid gel purified 2 µg 
Calf Intestine alkaline phosphatase (1U/µL) 2 µl 
10X buffer R 5 µl 
Total volume 50 µl  
Make desired total volume using DPEC H2O 
 
 
3.2.1.4. Generation of ds DNA-oligos encoding shRNAs 
Single-stranded forward and reverse oligonucleotide sequences were 
designed to silence the desired gene. In order to clone shRNA-expressing vectors, 
ds DNA-oligos were annealed. The synthesized ss DNA-oligos were dissolved in 
oligo annealing buffer in stock concentrations of 100µM. Equal amounts of forward 
and reverse oligos were mixed together to achieve a final concentration of 50µM. 
The mixture was then heated in a thermal cycler for 5 minutes at 95°C and 
incubated 5 min at room temperature for cooling. The ds DNA-oligos were stored 
at -20°C. 
 
3.2.1.5. Phosphorylation of Inserts 
The ds DNA-oligos generated by annealing of single-stranded 
oligonucleotides do not contain 5’ phosphate groups. For ligation, it is a pre-
requisite to have 5’ phosphate groups at least at one end of the insert. The target 
gene fragments obtained from cDNA clones already have 5’ phosphate groups. 
Therefore, it is not necessary to phosphorylate the inserts obtained from restriction 
digestion. However, PCR products and oligos will not have 5’ phosphate moieties. 
Hence, it is required to phosphorylate the ds DNA-oligos using T4 polynucleotide 
kinase. The reaction was incubated at 37°C for 20 minutes for phosphorylation and 
72°C for 10 minutes for inactivation of the enzyme. 
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Table 3.6: phosphorylation of shRNA 
Reagent Volume 
ds Oligo (50µM) 15 µl 
T4 polynucleotide kinase (10U/µL) 2 µl 
T4 ligase buffer 4 µl 
Total volume 60 µl 
 
3.2.1.6. Ligation 
The two fragments of the digested vector and the insert were joined together 
by a ligation reaction. DNA ligases catalyse the formation of a phosphodiester bond 
between the 3’-OH end of one fragment and the 5’-phosphate group of another 
fragment. Digestion of F6gW-dsRed and cDNA clone with EcoRI and BamHI 
resulted in sticky ends (3.2.1.1) and prevented relegation of vectors and also insert 
fragments in a directional manner. The ligation thus results in a circular plasmid 
containing the target sequence. The following formula was used to calculate the ng 
of insert required in the ligation reaction.   
= =ng	of	insert	required	 = ng	of	Vector	 × 	kb	size	of	Insertkb	size	of	vector	 	×	 InsertVector 	
Two different amounts of vectors were used, 50 ng and 100 ng, and two 
different inserts to vector ratios, 3:1 and 5:1, were used. The ligation reaction was 
incubated overnight at RT.  
The ligation mixture was then used for transformation of bacteria (3.1.5). 
 
Table 3.7: Ligation reaction 
Reagent volume 
Linear vector DNA 50 ng/100 ng 
Insert DNA As per above calculations 
10 X T4 DNA ligase buffer 2 µl 
T4 DNA ligase (5 U/µl) 1 µl 
Total volume 20 µl 
Make desired total volume using DPEC H2O 
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3.2.1.7. Colony PCR 
In order to confirm if the desired fragment is correctly inserted in the vector, 
a colony PCR was done using bacterial colonies. The antibiotic-resistant colonies 
obtained on the LB agar (3.1.5) plate were picked up and dissolved in 20µl of DPEC 
water. The PCR reaction was set up as follows in a total volume of 25µl in a 
Thermal cycler. The amplified product was then analysed on agarose gel. 
Table 3.8: Colony PCR 
Reagent Volume 
PuRe Taq Ready-to-Go PCR bead 1 bead 
Forward Primer 10µM 1 µl 
Reverse Primer 10µM 1 µl 
Dissolved colony 2 µl 
HPLC water 21 µl 
 
 
 
3.2.1.8. Plasmid isolation - Miniprep method 
Colonies with desired plasmids were used for Miniprep. 10µl of colony 
suspension or bacterial colony from the LB agar plate was inoculated in 5 ml of LB 
medium with 100µg/ml of Ampicillin. The culture was then grown in a bacterial 
shaker at 220 rpm overnight at 37°C. 
PCR conditions 
94°C 2 min  
59°C 1 min  
72°C 1 min  
94°C 30 secs 35 cycles 
59°C 1 min 
72°C 1 min 
72°C 7 min  
4°C hold  
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Plasmid Miniprep isolation was done using “QIAGEN Plasmid Mini Kit” 
according to manufactures instruction. Plasmids were eluted in 50 µl of TE buffer.  
 
3.2.1.9. Plasmid isolation - Maxiprep method 
Colonies with the correct sequence were inoculated for Maxiprep. 10 µl of 
the bacterial colony was inoculated in 5 ml of LB medium with 100 µg/ml of 
Ampicillin and incubated in a bacterial shaker at 220 rpm for 4-5 hrs at 37°C. This 
5 ml of bacterial culture was then inoculated in 100 ml of LB medium with 
100µg/ml of Ampicillin and flasks were incubated in a bacterial shaker at 220 rpm 
for 4-5 hrs at 37°. 
Plasmid isolation was done using “QIAGEN Plasmid Maxi Kit” according to 
manufactures instruction. The plasmid pellet was then suspended in TE buffer and 
diluted with DPEC H2O at the final concentration of 1µg/µl and stored at -20°C. 
 
3.2.1.10. Sequencing of DNA 
The sequence of the desired insert in the isolated plasmid was confirmed by 
sequencing. The sequencing was performed using “BigDye® Terminator v3.1 cycle 
sequencing kit” from Life Technologies (USA) in a thermal cycler. The following 
reaction was set up for sequencing: 
Table 3.9: Sequencing reaction 
Reagent Volume 
Big Dye 3.1 DNA polymerase 1 µl 
5x BDT Buffer 1 µl 
Primer F or R (5 pmol/µl) 1 µl 
Sample DNA (500 ng) 2 µl 
Total volume 5 µl 
 
The amplified product was then sequenced kindly by the Diagnostic 
department of the Institute of Virology and Immunobiology (Würzburg) in an "ABI 
PRISM® 310 Genetic Analyzer" Company Advance Biolab Service (Munich). The 
generated sequence was then analysed and confirmed using Lasergene software. 
 
Amplification conditions 
 96˚C 30 secs 
25 
cycles 
50˚C 15 secs 
60˚C 4 min 
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3.2.2. PCRs 
The PCR amplification was carried out using “illustra PuReTaq Ready-To-Go PCR 
Beads” in a thermal cycler. The following PCR reaction was pipetted in a total 
volume of 25µl. 
Table 3.10: PCR reaction     
Reagent Volume  PCR condition 
PuRe Taq Ready-to-Go PCR bead 1 bead  95°C 5 min  
Forward Primer 10µM 1 µl  95°C 1 min  
Reverse Primer 10µM 1 µl  68°C 1 min 
25 
cycles 
Template DNA (1µg) 2 µl  72°C 1 min  
HPLC water 21 µl  72°C 10 min  
   4°C Hold  
 
3.2.3. RNA isolation 
Two different methods were used for RNA isolation. 
 
3.2.3.1. TRIzol 
 For RNA isolation using TRIzol method, cells were trypsinised and washed 
once with cold PBS. 1 x 106 cells were centrifuged at 160 × g for 5 min at 4°C. The 
cell pellet was re-suspended in 1 ml TRIzol and transferred in Eppendorf cap. The 
mixture was then incubated at RT for 5 min. 200 µl of chloroform was then added 
and mixed for 15 secs followed by incubation at RT for 3 min.  The lysate was then 
centrifuged at 13000 rpm for 15 min at 4°C in a biofuge. The water phase was then 
carefully transferred into a new Eppendorf cap. Lysates were again treated with 
chloroform similarly to remove traces of TRIzol. 500 µl isopropanol was added to 
the water phase and mixed carefully. The mixture was incubated for 10 minutes 
at RT and then centrifuged at 13000 rpm for 10 min at 4°C. The supernatant was 
discarded and pelleted RNA was washed with 75% ethanol. RNA was centrifuged 
at 10000 rpm for 5 min at 4°C. Ethanol was carefully removed and the pellet was 
air dried for 5 min at RT (avoid over drying of pellet). RNA was then re-suspended 
in 50µl of DPEC H2O and incubated for 10 min at 55°C on a heating block to obtain 
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a better solubility of the RNA. The RNA was once freeze-thawed at -20°C before 
quantifying with Nano drop. 
 
3.2.3.2. GeneElute Mammalian Total RNA Miniprep Kit 
 Alternatively, the total cellular RNA was extracted using the GeneElute 
Mammalian Total RNA kit according to manufacturer’s instruction and eluted in 
50 µl of elution buffer. The RNA was aliquoted in small volumes and stored at -
80°C. 
 
3.2.4. Semi-quantitative PCR 
 For semi-quantitative PCR, four different amounts of RNA (4, 2, 1, 0.5 µg) 
were reverse transcribed. The following reaction was setup in a Thermal cycler for 
generating first strand cDNA in a total volume of 20µl. The cDNA was aliquoted 
and stored at -20°C till further use. The cDNA was then amplified using gene- 
specific primers (Table 2.4). The number of PCR cycles (25) was kept constant for 
all semi-quantitative PCRs and equal amounts from each sample were loaded on 
agarose gels. 
Table 3.11: cDNA synthesis 
Reagent Volume 
Template RNA 300 ng 
Oligo (dT)12-18 primer (0.5 µg/ml) 1 µl 
dNTP (10mM) 2 µl 
M-MLV Reverse transcriptase (200U/µl) 1 µl 
5X reaction buffer 4 µl 
 
Table 3.12: Semi quantitative PCR	
Reagent Volume 
PuRe Taq Ready-to-Go PCR bead 1 bead 
Forward Primer 10µM 1 µl 
Reverse Primer 10µM 1 µl 
RT product  4 µl 
HPLC water 19 µl 
 
cDNA synthesis reaction 
70°C 5 min 
4°C 2 min 
42°C 2 min 
42°C 60 min 
70°C 10 min 
PCR conditions 
95°C 5 min  
95°C 1 min 
25 
cycles 
68°C 1 min 
72°C 1 min 
72°C 10 min  
4°C Hold  
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3.2.5. Quantitative RT-PCR 
Cellular RNA was isolated from 1 x 106 cells by TRIzol Ô(3.2.3.1). Isolated 
RNA was then reverse transcribed to generate cDNA (3.2.4). 
 
Table 3.13: qRT PCR	
Reagent Volume 
Template cDNA 2.5µl 
Forward primer 1 µl 
Reverse primer 1 µl 
2X SYBR-Green transcriptase (200U/µl) 5 µl 
DPEC water 0.5 µl 
 
 
 
 
 
 
 
 
 
 
 
 
Gene-specific primers were used to amplify the target genes. Real-Time 
PCRs were performed using “2x SYBR Green qPCR Master Mix” from Biomake. 
The amplification was done in a “LightCycler 2.0 real-time PCR system” from 
Roche in a total volume of 10µl.  
 
3.2.6. siRNA transfection 
3.2.6.1. In PBL 
Generally, viral vector-based gene delivery methods are utilized for the 
expression of shRNAs or genes. However, the use is limited by the time and 
potential safety issues in primary cells. In addition, human PBL are refractory to 
qRT-PCR reaction 
95°C 180 secs  
95°C 10 secs   45 
cycles 60°C 30 secs 
95°C 10 secs 
Melting 
curve 
60°C 60 secs 
95°C 1 sec 
37°C 30 secs Cooling 
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viral DNA/RNA delivery methods. Hence, electroporation is a fast and safe way of 
delivering target siRNA in stimulated/non-stimulated PBL. 
siRNA duplexes were directly purchased from Dharmacon (Table 2.6) and 
dissolved in DPEC water to achieve a stock concentration of 100 µM. A final siRNA 
concentration of 20 nM in 1 ml was used for transfection of 1x107 PBMCs. 
Briefly, the PBL were isolated from human blood as described (3.1.13). 
Before the electroporation, 12-well plates were filled with RPMI containing 10% 
FCS and incubated in cell culture incubator at 37°C. The required number of cells 
was centrifuged in a 15 ml falcon at 160 × g  for 5 minutes at RT. The supernatant 
was carefully removed. 100 µl of electroporation buffer was added to the cells and 
they were re-suspended by gentle pipetting, followed by addition of 20 nM/ml of 
siRNA dilution and mixed by gentle pipetting. The electroporation mix was then 
transferred in cuvettes and cells were electroporated in Amaxa NucleofectorÒ using 
program U14 for unstimulated cells and U20 for stimulated cells. Cells were then 
immediately transferred into 3 ml of pre-warmed medium and incubated for 48 
hrs. The electroporation procedure was repeated a second time and cells were now 
incubated for 24 hrs. 
Electroporated cells were then stimulated with PHA (2.5 µg/ml) or IL-2 (25 ng/ml) 
for 24 hrs.  To determine the percentage of stimulated cells, 10000 cells were taken 
in a FACS tube and washed once with FACS buffer. Cells were then stained for 
surface expression of PE-CD3 for detection of T cells and APC-CD69 for detection 
of the activation marker CD69 (3.3.1.1). To estimate the siRNA silencing efficiency 
cells were lysed in RIPA buffer (3.3.3). The protein lysates were then analysed by 
SDS-PAGE (3.3.5) and respective proteins were detected by western blot (3.3.6). 2 
x 106 cells were infected with rMVIC323eGFP at a MOI of 0.2. The virus was 
harvested 48 hr post infection by freezing and thawing the complete culture. The 
virus was titrated on Vero hSLAM cell (3.4.2). 
 
3.2.6.2. In Vero Cells 
 Same siRNA duplexes were used for transfection of Vero cells as 
mentioned in 3.2.6.1. Final siRNA concentration of 50 nM was used for transfection 
of Vero cells. Briefly, 1 x 106 Vero cells were seeded in 6-well plate. A mixture of 
siRNA and transfection reagent DF2 (Dharmacon) was prepared according to the 
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manufacturer’s instructions.  The mix was then incubated at room-temperature for 
20 min. The medium was then replaced by the siRNA mix and incubated for 24 
hrs. Cells were then infected with rMV eGFP at a MOI of 0.1 and incubated for 48 
hrs. The virus was harvested and titrated on Vero hSLAM cells (3.4.2). Remaining 
cells were lysed in RIPA buffer (3.3.3). The protein lysates were then analysed by 
SDS-PAGE (3.3.5) and respective proteins were detected by western blot (3.3.6). 
 
3.3. Immunological methods 
3.3.1. Flow Cytometry 
Flow cytometry analyzes individual cells in a single stream of fluid. Light 
scattered based on the size (Forward scatter), granularity (Side scatter) or light 
emitted from fluorescently labelled antibodies help to distinguish wide array of 
surface and intracellular molecules of the cell.  The measurement of optical and 
fluorescent characteristics allows quantitative and qualitative analyses of several 
cell properties simultaneously. 
All flow cytometric measurements were performed in BD LSR II or BD 
FACSCalibur. Experimental data was then analysed by FlowJo Version 7.6 
software. Cells were prepared depending on the experimental requirement. All 
washing steps were done with cold FACS buffer by centrifugation at 200 × g for 5 
min at 4°C and supernatant was discarded. 
 
3.3.1.1. Surface expression of target molecules  
Adherent cells were first detached from flasks using ATV, whereas the 
required amounts of suspension cells were directly taken into FACS tubes. All 
subsequent steps were performed on ice. 10000-50000 cells were taken into FACS 
tube and washed once with cold FACS buffer. Cells were then re-suspended in 100 
µl of appropriate primary antibody dilution and incubated at 4°C for 30 min to 1hr. 
Later, cells were washed once and stained with fluorescent labelled secondary 
antibody at 4°C for 30 min to 1 hr. Cells were then washed thrice with FACS buffer 
and acquired in LSR II. 
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3.3.1.2. Intra-cellular expression of target molecules 
To determine the intracellular expression of target molecules, cells were 
permeabilized to facilitate the entry of antibodies. 
10000-50000 cells were taken into FACS tubes and washed once with cold 
FACS buffer. Cells were then fixed at RT for 15 min with 100 µl of 4% PFA and 
washed once with FACS buffer. These fixed cells were then permeabilized with 100 
µl of 0.1% Triton X 100 at 4°C for 15 minutes and washed once with FACS buffer. 
Cells were then blocked with FACS buffer containing 10% FCS followed by 
antibody staining protocol (3.3.1.1). Cells were washed thrice with FACS buffer 
and acquired in LSR II. 
 
3.3.1.3. GFP/Ds-Red2 expression in infected/transduced cells 
For the infection experiments, eGFP expressing measles virus was used. 
Whereas, for expression of shRNA, fluorescent DsRed2 labelled plasmids were 
used. Therefore, the percentage of virus-infected, or shRNA transduced cells was 
determined by directly measuring the expression of eGFP or DsRed2 by FACS. 
Measles virus is known to form syncytia. This results in multinucleated giant cells 
which are difficult to analyse by FACS. Hence to facilitate single cell analysis of 
infected GFP positive cells, the fusion inhibitory peptide (FIP) was used. This 
peptide was added to the cells at the final concentration of 200µM 2hrs after the 
infection. This prevents subsequent fusion of cells and the spread of virus without 
affecting replication of the virus in single cells. 
For FACS analysis 10000-50000 cells were taken into FACS tubes and fixed 
with 100 µl of 4% PFA at RT for 20 min. Cells were then washed and acquired by 
a flow cytometer or stained with antibodies depending on the experiment (3.3.1.2) 
and then acquired. 
 
3.3.2. Immunofluorescence staining 
Immunofluorescence microscopy combines light microscopy with 
fluorescence allowing visualization of dynamic processes of cells.  
Briefly, 10000 cells were seeded in 8-well chamber slides and incubated 
overnight. Depending on the experiment, cells were infected with MV (Edmonston 
strain) with a MOI of 1, and 2 hrs post infection the viral inoculum was removed 
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and eventually replaced with medium containing 200 µM of FIP. Cells were 
incubated for different times (8, 16, 18, 24 hrs) and then fixed for microscopy.  
Cells were washed gently with cold PBS and fixed with 4% PFA for 20 min 
at RT. Cells were washed thrice and then permeabilized with 0.1% Triton X 100 
for 10 min at 4°C. Blocking of non-specific antigens was done with 10% BSA 
(albumin fraction V) at 4°C overnight. Next day, cells were washed thrice with cold 
PBS and stained with 1:100 dilution of primary antibody in PBS with 1% BSA at 
4°C overnight. After washing thrice with PBS, 1:400 dilution of secondary antibody 
in PBS with 1% BSA was added and incubated at RT for 1 hr. Nuclear staining 
was done by adding 300 nM of DAPI. Cells were finally washed with PBS and the 
chambers were removed from the slide. Slides were briefly dried before adding 200 
µl of Fluoromount-G and carefully a coverslip was placed on the slides. Samples 
were then analysed by Zeiss LSM 780 confocal microscope. 
 
3.3.3. Protein lysate preparation 
In order to analyse specific proteins from cells, SDS-PAGE and western 
blotting is used to separate and identify proteins. There are different methods of 
protein extraction and one of the method is lysis of cells using radio-
immunoprecipitation assay (RIPA) buffer.  
All the steps were carried out on ice. Adherent cells were detached from 
plates using ATV before lysis, whereas suspension cells were used directly for lysis 
preparation. Cells were washed twice with ice cold PBS to remove any traces of 
proteins from growth media. The cell pellets of 1 x 106 adherent cells and 1 x 107 
PBL were then re-suspended in 80-100 µl of RIPA buffer containing 1:100 dilution 
of protease inhibitor cocktail II and 1µM DTT.  The cells were lysed on a shaker 
for 1hr at 4°C. The lysates were clarified by centrifugation at 10000 rpm for 5 min 
at 4°C in a Biofuge. Supernatants were carefully removed and transferred in pre-
cooled Eppendorf caps. The protein concentration in these lysates was quantified 
using BCA (3.3.4) and samples were stored at -20°C till further use. 
For the detection of phosphorylated proteins cell lysates were prepared by a 
different method to avoid any loss or degradation of phospho-proteins. All the steps 
were carried out on ice. Cells were washed once with ice cold PBS and then directly 
lysed in 2X Laemmeli buffer. Samples were mixed in Laemmeli buffer and 
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incubated at -80°C for 1-2 hrs. Samples were then immediately boiled at 95°C for 
10 min. These samples were used for SDS-PAGE analysis or stored at -20°C till 
further use. 
 
3.3.4. Quantification of proteins by BCA 
To determine the effects of various experimental procedures on the 
expression of proteins, equal amounts of proteins are required to be loaded for 
separation. Either equal numbers of cells were lysed in equal amounts of lysis 
buffer and equal volumes were loaded on the gel, or the protein concentrations 
were determined using the BCA protein quantification method.  
Peptide bonds in proteins reduce Cu2+ ions from CuSO4. The highly alkaline 
solution of Bicinchoninic acid (BCA) chelates Cu+ ions to form a purple colour 
complex at higher temperatures (60°C). The intensity of the colour complex is 
directly proportional to the protein concentration of the sample. This purple 
complex is then quantified using absorbance at 562 nm in a photometer. 
To determine the protein concentration, 1ml of BCA was aliquoted in 
Eppendorf caps followed by addition of 20µl of CuSO4 and 5 µl of protein 
sample/DPEC H2O/standard. Solutions were mixed by gentle vortexing and then 
heated at 60°C for 15 min. Samples were then transferred into cuvettes for 
measurement of the absorbance. The colorimetric readings were acquired in an 
Eppendorf Photometer using manufacturer’s instructions.  
 
3.3.5. SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is 
used to separate proteins based on their molecular mass in the electric field. In 
discontinues PAGE two gels are used to separate proteins. Proteins first migrate 
in the stacking gel with neutral pH. This helps to collect and concentrate samples 
before the actual separation starts in the resolving gel at pH 8.7.  This pH gradient 
gives a stacking effect resulting in sharper and narrower protein bands. 
All the gels used contained 10 or 12% polyacrylamide. 20-50 µg of protein 
lysates were mixed with 5X Laemmeli buffer and heated at 95°C for 5 min for 
denaturation. These samples then were used immediately or stored at -20°C.  
SDS-PAGE was carried out in the following steps: 
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1. Assembly and preparation of the gel for electrophoresis: 
Two glass plates were assembled in a gel apparatus separated by spacers. The 
assembly was checked for any leakage and the resolving gel was prepared (2.13.1). 
The components were poured immediately between the glass plates. The gel was 
layered with 1 ml of iso-propanol untill the gel was polymerised. The iso-propanol 
was removed before the stacking gel was poured on top and a comb was inserted 
in the stacking gel.  
2. Electrophoresis: 
The electrophoresis unit was then filled with protein gel running buffer. The 
comb was removed carefully from stacking gel and the wells were gently flushed 
with protein gel running buffer to remove gel residues. Samples and pre-stained 
protein marker (2-3µl) were then loaded in the wells and separated at 80V (10 cm 
gels) for 3-4 hrs or till the samples resolved completely.  
3. Electrophoretic transfer:  
To detect target proteins, they were immobilized by electrotransfer from the 
gels to a solid membrane support. For all experiments, nitrocellulose (NC) 
membranes were used. After soaking in the appropriate buffers (Fig. 3.2) the NC 
membrane and the gel were placed together with Whatman filter paper between 
two electrodes (Fig 3.2).  	
 
 
 
 
Figure 3.2: Western blot transfer setup  
Gel and NC membranes were placed between layers of Whatman filter paper soaked in Anode and Cathode buffer.  
 
The transfer set up was carefully placed in transfer assembly and any air 
bubbles were removed by gentle rolling. The transfer was carried out at 125 mA 
for 75 minutes for gels of approximately 10x12 cm. Due to the electrophoretic field 
generated between the electrodes, the proteins were transferred from the gel onto 
the NC membrane. The transfer was checked by successful transfer of all bands of 
the protein marker. The membranes were then probed with specific antibodies as 
described in (3.3.6). 
 
- 
+ 
Direction 
of 
transfer 
Whatman in Cathode buffer 
Gel in Cathode buffer 
NC membrane in Anode buffer 30mM 
Whatman in Anode buffer 30mM 
Whatman in Anode buffer 300mM 
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3.3.6. Detection of proteins on nitrocellulose membrane 
Following the transfer of protein on NC membrane, the unoccupied binding 
sites on the membrane have to be blocked to avoid non-specific binding of 
antibodies.  
The membranes were blocked at room temperature for 30 minutes in 5% 
non-fat dry milk or BSA in PBS-T. The blocked membranes were then probed with 
specific primary antibodies (1:500 – 1:2000) in 5% milk or BSA in PBS-T overnight 
at 4°C with gentle shaking. Membranes were then washed thrice for 5 minutes 
each with PBS-T and incubated with HRP or fluorescent labelled secondary 
antibodies (1:10000- 1:15000) in 5% milk for 1 hr at room temperature with gentle 
shaking. The membranes were then washed thrice with PBS-T. Images were 
acquired in a Li-cor OdysseyÒ Fc Imaging system. For HRP labelled secondary 
antibodies, Chemiluminescent FemtoMax™ Super Sensitive HRP Substrate 
(Rockland) was added on membranes before Imaging and acquired in Chemi 
channel whereas, fluorescent labelled secondary antibodies were imaged in 700 or 
800 channels directly depending on the fluorescent antibody used.  
 
3.3.7. Stripping of nitrocellulose membrane 
To remove primary and secondary antibodies bound on the membrane, the 
NC membranes were incubated in stripping buffer (2.13.1) for 30 minutes at 50 °C 
(stripping buffer was always prepared fresh). Membranes were then washed 5 
times thoroughly in PBS-T for 10 minutes each. The membranes were blocked with 
5% milk or BSA at room temperature for 20-30 minutes and then probed with 
another primary antibody (3.3.6).  
 
3.3.8. Co-immunoprecipitation 
Co-immunoprecipitation helps to determine whether two proteins interact 
in non-denaturing physiological conditions in-vitro. Interacting partners (prey 
protein) of labelled proteins (bait) are precipitated using a specific antibody and/or 
beads against the bait protein and detected using western blotting.  
Immunoprecipitation of FLAG (DYKDDDDK) tagged fusion proteins was 
done using ANTI-FLAG® M2 affinity gel. It is a purified murine IgG1 monoclonal 
antibody covalently attached to agarose beads by hydrazide linkage.  
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Vero-023 and Vero-KDELR2 cells were seeded in 60mm dish at a density of 
8 x 105 cells. Cells were incubated overnight at 37°C. Cells were then infected with 
MV eGFP virus at MOI of 0.1 and incubated at 37°C. 2 hrs post infection virus 
inoculum was removed and replaced with 5 ml MEM containing 2% of FCS. Cell 
lysates were prepared 48 hrs post infection. 
The cell monolayer was carefully washed with cold PBS. Cells were scraped 
gently in PBS and pelleted down by centrifugation at 13000 rpm at 4°C for 5 
minutes in a Biofuge. Cells were re-suspended in IP lysis buffer. Cells were then 
incubated on a shaker for 1 hrs at 4°C. Protein lysates were collected by 
centrifugation at 8000rpm at 4°C for 5 minutes. 
All the steps were performed on ice. One-third volume of the lysates was 
used as input control. This input samples were mixed with 5x Laemmeli buffer and 
boiled at 95°C for minutes and stored at -20°C till further use.  
For immunoprecipitation 10µl of ANTI-FLAG® M2 affinity gel was aliquoted 
in Eppendorf caps per sample. The beads were washed thrice with IP buffer 
(without SDS) and then lysates were added to the beads. Samples were then 
incubated using an orbital rotor at 4°C.  Lysates were then washed thrice with IP 
buffer (without SDS) and once with cold PBS. Anti-flag beads were pelleted down 
by centrifugation at 13000 rpm at 4°C for 5 minutes. The beads were then re-
suspended in 70-100 µl of 2x Lammeli buffer and boiled at 95°C for 5 minutes. 
These samples were then analysed by western blotting or stored at -20°C till 
further use. 
 
3.4. Virological methods 
3.4.1. Measles virus stock preparation 
The attenuated vaccine strain MV-Edmonston, the Edmonston based 
recombinant rMVEdtageGFP and recombinant wildtype rMVIC323eGFP were used. 
Required stocks of these viruses were prepared in Vero-hSLAM cells. These cells 
were cultured in 175cm2 flask at the 60-70% confluency. Cells were washed once 
with serum-free MEM and replaced with 3 ml required dilution of virus (MOI: 
0.01). Cells incubated for 2hrs at 37°C and then virus inoculum was replaced with 
fresh 20 ml of MEM with 2% of FCS. Infected flasks were incubated for 2-3 days 
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depending on cytopathic effect. Media from infected flask were reduced to 5 ml and 
the flasks were frozen at -80°C for at least 24hrs.  
The flasks were then thawed at 37°C and all the subsequent steps were 
carried on ice. The cells were scraped using cell scraper and virus suspension was 
collected in a precooled homogenizer. Cells were homogenized 10-15 times to 
release the intercellular virus and centrifuged at 280 × g for 15 minutes at 4°C. 
The viral supernatants were aliquoted in cryo-tubes and stored at -80°C. 
 
3.4.2. Titration of Measles virus 
For the titration of MV virus preparations (3.4.1.1) or from other 
experimental procedures, Vero or Vero-hSLAM cells were used depending on the 
virus. Cells were seeded in a 48 well plate (1 x 104 per well) and incubated at 37°C 
overnight. Virus dilutions from 10-1 to 10-6 were prepared in MEM with 2% FCS. 
Media from cells were replaced with 200 µl of virus dilutions in triplicates and 
plates were incubated for 72 hrs at 37°C. Infection-induced syncytia (plaques) were 
counted microscopically. The PFU/ml of the titrated virus preparation was 
determined by the following formula: 
PFU/ml = (mean number of plaques x dilution factor)/ volume of inoculum (ml) 
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4. Results 
 
4. Results 
 
4.1. APOBEC3G differentially regulated cellular gene 
expression upon overexpression in Vero cells 
4.1.1. Differential gene regulation at the mRNA level 
Our group previously reported that A3G expression in Vero cells 
significantly reduced transcription and expression of MV proteins in infected cells. 
However, the underlying mechanism is poorly understood [192]. In the scope of 
this thesis, we investigated the basis of the A3G mediated anti-viral activity 
against MV.  
The microarray analysis of gene expression in control and A3G expressing 
cells revealed a differential gene regulation in Vero cells. A3G expression 
significantly up-regulated 844 transcripts and down-regulated 598 transcripts in 
Vero cells. We selected the A3G up-regulated genes REDD1 and KDELR2 as 
possible candidate host factors affecting MV replication as discussed in the 
introduction.  
KDELR2 mRNA levels in Vero-A3G cells were confirmed using PCR. For 
Semi-quantitative PCR, the total cellular RNA was reverse transcribed, and cDNA 
was amplified by conventional PCR (Figure 4.1A). The mRNA expression was also 
validated by real-time qPCR (Figure 4.1B). The primers used for semi-quantitative 
PCR and real-time PCR are summarized in Table 2.4. KDELR2 mRNA levels were 
found to be increases by 1.5-2-fold in Vero-A3G cells as compared to Vero-023 
(empty vector control) (Figure 4.1A and B). 
		 																									  
Figure 4.1. A3G expression increased KDELR2 mRNA levels in Vero cells. 
(A) Four different concentrations of cellular RNA (0.5, 1, 2, 4 µg) were reverse transcribed to cDNA. 4µl of cDNA 
from each sample was amplified by conventional PCR. The PCR products analysed on 1% Agarose gel. (B) The 
relative KDELR2 mRNA levels were quantified by SYBR-Green Real-Time qPCR. (n=2). 
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4. Results 
4.1.2. Differential gene regulation at the protein level 
The differential regulation in A3G expressing cells was validated at the 
protein level by western blot. Equal amounts of protein lysates from control and 
A3G expressing cells were separated on denaturing SDS-PAGE, transferred on 
nitrocellulose membrane (NC) and probed with respective antibodies. The protein 
band densities were quantified using ImageJ software. The densities of each target 
protein were normalized to the densities of the respective loading control GAPDH. 
The relative fold increase/decrease for the protein of interest in Vero A3G cells was 
calculated and are depicted below each blot. 
Depending on the genes of interest and availability of antibodies, the 
following genes were selected to validate differential gene regulation at the protein 
level: A3G up-regulated genes REDD1 and KDELR2 and A3G down-regulated 
genes MOSC2, ACY1, TXNIP and PRDX2. The protein levels of REDD1 and 
KDELR2 were found to be increased by 3.3 and 1.3-fold respectively in A3G 
expressing Vero cells (Figure 2A). Whereas, the expression of MOSC2 and ACY1 
was decreased by 0.5 and 0.2-fold respectively (Figure 2B). Thus, validating the 
data of the microarray analysis. However, PRDX2 expression was not decreased, 
and TXNIP was not detected using available antibody (data not shown). Therefore, 
we investigated the possible antiviral role of the REDD1 and KDELR2 proteins in 
detail in this thesis. 
	
Figure 4.2: Differential gene regulation at the protein level. 
Protein lysate from Vero 023 and Vero A3G was analysed by western blot. Expression of each protein was 
compared with internal loading control GAPDH. The relative fold change is depicted in numbers below each blot. 
Protein levels of (A) A3G up-regulated genes and (B) A3G down-regulated genes. 
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4. Results 
4.2. Overexpression of A3G-regulated genes REDD1 and 
KDELR2 in Vero cells 
 
4.2.1. Stable expression of REDD1-Flag and KDELR2-Flag in Vero cells 
To evaluate the differential effects of the A3G regulated proteins REDD1 
and KDELR2, the corresponding genes were individually overexpressed in Vero 
cells. Vero cell lines stably overexpressing REDD1 and KDELR2 were prepared 
using 3rd generation lentiviral packaging system. REDD1 (RC202847) and 
KDELR2 (RC200007) cDNA clones were purchased from “ORIGENE”. REDD1 
expressing F6gW-REDD1-Flag plasmids and Vero REDD1 2X cells were prepared 
by Sabine Kendle.  
To determine the effect of overexpression of these target proteins on the 
replication of MV, first it was important to determine the levels of a target proteins 
in transformed cells. Therefore, Vero-REDD1 cells were stained for the REDD1 
protein which is Flag-tagged and analysed by FACS.  Uniform expression of target 
protein would result in a sharp peak. REDD1 cells transduced twice (2X) showed 
a shift in the peak of fluorescence intensities as compared to the cells transduced 
once (1X) (Figure 4.3A).  
	
Figure 4.3: Overexpression of REDD1 in Vero cells  
Transduced Vero cells were analysed for expression of the REDD1-Flag protein. (A) 1x 105 cells were fixed, 
permeabilized and blocked. The cells were stained with primary mouse anti-Flag antibody and secondary anti-
mouse Alexa-488. Histograms depict total expression of REDD1-Flag in cells transduced once (1x) or twice (2x) 
(B) Immunofluorescence staining with primary mouse anti-Flag antibody and secondary anti-mouse Alexa-488 for 
REDD1-Flag protein in REDD1 (2x) cells (100 x magnification; size bar = 100 µm). (C) Lysates from transduced 
and control cells were separated on 10% SDS PAGE. Transferred proteins on nitrocellulose membranes were 
probed with anti-Flag and anti-GAPDH antibodies. (Data (A) contributed by Sabine Kendle.) 
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The REDD1 protein is a cytoplasmic protein. Therefore, subcellular 
localization of this protein was confirmed by immunofluorescence staining. The 
staining for REDD1-Flag protein showed a cytoplasmic distribution of fluorescence 
intensities (Figure 4.3B). Also, the lysates of REDD1 expressing cells separated on 
a denaturing gel showed a band of ~ 24 kDa REDD1-Flag protein when probed 
with mouse anti-Flag antibody (Figure 4.3C). 
For the preparation of F6gW-KDELR2 expressing plasmids, the cDNA 
fragment encoding KDELR2-Myc-DKK tag was enzymatically cleaved using EcoRI 
and BamHI (Figure 4.4A).  This digestion resulted in a fragment of KDELR2-Flag 
insert of size 779bp (Figure 4.4B). Similarly, F6gW-dsRed2 plasmid was also 
enzymatically cleaved using EcoRI and BamHI to remove the dsRed2 fragment 
and to generate a vector backbone of 9527 bp (Figure 4.4B). The digested products 
of insert and vector were separated on a 1% agarose gel and purified using “QIA 
quick® Gel Extraction Kit”. 
 
Figure 4.4: Preparation of KDELR2 cDNA insert and F6gW vector. 
(A) Predicated size of F6gW backbone plasmid and KDELR2 insert using ApE1 software (B) EcoRI and BamHI 
digested KDELR2 cDNA clone and F6gW-dsRed2 plasmids were separated on 1% Agarose gel and then purified 
for subsequent use. 
 
Dephosphorylated vector F6gW and KDELR2-Flag cDNA insert were 
ligated to generate circular transfer plasmids. XL10-Gold ultracompetent cells 
were transformed with plasmids. Bacterial colonies were selected by addition of 
marker antibiotic. Selected colonies were then used for Maxiprep plasmid isolation 
and the isolated F6gW-KDELR2-Flag plasmids were sequenced.  
Cells stably expressing KDELR2 were prepared by transducing cells with 
F6gW-KDELR2-Flag Lentivirus particles. Transduced cells were then analysed for 
the expression of KDELR2-Flag. FACS analysis of KDELR2-Flag protein using 
mouse anti-Flag antibody showed 97.4% Flag positive cells in the FACS dot-plot. 
Also, the sharp peak in the histogram indicated a uniform expression of KDELR2 
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in Vero cells (Figure 4.5A). In western blot analysis, the KDELR2-Flag protein 
migrated as ~ 25 kDa (Figure 4.5B). As reported earlier in literature, Vero-
KDELR2 cells showed a strong expression of KDELR2-Flag in the ER (Figure 
4.5C). 
 
	
Figure 4.5: Overexpression of KDELR2 in Vero cell-line 
Transduced Vero cells were analysed for expression of KDELR2-Flag protein. (A) 1x 105 cells were fixed, 
permeabilized and blocked. The cells were stained with primary mouse anti-Flag antibody and secondary anti-
mouse Alexa-488. The dot plots indicate % Flag positive cells and Histograms depicts a uniform expression of 
KDELR2-Flag in the population (B) Lysates from transduced and control cells were separated on 10% SDS PAGE. 
Transferred proteins on nitrocellulose membranes were probed with anti-Flag and anti-GAPDH antibodies. (C) 
Immunofluorescence staining with primary mouse anti-Flag antibody and secondary anti-mouse Alexa 488 for 
KDELR2-Flag protein showed characteristic localization of KDELR2-Flag protein in ER-Golgi area around the 
nucleus (100 x magnification; size bar = 100 µm). 
 
 
4.2.2. Effect of overexpression of A3G, REDD1 and KDELR2 on Vero cell 
proliferation 
It is known that; cell proliferation influences the replication of viruses in 
tissue culture. Therefore, it was important to determine the effect of 
overexpression of A3G, REDD1 and KDELR2 on the cell proliferation before 
evaluating its role on viral replication. To quantify cell proliferation, the cell lines 
were stained with the cell proliferation dye eFluor™ 670. This dye binds to cellular 
proteins containing primary amines. Upon cell division, this dye is equally 
distributed in progeny cells resulting in decreased fluorescent intensity. Serum-
starved cells were stained with eFluor and incubated in MEM containing 5% FCS. 
Cells were then fixed and analysed after 24, 48 and 72 hrs. The decrease in 
fluorescent intensities at the different time point as cells divided are shown in 
 =
   
86 
4. Results 
histograms (Figure 4.6A). The percentages of proliferated cells were calculated for 
each cell line. As compared to control cells, Vero-A3G cells (blue line) showed 
decreased proliferation up to 70% after 24 hrs (Figure 4.6B). Whereas 80% of 
REDD1 expressing cells (green line) proliferated, the proliferation rate of Vero-
KDELR2 cells (red line) was almost equal to control cells. At later time points, the 
decrease in the efluor signal was almost equal in all cell lines. (Figure 4.6B) 
indicating no significant impact on the proliferative capacity of Vero cells after the 
stable transgene expression.  
 
	
Figure 4.6: Vero cell proliferation after overexpression of A3G, KDELR2 and REDD1. 
Individual cell division capacity in transduced Vero cell-line was compared by staining cells with eFluor670. The 
eFluor670 signal decrease upon cell division (A) Cells (3 x 105 Cells) stained with eFluor670 were collected at the 
different time point and analysed by FACS. The histograms show decreased efluor670 intensities as cells divided. 
(B) % proliferation in all transduced Vero cell. Data are shown as mean ± SEM of three independent experiments.  
 
 
4.2.3. Stable expression of KDELR2 shRNAs in Vero cells 
Breakthrough discovery of RNA interference (RNAi) to study gene functions 
was successfully extrapolated for the introduction of shRNA into cells. Retroviral 
vectors allowed stable integration and long-term knockdown of the target gene. 
Using this method, we prepared Vero cells stably expressing KDELR2 shRNA 
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resulting in long-term knockdown of the gene. This helped us to verify the role of 
this gene in MV replication. 
The target sequence of shRNA for knockdown of KDELR2 was designed by 
BLOCK-iT™ RNAi Designer. The KDELR2 NCBI Reference Sequence: 
NM_006854.3 was used to design the shRNAs. Three best shRNA sequences were 
selected (Table 2.5) and double-stranded shRNA oligos were generated.  
For the preparation of F6gW-KDELR2-shRNA expressing plasmids, the 
F6gW-dsRed2 plasmid was enzymatically cleaved using XhoI and KspAI (HpaI) 
(Figure 4.7). This digestion resulted in the opening of shRNA cloning site. The 
digested product of F6gW-dsRed2 plasmids was separated on a 1% agarose gel and 
purified using “QIA quick® Gel Extraction Kit”. 	
 
Figure 4.7: Predicated size of XhoI and HpaI digested F6gW-dsRed2 plasmid 
 
The dephosphorylated vector F6gW-dsRed2 and the phosphorylated DNA 
fragments coding for KDELR2-shRNAs were ligated to generate circular transfer 
plasmids. Selected bacterial colonies were used for Maxiprep plasmid isolation and 
F6gW-dsRed2-KDELR2-shRNA plasmids were sequenced. Lentiviral particles 
containing the corresponding sequences as RNA-genomes were generated as 
described (3.1.8). 
The cells stably expressing F6gW-DsRed2-KDELR2-shRNAs were prepared 
by transducing cells with the corresponding Lentivirus particles. Transduced cells 
were then FACS sorted based on the expression of DsRed2. The black dots in 
(Figure 4.8A) represent the population selected for sorting. FACS analysis of 
KDELR2-shRNA using DsRed2 expression showed 84-96% DsRed2 positive cells 
in FACS dot-plot (Figure 4.8B). Microscopic observation of cells showed strong 
dsRed2 expression in KDELR2-shRNA2 expressing cells (Figure 4.8C). Silencing 
of the KDELR2 gene at mRNA level was confirmed by semi-quantitative PCR. 
Total cellular RNA was reverse transcribed, and cDNA was then amplified by 
conventional PCR (Figure 4.8D) and real-time qPCR (Figure 4.8E). The KDELR2 
expression in Vero-KDELR2 cells was used as a control. In all three shRNA 
expressing cells, the KDELR2 expression was significantly reduced. 
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Figure 4.8: shRNA mediated knockdown of KDELR2 in Vero cells.  
Vero cells were transduced with three different shRNAs to knockdown the expression of KDELR2. (A) Transduced 
cells were FACS sorted based on the DsRed2 fluorescence. The dot-plots shows the population selected for sorting. 
(B) 1x 105 cells were fixed and analysed for dsRed2 expression by FACS. Histograms depict uniform expression of 
dsRed2 expression in the sorted population. (C) dsRed2 expression in sorted cells was analysed by microscopy 
(100 x magnification; size bar = 100 µm). (D) The shRNA mediated knockdown at mRNA level was confirmed by 
semi-quantitative PCR. Four concentrations of RNA (4, 2, 1, 0.5 µg) were reverse transcribed. The cDNA product 
was amplified by PCR and analysed on 1% Agarose gel. (E) The relative KDELR2 mRNA levels in KDELR2 shRNA2 
expressing Vero cells were quantified by SYBR-Green Real-Time qPCR using two different set of primers. (n=3). 
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4.3. Overexpression of REDD1 and KDELR2 in CEMSS T 
cells 
 
4.3.1. Stable expression of REDD1-Flag and KDELR2-Flag in CEMSS T cell line  
To demonstrate that the effects of REDD1 and KDELR2 are cell type 
independent, and because in vivo MV replicates in lymphocytes, CEMSS cells, a T 
lymphoblast cell line, were stably transduced to overexpress these genes.   
	
	
Figure 4.9: Overexpression of REDD1 and KDELR2 in CEMSS T cells.  
Transduced CEMSS cells were analysed for the expression of REDD1-Flag and KDELR2-Flag proteins. 1x 105 
cells were fixed, permeabilized and blocked. The cells were stained with primary mouse anti-Flag antibody and 
secondary anti-mouse Alexa-488. The dot-plots indicate % of Flag positive cells and Histograms depicts uniform 
expression of REDD1-Flag and KDELR2-Flag in the population (A) Upper panel: FACS analysis of CEMSS- REDD1 
cells and Lower panel: FACS analysis of CEMSS-KDELR2 cells. (B) and (C) Transduced and control cells were 
separated on 10% SDS PAGE. Transferred proteins on nitrocellulose membranes were probed with anti-Flag and 
anti-GAPDH antibodies. Flag expression in CEMSS-REDD1 cells (B) and Flag expression in CEMSS-KDELR2 cells 
(C). 	
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REDD1 and KDELR2 expressing lentiviral plasmids were prepared as 
described (4.2.1). CEM-SS pcMS cells stably expressing REDD1 and KDELR2 were 
prepared by transducing these cells with respective lentivirus particles. 
Transduced cells were then analysed for the expression of REDD1-Flag and 
KDELR2-Flag. FACS analysis of REDD1-Flag and KDELR2-Flag protein using 
mouse anti-Flag antibody showed 79% (upper panel) and 85% (lower panel) Flag 
positive cells in FACS dot-plot (Figure 4.9A). Also, the sharp peak in the histogram 
indicated uniform expression in cells. Western blot analysis confirmed REDD1-
Flag (Figure 4.9B) and KDELR2-Flag (Figure 4.9C) expression as the Flag-tagged 
protein migrated as ~ 25 kDa band. 
 
4.3.2. Effect of overexpression of A3G, REDD1 and KDELR2 on CEM-SS cell 
proliferation  
The effect of overexpression of REDD1 and KDELR2 on CEM-SS cells was 
evaluated by staining cells with cell proliferation dye eFluor™ 670 (similar to 
7.2.2). As shown in (Figure 4.10A) serum-starved cells were stained with eFluor, 
fixed and analysed after 24, 48 and 72 hrs same as above (4.2.2). The histograms 
show decreased fluorescent intensities at the different time points as the cells 
divided. The decrease in the efluor signal was almost equal in all cell lines. The 
percentages of proliferated cells were calculated for each cell line (Figure 4.10B).  
CEM-pcMS (empty vector control), CEM-A3G, CEM-REDD1 and CEM-KDELR2 
overexpressing cells proliferated equally after 48 and 72 hrs of incubation 
indicating no significant effect on the proliferative capacity of CEM-SS cells after 
the transgene expression.  
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Figure 4.10. CEMSS T cell proliferation after over-expression of A3G, KDELR2 and REDD1 
Individual cell division capacity in transduced CEMSS cell-line was compared by staining cells with eFluor670. The 
eFluor670 signal decreased upon cell division (A) Cells (3 x 105 Cells) stained with eFluor670 were collected at the 
different time point and analysed by FACS. The histograms show decreased efluor670 intensities as cells divided. 
The decrease in the signal was almost equal in all the cells. (B) % proliferation in all transduced CEMSS cell lines. 
Data are shown as mean ± SEM of three independent experiments.  
 
4.4. REDD1 expression inhibited MV infection as efficiently 
as A3G in Vero cells 
 
REDD1 protein, a negative regulator of mTORC1, has been shown to affect 
replication of Influenza and VSV [223]. As a next step, the antiviral activity of 
REDD1 on MV laboratory-adapted strain of rMVEdtageGFP was evaluated (Figure 
4.11A). The cells transduced with empty vector (Vero-023) served as control cells 
(negative-control) and Vero-A3G cells were used as a positive-control in 
subsequent experiments.  
The viral syncytia were observed daily under the fluorescent microscope and 
the 48 hr post-infection (hpi) time point was selected as the maximum infection 
rate was attained at this time point in control cells. The apparent size of GFP 
positive syncytia in Vero REDD1 was significantly reduced as compared to control 
Vero-023 cells. Indeed, the size of syncytia was similar to that observed in Vero-
A3G cells (Figure 4.11B). The total virus synthesised in the cells was collected by 
scraping the cells 48 hr post-infection and the titre was determined on Vero cells. 
The virus titre was reduced by 90% in Vero-REDD1 cells, whereas the reduction 
was more than 95% in Vero-A3G. These findings demonstrated that the individual 
expression of REDD1 efficiently inhibited MV in Vero cells. 
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Figure 4.11: REDD1 expression reduced MV titre in Vero cells 
Transduced Vero cells were infected with rMV Edtag eGFP with MOI of 0.1. (A) Scheme of infection and titration (B) 
Representative micrographs of eGFP expressing syncytium formation in control and transduced cells were taken 
48 hpi (100 x magnification; size bar = 100 µm) (C) Titre of newly synthesized virus from transduced cells was 
determined 48 hrs post infection on Vero cells. Each titration was done in triplicate and data are shown as mean ± 
SEM of three independent experiments. **p<0.01 (Unpaired Student’s t-test). Data contributed by Sabine Kendle.  
 
4.5. KDELR2 expression reduced MV infection in Vero cells 
KDELR2 is ER-Golgi resident cargo receptor with known function in 
retrograde and anterograde transport of protein in ER and Golgi. Recent evidence 
suggested a crucial role of this protein in viral egress. We assessed the antiviral 
activity of this protein on MV laboratory-adapted strain rMVEdtageGFP using a 
similar experimental strategy as mentioned in 4.4. Vero-023 cells served as empty 
vector control and Vero-A3G cells used as a positive control. MV induced syncytium 
formation was significantly reduced in KDELR2 overexpressing cells, however, not 
as efficient as seen with REDD1 (Figure 4.12A: upper panel). The total virus 
PF
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synthesised in the cells was collected by scraping cells 48 hrs post infection and 
the titre was determined on Vero cells. The virus titre was reduced by 85% in Vero-
KDELR2 cells (Figure 4.12B). To validate the role of KDELR2 in MV replication, 
KDELR2 was knocked down in Vero cells using shRNA mediated silencing. We 
therefore, tested MV-induced syncytium formation in KDELR2 knock-down cells 
using three different shRNAs. Interestingly, all three KDELR2 knock-down cell 
significantly increased MV syncytium formation (Figure 4.12A: lower panel) and 
restored the virus titre equal to control cells (Figure 4.12B). These experiments 
indicated that individual expression of KDELR2 restricted MV replication in Vero 
cells.  
	
Figure 4.12:  KDELR2 expression reduced MV titre in Vero cells. 
KDELR2 overexpressing and KDELR2 knockdown Vero cells (3 x 105 cells) were infected with rMV Edtag eGFP with 
MOI of 0.1 (A) Representative micrographs of eGFP expressing syncytium formation in control and transduced cells 
were taken 48 hpi (100 x magnification; size bar = 100 µm) (B) Titre of newly synthesized virus from transduced 
cells was determined 48 hrs post infection on Vero cells. Data shows mean value ± SEM of three independent 
experiments and statistical significance was calculated by Unpaired Student’s t-test (*p< 0.05, **p < 0.01, 
***p<0.001). 
 
 
4.6. REDD1 and KDELR2 reduced MV titre in CEMSS T cells 
The MV restriction by REDD1 and KDELR2 so far was tested in Vero cells. 
Vero cells are kidney epithelial cells of primate origin and deficient in mounting 
interferon response. Because naturally MV replicates in human lymphocytes, we 
assessed the ability of REDD1 and KDELR2 mediated MV inhibition in the human 
T cell line CEM-SS. CEM-SS are human lymphosarcoma T cells that are highly 
 =
   
94 
4. Results 
permissive to HIV-1 infection. CEM-SS A3G and CEM-SS pcMS (empty vector 
control) cells were a kind gift from Prof. Michael Malim (Kings College London). 
	
 
Figure 4.13: REDD1 and KDELR2 expression reduced MV titre in CEMSS T cells. 
REDD1 and KDELR2 overexpressing CEMSS cells (2 x 105 cells) were infected with rMV Edtag eGFP with MOI of 
0.1 (A) Representative micrographs of eGFP expressing syncytium formation in control and transduced cells were 
taken 48 hpi (100x magnification; size bar = 100 µm) (B) Titre of newly synthesized virus from transduced cells was 
determined 48 hpi on Vero cells. Histograms shows mean value ± SEM of three independent experiments and 
statistical significance was calculated by unpaired Student’s t-test (*p<0.05, **p<0.01, ***p<0.001). 
 
Viral syncytium formation was significantly reduced in A3G expressing cells 
as demonstrated earlier [192]. The total virus synthesised in these cells was 
titrated on Vero cells 48 hr post infection. Interestingly, REDD1 and KDELR2 
expressing cells also reduced viral syncytium formation in CEMSS cells (Figure 
4.13A).  The virus titre was reduced by 95% in CEM-SS REDD1 cells and by 84% 
in CEM-SS KDELR2 cells (Figure 4.13B).  
 
4.7. Silencing of REDD1 and KDELR2 in A3G expressing 
cells abrogated the antiviral effect exerted by A3G 
 
As demonstrated above (Figure 4.11-13) the individual expression of REDD1 
and KDELR2 significantly affected MV replication independent of cell type. As a 
next step, it was important to confirm the role of REDD1 and KDELR2 in A3G 
mediated inhibition of MV replication. Therefore, we depleted these two factors 
(B) 
(A) 
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individually or together in Vero cells using shRNAs. Vero cells stably expressing 
A3G were transduced using lentiviruses expressing shRNAs targeting REDD1 
and/or KDELR2 and FACS sorted based on dsRed2 expression (Figure 4.14A).  
FACS analysis of dsRed2 expression showed 99%, 70% and 92% dsRed2 
positive cells in Vero A3G-shREDD1, Vero A3G-shKDELR2 and Vero A3G-
shREDD1+shKDELR2 respectively (Figure 4.14B). All three cell lines showed a 
strong dsRed2 expression microscopically (Figure 4.14C). Silencing of the 
respective gene was confirmed by western blotting. Cell lysates were separated on 
SDS-PAGE and probed with respective antibodies. REDD1 and KDELR2 were not 
detected in the cells transduced with respective shRNAs (Figure 4.14D). 
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Figure 4.14: Silencing of REDD1 and KDELR2 in A3G expressing Vero cells. 
Vero A3G expressing cells were transduced with shRNAs to knockdown the expression of REDD1 and/or KDELR2. 
(A) Transduced cells were FACS sorted based on the dsRed2 fluorescence. The dot-plots shows the population 
selected for sorting. (B) 1x 105 cells were fixed and analysed for dsRed2 expression by FACS. Histograms depict 
a uniform expression of dsRed2 expression in the sorted population. (C) dsRed2 expression in sorted cells was 
analysed by microscopy (100 x magnification; size bar = 100 µm). (D) Protein expression in cells was analysed by 
western blot. 20 µg lysates of Vero-023, Vero-A3G, Vero-REDD1, Vero-KDELR2, REDD1 and/or KDELR2 shRNA 
transduced Vero A3G cells were separated on 10% SDS PAGE. Transferred proteins on nitrocellulose membrane  
Were probed with respective primary and HRP antibodies, followed by visualization with ECL. 
 
Now, Vero-A3G cells in which REDD1 and KDELR2 expression were 
knocked down were used to assess the effects on replication of rMVEdtageGFP. Vero-
023 cells transduced with scrambled shRNA were used as a control. MV induced 
syncytium formation in knock-down cells was comparable to that in Vero-023 and 
023 scrambled shRNA expressing cells (Figure 4.15A). The silencing of REDD1 
and/or KDELR2 significantly increased the viral titres as compared to parental 
Vero A3G cells abrogating the antiviral effect exerted by A3G (Figure 4.15B). 
 
                     
Figure 4.15: Silencing of KDELR2 and REDD1 in A3G expressing Vero cells abrogated the antiviral effect 
exerted by A3G  
REDD1 and KDELR2 were knocked down by shRNA mediated gene silencing in A3G expressing Vero cells. (A) 3 
x 105 cells were infected with rMV Edtag eGFP with MOI of 0.1. Representative micrographs of eGFP expressing 
syncytium formation in control and transduced cells were taken 48 hpi (100 x magnification; size bar = 100 µm) (B) 
Titre of newly synthesized virus from infected cells were determined 48 hrs post infection on Vero cells. Histograms 
shows mean value ± SEM of three independent experiments and statistical significance was calculated by Unpaired 
Student’s t-test (*p< 0.05, **p < 0.01, ***p<0.001). 
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4.8. REDD1 exerts antiviral effect via inhibition of mTORC1 
 
4.8.1. Viability of cells upon Rapamycin treatment 
REDD1 is a stress response protein and plays a vital role in the regulation 
of mammalian target of rapamycin complex 1 (mTORC1) signalling. Therefore, we 
investigated if REDD1 mediated inhibition of mTORC1 is responsible for the 
antiviral effect, and if the same effect can be achieved by the known inhibitor of 
mTORC1, rapamycin. To test this hypothesis, we first determined the range of 
rapamycin concentration in Vero and CEM-SS cells which does not result in 
cytotoxicity. As described in the literature [254][255], we tested 0.1 to 2µM of 
rapamycin concentrations.  
 
     
Figure 4.16: Viability of Vero and CEMSS cell line upon Rapamycin Treatment  
Control, A3G, KDELR2 and REDD1 expressing cells (3 x 105 cells) were treated with different concentrations of 
Rapamycin and 48 hrs later cell viability was determined by staining cells with Propidium iodide. (A) Vero cells were 
treated with increasing concentration of Rapamycin (100, 200, 400, 800, 1000, 2000 nm). % Viability in the control 
group was set to 100% and relative viability was determined in treated groups. Histograms shows mean value ± 
SEM of three independent experiments. (B) CEMSS cells (1 x 106 cells) were treated with increasing concentration 
of Rapamycin (100, 200, 500, 1000 nm). Viability in the control group was set to 100% and relative viability was 
determined in treated groups.  
 
Vero 023, A3G, REDD1 and KDELR2 overexpressing cells were treated with 
an increasing concentration of rapamycin for 48 hrs and the % of living cells was 
calculated by staining cells with propidium iodide. The viability of control, 
overexpressing Vero (Figure 4.16A) and CEM-SS cell lines (Figure 4.16B) was 
found to be not affected upon rapamycin treatment for all concentration we tested. 
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4.8.2. Pharmacological inhibition of mTORC1 by Rapamycin reduced replication 
of the laboratory-adapted MV strain in both Vero cells and CEM-SS cells 
After determination of the suitable concentration of rapamycin for our 
experiments, we tested if the observed REDD1 effect was mediated by inhibition 
of mTOR1 signalling. Vero-023, Vero-KDELR2 and Vero-REDD1 expressing cells 
were infected with rMVEdtageGFP and treated with increasing concentrations of 
Rapamycin throughout the incubation period. Rapamycin treatment showed a 
dose-dependent decrease in MV syncytium formation in Vero-023, Vero-KDELR2 
and Vero-REDD1 cells. No increased (or additive) effect on the syncytium 
formation was seen in Vero-REDD1 cells after rapamycin treatment (Figure 
4.17A). Similarly, rapamycin exerted a significant dose-dependent decrease of 
virus titres in Vero-023 and Vero-KDELR2 cells, but not in Vero-REDD1 cells 
(Figure 4.17B).  
 
	
Figure 4.17: Rapamycin treatment significantly reduced MV replication in Vero cells 
Control, KDELR2 and REDD1 expressing Vero cells (3 x 105 cells) were infected with rMV Edtag eGFP with MOI of 
0.1 for two hrs and then treated with Rapamycin (0, 0.1, 0.5, 1 µM) for 48 hrs. (A) Representative micrographs of 
eGFP expressing syncytium formation in control and Rapamycin treated cells were taken 48 hpi (100x 
magnification; size bar = 100 µm) (B) Titre of newly synthesized virus from infected cells were determined 48 hrs 
post infection on Vero cells. Data shows mean value ± SEM of three independent experiments and statistical 
significance was calculated for each cell line by one-way ANOVA test (n.s – non-significant, **p < 0.01, ***p<0.001).  
 
We also performed a similar experiment in CEM-SS cells. Control CEMSS 
pcMS cells, CEMSS KDELR2, and CEMSS REDD1 expressing cells were infected 
with rMVEdtageGFP and then treated with rapamycin. Interestingly, CEMSS-pcMS 
and CEMSS-KDELR2 cells did not show a rapamycin dose-dependent decrease in 
virus-induced syncytium formation (Figure 4.18A) and in virus titre (Figure 
(B) (A) 
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4.18B), whereas CEM-SS-REDD1 cells showed dose-dependent decrease in 
syncytium formation and virus titre.	 
 
 
 
Figure 4.18: Syncytium formation and viral titres in rapamycin-treated CEM-SS cells  
Control, KDELR2 and REDD1 expressing cells (3 x 105 cells) were infected with rMV Edtag eGFP with MOI of 0.1 for 
two hrs and then treated with Rapamycin (0, 0.1, 0.5, 1 µM) for 48 hrs. (A) Representative micrographs of eGFP 
expressing syncytium formation in control and Rapamycin treated cells were taken 48 hpi (100 x magnification; size 
bar = 100 µm) (B) Titre of newly synthesized virus from infected CEMSS cells were determined 48 hrs post infection 
on Vero cells. Data shows mean value ± SEM of three independent experiments and statistical significance was 
calculated for each cell line by one-way ANOVA test (***p<0.001). 	
4.8.3. REDD1 expressing cells showed decreased p70S6K phosphorylation  
To further assess the effect on mTORC1 signalling, we decided to quantify 
the phosphorylation levels of the ribosomal protein S6 kinase 1 (S6K1). mTORC1 
signalling regulates mRNA translation via phosphorylation of S6K1. The 
phosphorylation activates it and leads to the phosphorylation of various substrates 
involved in cellular translation. S6K1 phosphorylation sites have been shown to be 
highly sensitive to rapamycin [256]. Therefore, we quantified and compared 
phospho-P70S6K1 levels in the presence and absence of rapamycin. Vero-023, 
Vero-A3G, VERO-KDELR2 and VERO-REDD1 cells were treated with 1µM 
rapamycin, or with 0.1% DMSO or serum starved and then treated with EGF as a 
positive control. P70S6K phosphorylation at Thr389 position was then detected by 
western blotting (Figure 4.19A).  
Indeed, untreated A3G and REDD1 expressing Vero cells showed a 
significant decrease in phosphorylation of p70S6K by 50% and 80%, respectively, 
and rapamycin treatment reduced these levels significantly. Interestingly, 
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4. Results 
untreated KDELR2 expressing cells did not show any significant impact on the 
levels of phospho-p70S6K. (Figure 4.19B), whereas rapamycin further reduced the 
levels of phospho-p70S6K to undetectable levels in Vero-KDELR2 cells. In REDD1 
expressing cells, rapamycin reduced the phosphorylation of p70S6K also to 
undetectable levels, however, the difference to untreated REDD1 cells was not 
significant indicating that both act in the same pathway (Figure 4.19B). These 
results showed that the ectopic expression of A3G and REDD1 resulted in a 
substantial decrease in mTORC1 signalling.	 	
	
Figure 4.19: REDD1 and A3G expressing Vero cells showed decreased p70S6K phosphorylation  
Control, A3G, KDELR2 and REDD1 expressing Vero cells (3 x 105 cells) were treated with 1µM of Rapamycin or 
0.01% DMSO for 24hrs. For positive control, cells were serum starved overnight and then treated with 50ng/ml of 
EGF for 15 minutes. Cells were directly lysed in the 2X lammeli buffer. Transferred proteins on nitrocellulose 
membrane were probed with respective primary and HRP conjugated antibodies, followed by visualization with 
ECL. (A) Representative NC membrane from Immunoblot analysis against the depicted proteins (B) Total S6K 
and p70S6K levels in each lane were normalized with GAPDH loading control in the same lane. Ratio of normalized 
p70S6K and Total S6K were used for analysis. Data shows mean value ± SEM of densitometric analysis of three 
independent experiments and statistical significance was calculated by Unpaired Student’s t-test (*p< 0.05, **p < 
0.01, ***p<0.001, ns: not significant). 
 
 
4.8.4. A3G, REDD1 and KDELR2 were found to be increased in stimulated human 
Peripheral blood lymphocytes 
A3G and REDD1 levels have been studied independently in stimulated PBL 
[164][257], however, there is no evidence about the levels of KDELR2 in stimulated 
PBL. Therefore, we determined A3G, REDD1 and KDELR2 protein levels in 
unstimulated and stimulated PBL. Freshly isolated human PBL were stimulated 
with 2.5 µg/ml of PHA or with 25 ng/ml of human IL-2. 48 hrs after stimulation 
protein levels were determined by western blotting. 
Upon stimulation with PHA and IL-2, A3G levels were increased by 2-3 
folds. However, due to the high variation between each individual donor the 
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4. Results 
increase was not statistically significant. Interestingly levels of REDD1 and 
KDELR2 were also found to be simultaneously increased in stimulated PBL 
(Figure 4.20A). Next, we compared levels of A3G in stimulated PBL to Vero-A3G 
cells. Since stimulation with IL-2 resulted in higher A3G expression, we used IL-2 
stimulated cells as a control. We found comparable levels of A3G in Vero cells 
ectopically expressing A3G to that of IL-2 stimulated PBL (Figure 4.20B). Thus, 
the A3G over-expression in Vero A3G cells was found to be within in the range of 
physiological conditions and therefore, ruling out the possibility that massive 
overexpression would have contributed to the MV restrictionK 
	
	
Figure 4.20: A3G, REDD1 and KDELR2 levels were increased in stimulated PBL 
(A) 1 x 106 primary human PBL were stimulated with 2.5 µg/ml of PHA or 25 ng/ml of human IL-2 for 48 hrs. cells 
were lysed and separated on 10% SDS PAGE. Transferred proteins were probed with respective primary and HRP 
labelled secondary antibodies, followed by visualization with ECL. Levels of A3G, REDD1 and KDELR2 in each 
lane were normalized with GAPDH loading control in the same lane. Ratio of relative protein expression normalised 
to the values of unstimulated PBL were used for quantification. Data shows mean value ± SEM of densitometric 
analysis of three donors (above). Representative NC membrane from Immunoblot analysis against the depicted 
proteins (below) (B) Comparison of A3G expression in primary human PBL (left panel) and Vero-A3G cells (right 
panel). 
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4. Results 
4.8.5. Rapamycin treatment inhibited replication of wildtype MV strain in 
activated PBL 
The rapamycin treatment of Vero cells resulted in a reduced titre of the 
laboratory-adapted MV strain as well as reduced downstream signalling events in 
Vero cells (Figure 4.17 and 4.19). This finding led to the important question of 
whether pharmacological inhibition of mTORC1 activity by rapamycin would 
inhibit the replication of wildtype MV in primary human PBL. For this study, we 
used PHA stimulated human PBL and infected them with wildtype rMVIC323eGFP. 
These MV-infected cells were then further incubated without and with rapamycin 
throughout the incubation period.  
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Figure 4.21: Pharmacological inhibition of mTORC1 reduced wildtype MV titres in stimulated human PBL. 
1 x 10 6 unstimulated and 24 hr. stimulated PBL were infected with MVIC323eGFP with MOI of 0.1 for two hours and 
then treated with Rapamycin (0.5, 1 µM) for 48 hrs. (A) stimulation of PBL was controlled by detecting the expression 
of stimulation marker CD69 by FACS. 1x 105 cells were stained with CD3-PE and /or CD69-APC. The representative 
dot plots indicate % CD3 and or CD69 positive cells (B) Representative micrographs of eGFP expressing syncytium 
formation in control and Rapamycin treated cells were taken 48 hpi (100 x magnification; size bar = 100 µm) (C) 
Titre of newly synthesized virus from infected PBL were determined 48 hrs post infection on Vero hSLAM cells. 
Data shows mean value ± SEM of three donors and statistical significance was by one-way ANOVA test (**p < 
0.01). 
 
 
The stimulation of the PBL of each donor was controlled by staining of the 
early activation marker CD69 before infection (Figure 4.21A). As shown in Figure 
4.21B inhibition of mTOCRC1 by rapamycin reduced the virus-induced syncytium 
formation significantly. Similarly, the titre of newly synthesised virus was reduced 
by 1 log (Figure 4.21C).  
Taken together, findings in Figure 17,19 and 21 demonstrate that mTORC1 
activity plays an important role in enhancing MV replication not only in Vero cells 
but also in human PBL.  
 
4.8.6. Antiviral role of A3G on MV replication in primary human PBL 
As described, we found a simultaneous increase of the A3G and REDD1 
expression upon stimulation of human PBL (Figure 4.20). Now, we aimed to 
investigate the possible role of A3G in MV replication in stimulated PBL by siRNA 
mediated depletion of A3G. PBL were nucleofected with A3G targeted or with non- 
targeted siRNA. The newly synthesised viruses in PHA or IL-2 stimulated cells 
were titrated on Vero-hSLAM cells.  Stimulation in each donor was controlled by 
FACS staining for early activation marker CD69 (Figure 4.22A). A3G depletion 
(C) 
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resulted in visually better viral syncytium formation (Figure 4.22B) and 
significantly improved MV titre in PHA stimulated PBL as compared to non-
targeted siRNA control (Figure 4.22C). IL-2 stimulated PBL showed a similar 
tendency, however, the difference was not significant due to the high variation 
between blood donors. The A3G expression in transfected PBL was controlled by 
western blot for each donor (Figure 4.22D upper panel). Interestingly, 
quantification of REDD1 expression in cells transfected with siA3G revealed that 
REDD1 expression was also affected by A3G-specific siRNA (Figure 4.22D lower 
panel). Quantification of the relative expression clearly showed that increased 
REDD1 levels were associated with increased A3G expression and deletion of A3G 
resulted in decreased REDD1 expression (Figure 4.22D). 
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Figure 4.22: Depletion of A3G in stimulated PBL resulted in improved MV replication 
10 x 106 of freshly isolated primary human PBL were nucleofected with 400 nM of A3G targeted or non-targeted 
siRNA. Cells were stimulated with 2.5 µg/ml of PHA or 25ng/ml of human IL-2. 24hr after stimulation cells were 
infected with MVIC323eGFP at MOI 0.1 for 48 hrs. (A) stimulation of PBL was controlled detecting expression of 
stimulation marker CD69 by FACS. 1x 105 cells were stained with CD3-PE and /or CD69-APC. The representative 
dot plots indicate % CD3 and or CD69 positive cells (B) Representative micrographs of eGFP expressing syncytium 
formation in control and siA3G transfected cells were taken 48 hpi (100 x magnification; size bar = 100 µm) (C) Titre 
of the newly synthesized virus was determined on Vero hSLAM cells. Data shows mean value ± SEM of three 
donors and statistical significance was calculated by Unpaired Student’s t-test (*p< 0.05) (D) 48 hrs after transfection 
with siRNA cell lysates were prepared and an equal amount (30µg) of proteins were separated on 12 % SDS-
PAGE. Proteins were transferred on NC membrane and probed with specific primary and HRP conjugated 
secondary antibodies. The protein bands were then visualized by ECL (upper panel).  A3G and REDD1 levels in 
each lane were quantified using ImageJ and normalized with respective GAPDH loading control. Data shows 
quantification of relative expression of A3G and REDD1 from PBL of three independent donors (lower panel). 
 
To sum up, this study showed that in primary PBL, A3G was induced upon 
stimulation and resulted in up-regulation of REDD1 as observed in Vero cells 
(Figure 4.2A). This indicates a clear association between the expression of A3G and 
REDD1 which requires further investigation. 
 
4.8.7. Antiviral role of REDD1 on MV replication in primary human PBL 
We earlier showed that depletion of A3G in stimulated PBL resulted in 
improved MV replication and also effected REDD1 expression (Figure 4.22). 
Furthermore, depletion of REDD1 in Vero-A3G cells led to higher MV titres which 
(C) (D) 
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indicated that anti-MV activity is majorly attributed to REDD1 (Figure 4.14-4.15). 
Therefore, we now investigated the potential anti-viral role of REDD1 in human 
PBL. PBL were transfected with siREDD1 or non-targeted siRNA. 24 hr PHA 
stimulated cells were infected with MV and titre of newly synthesised virus was 
determined on Vero-hSLAM cells. Stimulation in each donor was controlled by 
FACS staining (Figure 4.23A). REDD1 depletion resulted in comparatively bigger 
syncytium formation (Figure 4.23B) and significantly higher viral titre (Figure 
4.23 C; upper panel). The REDD1 expression for each donor was controlled by 
western blotting (Figure 4.23C; lower panel).  
              
 
Figure 4.23: Depletion of REDD1 in stimulated PBL resulted in increased MV replication 
10 x 106 of freshly isolated primary human PBL were nucleofected with 400 nM of REDD1 targeted or non-targeted 
siRNA. Cells were stimulated with 2.5 µg/ml of PHA. 24hr after stimulation cells were infected with MVIC323eGFP at 
MOI 0.1 for 48 hrs. (A) Stimulation of PBL was controlled detecting expression of stimulation marker CD69 by 
FACS. 1x 105 cells were stained with CD3-PE and /or CD69-APC. The representative dot plots indicate % CD3 and 
or CD69 positive cells (B) Representative micrographs of eGFP expressing syncytium formation in control and 
siREDD1 transfected PBL were taken 48 hpi (100 x magnification; size bar = 100 µm) (C) (upper panel) Titre of 
newly synthesized virus was determined on Vero-hSLAM cells. Data shows mean value ± SEM of three independent 
donors and statistical significance was calculated by Unpaired Student’s t-test (***p<0.0005, *p< 0.05). 48 hrs after 
(B) 
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transfection with siRNA cell lysates were prepared and an equal amount (30µg) of proteins were separated on 12 
% SDS-PAGE. Proteins were transferred on NC membrane and probed with specific primary and HRP conjugated 
secondary antibodies. The protein bands were then visualized by ECL. A representative WB is shown here (lower 
panel). 
 
Taken together, our findings demonstrated that treatment with rapamycin 
resulted in a reduction of the MV titre (Figure 4.21) and depletion of REDD1 
improved MV titre in human PBL (Figure 4.23), thus highlighted an important 
role of mTORC1 in enhancing MV replication in human PBL. 
=
4.9. KDELR2 expression affects MV spread indirectly 
 
The KDELR2 receptor is known to play a crucial role in the retrieval of ER 
resident chaperones. Recent findings have suggested its role in flaviviral egress 
[258]. We have found that A3G expression resulted in up-regulation of KDELR2 
(Figure 4.2) and ectopic expression of KDELR2 in Vero and CEM-SS cells 
significantly reduced MV titres (Figure 4.12-15). Interestingly, MV glycoproteins 
undergo post-translational modifications in the ER [259]. Therefore, we 
investigated the role of KDELR2 in MV assembly and egress. 
 
4.9.1. KDELR2 expression reduced the MV-H surface expression  
The MV glycoproteins H and F are expressed on the surface of infected cells 
[259][260]. Therefore, in this study, we measured the cell surface expression of MV-
H and -F in KDELR2 expressing cells. To prevent the MV-induced syncytium 
formation without affecting MV viral protein synthesis, we added the so-called 
fusion inhibitory peptide (FIP) after the entry of the virus into cells 
[261][262](Experimental setup Figure 4.24A). This facilitated single cell surface 
expression analysis of MV-H and -F by FACS. The mean fluorescence intensity 
(MFI) of surface and total expression of MV-H and -F was determined in MV-GFP 
expressing cells (Figure 4.24B).   
Interestingly, the surface expression of MV-H was significantly reduced in 
Vero KDELR2 expressing cells by 31% as well as in Vero A3G by 35%, whereas the 
levels remained unaffected in Vero-REDD1 cells. In contrast, the surface 
expression of MV-F was not altered significantly in A3G and KDELR2 expressing 
cells (Figure 4.24 C and D). Hence, KDELR2 and A3G expression abated MV-H 
transport to the cell surface. However, the total expression of MV-H in Vero-
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KDELR2 was significantly higher, whereas the Vero-A3G cells showed an 
analogues reduction in total MV-H expression (Figure 4.24C: lower panel). These 
findings suggested that A3G expression completely inhibited MV replication, 
therefore the decrease was also reflected in total GFP expression, whereas, in Vero-
KDELR2 cells, only the surface transport of glycoprotein H was affected and 
therefore, the total GFP expression was not reduced.  
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Figure 4.24: Surface expression of MV-H was reduced in KDELR2 expressing cells 
Vero 023, Vero A3G, Vero KDELR2 and Vero REDD1 expressing cells (3 x 105 cells) were infected with rMV Edtag 
eGFP with MOI of 0.1 for 48 hrs. For single cell analysis of infected cells fusion inhibitory peptide (FIP) 200 µM was 
added. Cells were stained with respective antibodies and then fixed for surface expression or fixed, permeabilized 
and stained for total expression. Cells were then analysed by FACS. (A) Scheme of infection and FACS analysis. 
(B) Dot-plots shows MV GFP positive cells and surface/total expression of MV-H/F (APC labelled) proteins. The 
double positive population was used to calculate MFI. (C) The representative histogram shows MV-H (upper panel) 
and MV-F (lower panel) mean fluorescent intensities of in infected Vero 023 and Vero KDELR2 cells. (D) Data 
shows mean fluorescence intensities (MFI) ± SEM were presented as percent of control normalized to values of 
Vero-023 cells of three independent experiments. Statistical significance was calculated using the Student’s t-test. 
(*p< 0.05). (E) Vero 023, Vero KDELR2 and Vero REDD1 expressing cells (3 x 105 cells) were infected with rMV 
Edtag eGFP with MOI of 0.1 and 2hrs post infection 200µm of FIP was added. Cell were fixed 24 and 48 hpi and 
analysed by FACS. The figure shows % GFP positive cells at each time point relative to the values of control Vero-
023 cells. Data shows mean value ± SEM of three independent experiments. 
 
 
We also confirmed above findings by comparing % GFP positive cells in Vero-
KDELR2 cells and compared it with Vero-REDD1 cells. Since Vero-REDD1 cells 
have earlier been shown to inhibit MV replication they would serve as an 
appropriate control. The quantification of the percentage of GFP positive cells 
revealed that in KDELR2 expressing cells the % of MV GFP positive cell was not 
affected, while as expected the % of GFP positive cells was reduced in Vero-REDD1 
cells (Figure 4.24 E). 
Taken together, these experiments have shown that, upon ectopic 
expression of KDELR2, MV-H surface expression was reduced (Figure 4.24 D), 
whereas there is no significant impact on viral replication in the cell (Figure 4.24 
E) indicating MV spread is affected upon KDELR2 expression. 
 
 
4.9.2. MV spread, but not viral replication, was affected by KDELR2 
overexpression  
FACS analysis of total expression of MV-H in Vero-KDELR2 cells showed 
high accumulation of MV-H in infected cells (Figure 4.24). In contrary, we have 
found earlier that ectopic expression of KDELR2 resulted in a significant decrease 
in MV titre (Figure 4.12D; lower panel). To address this conflicting finding, we 
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compared MV-H protein expression in cells where viral spread was restricted by 
addition of FIP after the infection of the cells (Figure 4.25A). 
Corroborating with our previous finding, MV-H protein expression was 
reduced by 50% in the Vero-KDELR2 cells when virus spread was unrestricted (in 
absence of FIP) and significantly higher MV-H expression was seen in KDELR2 
depleted cells (Figure 4.25B: left panel). Interestingly, the restriction of MV spread 
by addition of FIP resulted in the accumulation of MV-H in the cells (Figure 4.25B: 
right panel). These findings and the reduction of the size of syncytia by KDELR2 
overexpression (Figure 4.12A) indicated that the ectopic expression of KDELR2 
only affected syncytium formation and viral spread without affecting viral 
replication, thus explains the reduction in MV titre as observed in (Figure 4.12B). 	
									 	
Figure 4.25: Total MV-H expression is affected by KDELR2 overexpression when syncytium formation is 
allowed (in absence of FIP) 
Vero 023, Vero KDELR2 and Vero KDELR2 shRNA expressing cells (3 x 105 cells) were infected with rMV Edtag 
eGFP with MOI of 0.1 for 2hrs. Cells were then incubated for 48 hrs in presence or absence of 200µm fusion 
inhibitory peptide (FIP). Cell lysates were separated on 10%SDS PAGE and probed with respective primary and 
HRP labelled secondary antibodies. (A) Representative NC membrane from Immunoblot analysis against the 
depicted proteins (B) MV-H levels in each lane was normalized with GAPDH loading control in the same lane. The 
ratio of relative MV-H expression normalized to the values of Vero-023 was used for analysis. Data shows mean 
value ± SEM of densitometric analysis of three independent experiments. 
 	
4.9.3. No direct interaction was seen between KDELR2 and MV-H protein 
Our experiments illustrated that upon expression of KDELR2 in Vero cells 
MV spread was affected (Figure 4.12). It has been previously reported that MV-H 
and -F glycoproteins associate in the ER and that the addition of retention 
sequences has a significant impact on MV particle assembly [259]. Interestingly, 
Dengue virus prM protein directly interacts with KDELRs, which plays a crucial 
(B) (A) 
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role in viral egress [243]. Therefore, we investigated by microscopy and co-
immunoprecipitation if there might be an interaction between KDELR2 and the 
MV-H glycoprotein. 
The KDELR2 and MV-H proteins did not show any co-localization at 
different time points post infection. Both signals were clearly separated from each 
other. Rather at late time points, MV-H signals were found to be accumulated 
inside the cell (Figure 4.26 A). GRP-78, a known interacting chaperone of KDELR 
2 [263] was immune precipitated with KDELR2-Flag whereas no 
immunoprecipitation of MV-H was seen with KDELR2-Flag. Thus, indicating no 
direct interaction between KDELR2 and MV-H.  
 
 
Figure 4.26: No interaction was observed between KDELR2 and MV-H but KDELR2 interacted with GRP78 
(A) KDELR2 over-expressing Vero cells (1 x 104 cells) were seeded overnight in chamber slides. Cells were then 
infected with rMVEdtag at MOI of 1. Cells were fixed at depicted time points and stained with antibodies (mouse anti-
Flag and anti-mouse Alexa-488, Rabbit MV-H and anti-rabbit Alexa-594) and DAPI for nuclear staining. Confocal 
images were taken for co-localization analysis (400x magnification; size bar = 20µm). (B) The interaction was also 
confirmed by co-immunoprecipitation analysis. Lysates of MV-infected and uninfected Vero 023 and Vero KDELR2 
cells were treated with anti-flag affinity gel for immuno-precipitation. Precipitated proteins were the separated on 
10% SDS PAGE, blotted on nitrocellulose membrane and probed with anti MV-H, anti-Flag antibodies and 
respective secondary HRP conjugated antibodies. (C) To confirm the interaction of KDELR2-Flag and GRP78, 
same immuno-precipitated samples were probed with anti-GRP78 and anti-Flag antibodies. Representative images 
from three independent experiments. 
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4.9.4. Sub-cellular interaction between KDELR2 and ER Chaperones 
It has been reported earlier that measles virus glycoproteins interact with 
various ER resident chaperones such as Calnexin, Calreticulin and GRP78 [31]. 
During MV infection, these chaperones are up-regulated which may play an 
important role in MV pathogenesis [31]. Interestingly, GRP78 and Calreticulin 
possess C-terminal KDEL tetra peptide signals [31].   
Since KDELR2 was ectopically overexpressed in Vero cells, it was essential 
to confirm that it interacts with known interacting proteins. Co-
immunoprecipitation of GRP78 with KDELR2-Flag was reported in a previous 
experiment (Figure 4.26 C).  Now, its interaction with cellular chaperones was 
further evaluated by confocal microscopy (Figure 4.27 A). 
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Figure 4.27: Sub-cellular interaction between KDELR2-Flag and Chaperones was evaluated by co-
localization analysis 
KDELR2 over-expressing Vero cells (1 x 104 cells) were seeded overnight in chamber slides. Cells were then fixed 
and stained with antibodies (primary: mouse anti-Flag, Rabbit Calnexin/GRP78/ Calreticulin and secondary: anti-
mouse Alexa-488, anti-rabbit Alexa-594) and DAPI for nuclear staining. (A) Representative confocal images that 
were used for co-localization analysis (400x magnification; size bar = 20µm) (B) Representative scatter plot of 
individual red and green pixel intensities of KDELR2-Flag Green v/s Chaperons Red. (C) For analysis of co-
localization between KDELR2 and Chaperones, Pearson's correlation coefficients were calculated in the region of 
interest ROI (represented by a square in above images) in each cell using Zen software. The data represents the 
overlap coefficient of 14-30 images. 	
Ectopically expressed KDELR2-Flag significantly co-localized with GRP 78 
(correlation coefficient: 0.75), whereas Calnexin and Calreticulin showed moderate 
co-localization with KDELR2-Flag (correlation coefficient: 0.66 and 0.54, 
respectively). Thus, confirming a functional role of KDELR2-Flag in Vero cells.  
 
4.9.5. Surface expression of ER chaperones was reduced significantly in MV 
infected KDELR2 expressing cells 
As mentioned in above, MV infection results in increased surface expression 
of ER chaperones (Calnexin, Calreticulin and GRP78). This increased surface 
expression of chaperones was associated with an effective transport of MV 
glycoproteins to the cell surface [264]. As shown in Figure 4.24, surface expression 
of MV-H was significantly reduced in Vero-KDELR2 cells. These findings raised 
the important question if the inhibition of MV in KDELR2 expressing cells was 
attributed to a reduced function of chaperones. Therefore, the cell surface 
expression of Calnexin, GRP78 and Calreticulin was measured by FACS 
(Experimental setup Figure 4.24A). To prevent the MV-induced syncytium 
formation without affecting MV viral protein synthesis, we again added FIP after 
virus entry. This facilitated single-cell analysis of the chaperone expression on MV-
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GFP positive cells (Figure 4.28 A). Relative MFI of surface and total expression of 
chaperones was determined.  
 
 
	
Figure 4.28: Surface expression of Chaperones is significantly reduced in KDELR2 expressing cells 
Vero 023, Vero KDELR2 and Vero KDELR2 shRNA expressing cells (3 x 105 cells) were infected with rMV Edtag 
eGFP with MOI of 0.1 for 48 hrs. For single cell analysis of infected cells Fusion inhibitory peptide (FIP) 200 µM 
was added. Cells were stained with respective antibodies and then fixed for surface expression or fixed, 
permeabilized and stained for total expression. Cells were then analysed by FACS. (A) Dot-plots shows 
surface/total expression of Cellular chaperones Calnexin, GRP78, Calreticulin (APC labelled) in uninfected (upper 
panel) and MV-infected (lower panel) cells. The double positive population was used to calculate MFI. (B) 
Representative histograms show MFI in infected Vero 023 and Vero KDELR2 cells. Mean fluorescence intensities 
(MFI) ± SEM were presented as percent of control normalized to values of Vero-023 cells of three independent 
experiments. Statistical significance was calculated using the Student’s t-test (*p< 0.05, **p < 0.01, ***p<0.001). 
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KDELR2 overexpression significantly reduced the surface expression of 
Calnexin and GRP78 in uninfected as well as in MV-infected cells as compared to 
control Vero-023 cells. In contrast, in KDELR2 depleted cells the surface 
expression was similar to control cells. In other words, MV infection failed to 
increase the Calnexin and GRP78 surface expression in KDELR2 expressing cells. 
(Figure 4.28 B: Left panel).  Interestingly, the total levels of Calnexin and GRP78 
were not affected in control and Vero-KDELR2 cells (Figure 4.28 B: right panel). A 
similar trend was seen also for the third chaperone, Calreticulin. However, in this 
case, the differences were not statistically significant. 	
Taken together, microscopic and FACS analysis of viral and cellular 
chaperones revealed a correlation between MV-H and Chaperone surface 
expression resulting in less surface MV-H expression upon KDELR2 
overexpression. Furthermore, our findings showed that overexpressed KDELR2 
competes with MV-H for binding to Calnexin and GRP78. This binding results in 
ER retention of these chaperones and curtails their subsequent surface transport.  
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With more than 90,000 deaths reported worldwide in 2016, measles remains 
the leading cause of vaccine-preventable disease. MV incident rates are notably 
increasing in developed countries due to personal, parental, religious and 
philosophical beliefs. Whereas, in developing countries of Africa and Asia people 
do not have access to vaccination due to the lack of health infrastructures. 
Therefore, to achieve the goal of MV eradication a combination of vaccination and 
therapeutic strategies are required. This highlights the need for an effective post- 
exposure antiviral drug. Directing an antiviral strategy towards viral proteins is 
more beneficial than targeting host proteins to avoid any cytotoxic effects. Hence, 
it is important to understand the role of viral proteins and their interaction with 
host proteins. This may help in designing novel and effective target-specific 
inhibitors with potent antiviral activity. The aim of this study was to thoroughly 
understand the role of APOBEC3G (A3G) regulated novel host factors in 
restricting MV.  
5.1. A novel function of A3G: regulation of cellular gene 
expression 
APOBEC proteins have been known to induce cytidine deamination in viral 
cDNA. The C-terminal is responsible to perform cytidine deaminase functions 
resulting in hypermutated viral genomes and for a long time, these functions were 
studied in excessive details. Various evidence has suggested that deamination 
alone is not sufficient to restrict viral replication. Catalytically inactive mutants of 
A3G were shown to have considerable antiviral activity [159]. Specifically, these 
mechanisms prevent accumulation of reverse transcription products [161]. The N-
terminal domain binds to viral nucleic acids and is involved in several deaminase 
independent functions which are still poorly understood. It is yet to determine if 
these are the only deaminase independent functions of APOBEC proteins. Overall, 
cytidine independent mechanisms also equally contribute to the cumulative 
antiviral effect mediated by A3G.   
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A3G recruitment in HMM and LMM complexes is responsible for its 
catalytic and antiviral functions. In the HMM complex, the enzymatic functions of 
A3G are significantly diminished. The HMM-RNP complex contains a variety of 
cellular proteins especially those that are involved in RNA metabolism. Also, a 
significant amount of A3G was detected in cytoplasmic P bodies and stress 
granules, which regulate cellular mRNA translation and processing [182]. The 
exact mechanism of A3G interaction with cellular RNAs and proteins in these 
cytoplasmic structures is not known. However, based on these findings it has been 
speculated that A3G plays an important role in cellular RNA function.  
Usually, the overexpression of a gene of interest is extensively used to 
analyse its biological function. Parallel to overexpression, loss of function studies 
is also required for complete understanding of gene functions. Previous studies in 
our group were based on A3G overexpression in IFN deficient Vero cells (Vero-
A3G). Studies in Vero-A3G cells showed that A3G can mediate the inhibition of 
MV, MuV and RSV and this effect was independent of catalytic activity of A3G 
[192]. These findings contributed to the list of viruses that are restricted due to 
A3G.  Based on the results of this study, we hypothesised that A3G may alter the 
expression of cellular genes.  
The human genome contains more than 20000 protein-encoding genes. 
Simultaneous and parallel analysis of such a number of genes is quite challenging. 
A microarray analysis is a universal and powerful tool used to study the expression 
of numerous genes at a time. It is the easiest and quickest way to provide a 
composite image of cells under a particular condition. Overexpression of a gene 
followed by microarray can help to understand the broader physiological role of 
this single gene [265].  
Therefore, our group studied the cellular gene expression in the presence 
and absence of A3G using a microarray. This experiment revealed significant 
differential regulation of around 1500 genes in Vero cells [266]. Interestingly, in 
parallel with our finding another group has shown the differential expression of 
7500 genes in 293T cells upon A3G overexpression [267]. A3G induced site-specific 
mutations in more than 600 mRNA transcripts and these transcripts were 
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specifically involved in HIV-1 infection [267]. Similarly, it was also reported that 
A3A can edit more than hundreds of cellular transcripts in monocytes and 
macrophages [268]. From these findings, it appears that, apart from editing viral 
nucleic acid, A3G may alter the cellular host environment by RNA editing to 
retaliate against viral invasion. Here we reported for the first time a novel function 
of A3G in regulating cellular gene expression [266]. 
The microarray study revealed various interesting candidate genes as 
shown in Figure 5.1. Because post-translational mechanisms are known to control 
protein turnover in cells, mRNA levels seldom predict corresponding protein levels 
[269]. Protein expression analysis by western blot demonstrated that REDD1 and 
KDELR2 proteins levels were significantly increased due to A3G expression 
(Figure 4.2). Interestingly, REDD1 is a stress response protein known to negatively 
regulate mTORC1 (1.4.2) and recently was shown to act as a host defence factor 
against Influenza [223]. KDELR2 has also been found to influence viral replication 
(1.5.1). Therefore, we more closely investigated the role of these two proteins in 
A3G mediated inhibition of MV. 
Figure 5.1. list of differentially regulated genes in A3G expressing Vero cells 
5.2. REDD1 and KDELR2 expression inhibited MV infection 
In the first part of this thesis, the preparation of REDD1 and KDELR2 
overexpressing Vero and CEMSS cells is described (Figure 4.3-4.5). REDD1-Flag 
Vero cells showed significant expression of the 24 kDa REDD1-Flag protein (Figure 
4.3C) and cytoplasmic distribution of REDD1 in Vero cells (Figure 4.3B). Similarly, 
KDELR2-Flag Vero cells also showed significant expression of KDELR2 in the ER 
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(Figure 4.5B and C). KDELRs are known to be localized in the Golgi complex in 
low amounts. Increased expression of KDELRs results in ligand-independent 
activation of KDELRs and in the increased retrograde transport of KDELRs to the 
ER [228].  
Expression of REDD1 and KDELR2 regulates crucial signalling events in 
cells. Therefore, it was important to assess the effect of ectopic expression of these 
proteins on cell proliferation before evaluating their impact on viral replication. 
The Assessment of the proliferative ability of transduced Vero cell using eFluor670 
showed no significant impact on cell division at 48 and 72 hrs timepoint (Figure 
4.6A). However, cell proliferation was partially affected at the 24 hrs time point in 
Vero-A3G cells (Figure 4.6A and B). The APOBEC family of proteins A3A, A3C 
and A3H have shown to have nuclear localization and may have access to cellular 
chromatin network during mitosis [270]. Specifically, A3A and A3B have been 
shown to alter the cell cycle profile and trigger DNA damage response [271]. 
Interestingly, the cytidine deaminase A3G is excluded from cellular chromatin 
throughout mitosis [270] [272]. It is not known how A3G influences cell 
proliferation or the cell cycle. On the other hand, KDELR2 and REDD1 expressing 
Vero cells proliferated equally as compared with parent cells.    
After infection with rMVEdtageGFP, REDD1 expressing cells showed a 
substantial decrease in viral-induced syncytium formation (Figure 4.11B) and 90% 
reduction of the viral titre (Figure 4.11C) as compared to control cells, and shRNA-
mediated silencing of REDD1 abolished these negative effects (Figure 4.15B). MV 
is known to form giant multinucleated cells in Vero [273] as well as in small airway 
epithelial cells [274]. Interactions between MV H and F are required for the 
formation of syncytia and for efficient virus replication [260]. An alteration in MV-
H impairing this interaction with MV-F leads to decreased syncytium formation 
[275]. Currently, there is no evidence of a direct interaction between MV proteins 
and REDD1. However, the cellular stress response in Vero cells induced by 
hyperthermia and heavy metal exposure was shown to lead to a larger plaque 
phenotype mainly by induction of HSPs (heat shock proteins) [276]. Interestingly, 
REDD1 is also known to induce a stress response in cells, especially during hypoxic 
conditions. However, we observed a decrease in syncytium formation upon 
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overexpression of REDD1, which might be due to reduced viral protein expression, 
especially of MV-H. If there is no direct interaction of REDD1 with  viral proteins 
or nucleic acid, it might influence viral replication also via indirect mechanisms 
involving other host factors. Recently, REDD1 was shown to act as host defence 
factor against influenza virus with concomitant inhibition of mTORC1 [223]. 
Therefore, the role of REDD1 mediated inhibition via mTORC1 was investigated. 
The second A3G regulated gene of interest was KDELR2. MV induced 
syncytium formation in Vero-KDELR2 cells was reduced significantly (Figure 
4.12A) with 85% decrease in virus titre (Figure 4.12B). shRNA mediated ablation 
of KDELR2 restored the virus titre to control cells (Figure 4.12 A and B). It has 
been shown that addition of the KDEL motif to the F protein of HPIV3 (Human 
Parainfluenza virus) resulted in ER retention of this protein and subsequently 
reduced surface expression [277], whereas DENV requires KDELR1 and KDELR2 
for the viral export across ER and Golgi. The prM protein of DENV interacts with 
KDELRs in the ER [243], although there is no KDEL motif present in DENV 
proteins. However, in contrast to MV, membranous web structures of the ER are 
replication and assembly sites of various viruses such as HCV, DENV, Vaccinia 
Virus and Rota virus. In addition, viral glycoproteins undergo folding and 
oligomerization in the ER similar to cellular proteins. Therefore, viruses have 
evolved to use ER membranes and ER proteins efficiently for their own benefit in 
very virus-specific ways [240].  
MV is known to induce cell type-specific changes in lymphoid and non- 
lymphoid cell lines [278]. Therefore, we evaluated REDD1 and KDELR2 mediated 
inhibition of MV not only in Vero cells but also in a lymphoid cell type. CEMSS 
cells are susceptible to MV infection and earlier we reported that A3G expression 
in CEMSS cells also inhibited MV replication [192]. It is a human lymphosarcoma 
T cell line used for HIV-1 studies. Here we showed that ectopic expression of 
REDD1 and KDELR2 in CEMSS cell effectively reduced MV titres (Figure 4.13). 
These findings confirm that REDD1 and KDELR2 mediated inhibitory effects on 
MV are a cell type independent phenomenon.  
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We first showed that individual overexpression of REDD1 and KDELR2 was 
sufficient to inhibit MV replication. These findings raised an important question 
of whether these factors contribute to A3G mediated inhibition of MV. To answer 
this question, REDD1 and KDELR2 expression were targeted individually or 
together by shRNA. Knockdown of these mRNAs and effects on protein expression 
were confirmed by western blot and a substantial decrease in expression of REDD1 
and KDELR2 was observed (Figure 4.14D). MV induced syncytium formation in 
REDD1 and/or KDELR2 depleted Vero-A3G cells were similar to that of control 
cells (Figure 4.15A) and the virus titre was restored in these cells (Figure 4.15B). 
Therefore, this study clearly showed that the A3G mediated antiviral effect on MV 
is mediated by REDD1 and KDELR2.   
5.3. REDD1 exerts its antiviral effect via inhibition of 
mTORC1 
REDD1 mediated inhibition of mTORC1 has been reported to be a cell type 
-dependent phenomenon [279]. In renal cancer cells, constitutively upregulated  
REDD1 levels failed to inhibit mTORC1 [280], whereas in other cells during 
hypoxic and stress conditions REDD1 inhibits mTORC1 signalling in a TSC2 
dependent manner (1.4.2). To validate role of mTORC1 in MV replication, we used 
the pharmacological inhibitor rapamycin (1.4.2). As determined by viability 
staining with propidium iodide, control and transduced Vero cells tolerated 1µM 
concentration of rapamycin without any impact on cell proliferation (Figure 4.16A). 
We observed a strong dose-dependent decrease in MV syncytium formation as well 
as in titre upon rapamycin treatment in Vero-023 cells. A similar trend of dose- 
dependent decrease was seen in Vero-KDELR2 cells. However, no additive effect 
of rapamycin was seen in Vero-REDD1 cells (Figure 4.17). This demonstrated that 
rapamycin and REDD1 act on the same pathways.  
Unstimulated peripheral blood mononuclear cells (PBMC) support 
replication of wildtype MV only on a very low level. Usually, less than 20% PBMC 
are infected with MV [281]. In contrast, mitogen stimulation of lymphocytes leads 
to effective viral replication and release of infectious virus [282][283]. 
CD150/SLAM is known to be expressed on stimulated lymphocytes and APCs and 
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is used as an entry receptor by WT MV (1.1.4). Corroborating with earlier findings, 
MV titre was increased by 1 log upon stimulation in three donors that we tested. 
Additionally, we found that pharmacological inhibition of mTORC1 by rapamycin 
effectively reduced viral giant cell formation and MV replication in PHA 
stimulated human PBL (Figure 4.21). This demonstrated that mTORC1 signalling 
is required for active replication of not only lab adapted strain but also for WT MV 
in primary human cells. Similar to our findings, rapamycin has been shown to 
reduce MV syncytium formation in NSCLC (non-small-lung carcinoma cells) [284]. 
In contrast, one study reported that rapamycin treatment led to more virus 
production in HeLa cells with increased expression of MV-N and MV-P proteins 
[262]. This may be due to the fact that in this experiment a low concentration of 
Rapamycin (0.125nM) was used against very high MOI of MV and also no dose- 
dependent effect was studied. Interestingly, rapamycin has also been shown to 
effectively target HIV-1 replication in PBL [285], which suggested a role of 
mTORC1/2 in the maintenance of HIV1 latency [286].  
Phosphorylation of TOR by upstream signalling results in activation of S6 
kinases which regulate mRNA translation and ribosomal biogenesis [215]. A 
complex series of phosphorylation events regulate activation of p70S6K [287]. 
Phosphorylation at Thr389 is often used as a marker of active mTOR1 signalling. 
Rapamycin inhibits phosphorylation signals for activation of p70S6K [288]. We 
observed a significant reduction of the p70S6K phosphorylation in untreated Vero-
A3G and in Vero-REDD1 cells. These levels were further diminished by rapamycin 
treatment. Interestingly, Vero-KDELR2 cells showed decreased p70S6K levels 
only after rapamycin treatment (Figure 4.19 A and B). These findings further 
highlighted the following facts: first, in Vero-A3G cells REDD1 levels are induced 
which is responsible for decreased mTORC1 signalling, second, this decrease in 
mTORC1 signalling is responsible for the observed inhibitory effect on MV 
replication in Vero-A3G and Vero-REDD1 cells (Figure 4.11C), third, REDD1 and 
rapamycin act upstream of mTORC1 signalling, and fourth, in KDELR2 
overexpressing cells a mTORC1 independent mechanism is responsible for the 
observed antiviral activity. It would be worth investigating the effect of rapamycin 
on mTORC1 signalling in PBL, which would help to strengthen the role of 
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mTORC1 in MV replication. Importantly, S6K1 is not the only protein affected by 
mTORC1 activation. Several other complex signalling events govern overall 
cellular metabolism, protein and mRNA turnover (as summarized in Figure 1.16). 
Further investigations focused on these signalling events are also required to 
determine the exact consequence of A3G and REDD1 expression on these 
signalling events.  
Our group and several other groups have reported increased A3G expression 
upon stimulation of human PBL [192][164]. Upregulated REDD1 levels were 
observed in activated T cells without significant impact on T cell activation [257]. 
Here we showed that upon stimulation with PHA and IL-2 not only A3G and 
REDD1 levels were increased, but also KDELR2 expression was increased (Figure 
4.20). Further, we found that siRNA mediated knockdown of A3G in PHA and IL-
2 stimulated PBL resulted in reduced REDD1 expression with corresponding 
increased MV titres as compared to non-targeted siRNA application (Figure 4.22C 
and D). This finding indicates that in stimulated PBL, REDD1 was induced due to 
the expression of A3G. To understand the antiviral role of REDD1 in human PBL, 
REDD1 levels were also directly targeted by REDD1-specific siRNA. MV titres 
were found to be improved upon depletion of REDD1. These findings corroborate 
with our earlier results as discussed above and show that high mTORC1 activity 
is important for the replication of lab-adapted and wildtype MV. At this point, we 
did not determine the corresponding effect on mTORC1 activity. However, 
transient transfection of siREDD1 was shown earlier to hinder dephosphorylation 
of p70S6K which impedes subsequent inhibition of mTORC1 [289].   
In summary, as shown in Figure 5.2, we can state that A3G up-regulates 
REDD1 expression in Vero cells and PBL. REDD1 expression and rapamycin 
treatment exerted strong antiviral effects on MV replication. Interestingly, the 
combination of both did not had any additive antiviral effect. These findings 
underlined the role of active mTORC1 signalling in MV replication. 
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Figure 5.2. Schematic summary of A3G mediated inhibition of MV 
(A) Under physiological condition mTORC1 signalling in absence of REDD1 results in active MV replication. (B) 
Increased A3G expression induces REDD1, which results in inhibition of mTORC1 and downstream signalling of 
p70S6K. The reduced mTORC1 levels are responsible for reduced MV replication and siRNA mediated silencing 
of REDD1 and A3G rescue this inhibitory block on MV replication. 
 
5.4. KDELR2 expression affects MV spread 
KDELR2 functions in retrograde transport of chaperones from the Golgi to 
the ER. Apart from transport functions, KDELRs have been shown to stimulate 
Golgi SFKs and cellular MAPK (1.5.1). Knowledge about the role of KDEL 
receptors in viral egress has developed recently. Flaviviruses such as DENV and 
JEV were shown to exploit the KDELR function for viral particle transport across 
Golgi and ER (1.5.2). As defined by the name itself, KDELRs are known to bind 
with proteins containing KDEL motifs. Although no such motif was found in 
Flaviviruses, the DENV prM protein was shown to interact with KDELRs and 
disruption of this interaction affected DENV egress [243]. Interestingly, prM 
assists in folding and maturation of the DENV envelope protein E in such a way 
that it can be released after maturation [290]. Details about the role of KDERLs 
in benefiting these interactions are not yet investigated. Only FIPV proteins have 
been shown to possess the retention signal KTEL, which is required for the 
extremely slow release of viral proteins across the ER [246].  
(A) No A3G (B) A3G expression 
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MV H and F proteins are oligomers. Cleavage of the F protein inactive 
precursor (F0) by cellular enzymes in trans-Golgi network is required for 
trimerization of this protein. Similarly, H protein glycosylation and 
oligomerization occurs in the ER (1.1.3). MV H and F have been shown to interact 
with ER chaperones for the maturation and transport of viral proteins to the 
plasma membrane. To meet the excessive requirement of chaperones during active 
viral replication, MV induces the expression of Calreticulin, Calnexin and GRP78. 
A significant amount of these chaperones is expressed on the infected cell surface 
[264]. Here, we showed using FACS analysis that in KDELR2 expressing cells the 
surface expression of H and F proteins (Figure 4.24) and simultaneously the 
surface expression of GRP78, Calnexin and CRT was reduced (Figure 4.28). A 
significant degree of colocalization between overexpressed KDELR2 and 
Calreticulin/ GRP78 was observed (Figure 4.27) and overexpressed KDELR2 
immunoprecipitated with its known interacting partner GRP78 (Figure 4.16C). 
These results further confirmed previous findings that ER chaperons contain 
KDEL motifs for their retrieval [291]. Interestingly, no interaction of MV-H with 
KDELR2 was observed (Figure 4.26A and B). As mentioned earlier, the ER appears 
to be the most probable site for interaction of KDELR2 with Chaperones and for 
Chaperones with MV. The finding that overexpression of KDELR2 results in its 
redistribution to the ER [292] suggests that KDELR2 competes with MV-H 
proteins for binding to chaperones. Since these chaperons contain KDEL binding 
motifs they may be quickly occupied by overexpressed KDELR2 making them 
unavailable for MV H and F proteins to assist their maturation and transport to 
the infected cell surface (Figure 5.3).  
Interestingly, when MV spread was restricted by the addition of FIP, an 
increased accumulation of MV-H was observed in Vero-KDELR2 cells. Using same 
MOI, Vero-KDELR2 cells showed less expression of MV-H in absence of FIP 
(Figure 4.25). Similarly, the MV GFP expression remained similar in Vero-
KDELR2 cells for 48 hrs whereas Vero-REDD1 cells showed a significantly 
decreased MV GFP expression after 24 hr (Figure 4.24E).  
 
 =
   
126 
5. Discussion 
    
 
Figure 5.3. Schematic summary of KDELR2 mediated indirect effect on MV H surface transport. 
(A) Under physiological condition, MV infection increases ER chaperones and chaperones mediated surface 
expression of MV-H. This results in efficient MV spread. (B) Increased A3G induces KDELR2 and this KDELR2 
competes with MV-H for binding with ER chaperones such as GRP78. Thus, results in decreases surface 
expression of MV-H and GRP78 and diminished MV spread.  
 
Taken together, in KDELR2 cells it appears that only the viral spread is 
affected without significant impact on viral replication (Figure 5.3). Due to 
overexpression of KDELR2 chaperones are no longer available for MV glycoprotein 
maturation. Therefore, MV H and F although translated from the viral genome are 
not transported to the cell surface for final assembly and egress. To determine if 
the H and F proteins are degraded in the ER or simply accumulate requires further 
investigation. Similarly, quantification of the outcoming amount of MV using 
different MOI would help to confirm if the viral release is affected upon expression 
of KDELR2.   
Targeting GRP78 by chemical inhibitors or depletion of KDER2 would help 
further to confirm these dynamic interactions between chaperones, KDELR2 and 
MV. The GRP78 inhibitor IT-139 is a ruthenium-based anticancer drug which is 
used to increase the efficacy and to overcome chemo-resistance in certain cancer 
therapies [293]. However, considering the crucial role of chaperones and KDELRs 
in cellular signalling it would be challenging to target these molecules to hinder 
MV replication without evident cytotoxic effect on cells. 
(A) No A3G (B) A3G expression 
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Appendices 
A. Acronyms and symbols 
°C Centigrade 
3D 3-Dimensional 
A Adenine 
AAV Adeno-Associated Virus  
Abs Antibody 
ACY1 Aminoacylase 1 
ADRB2  b2-Adrenergic Receptor 
Ag  Antigen 
AG  Arbeit Gruppe 
AID Activation-Induced Cytidine Deaminase 
AIDS Acquired Immunodeficiency Syndrome 
Akt  Protein Kinases B 
APC Antigen Presenting Cell 
APOBEC3G Apolipoprotein B mRNA editing enzyme, catalytic peptide-like 3G 
APS Ammonium Per Sulphate 
ARF1 ADP Ribosylation Factor 
Asp Aspartate 
ATV Antibiotic-Trypsin-Versene 
b-TRCP Beta-Transducin Repeat-Containing Protein 
BALT  Bronchus-Associated Lymphoid Tissue 
BCA Bicinchoninic acid 
bp Base pair 
BSA Bovine serum albumin 
BSS Balanced salt solution 
C-Terminus Carboxy-Terminus 
CaCl2 Calcium chloride 
CBF-b Core-binding factor subunit beta 
CD Cluster of differentiation 
cDNA Complementary DNA 
CDV Canine distemper virus 
CEM15 APOBEC3G 
CIAP Calf intestine alkaline phosphatase 
cm Centimetre 
cm2 Centimetre Square 
CNS Central nervous system 
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CoIP Co-Immunoprecipitation 
CPE Cytopathic effect 
CRT Calreticulin 
CSF  Cerebrospinal Fluid 
CT Cytoplasmic Tail 
CTD C-terminal Domain 
CUL4A Cullin 4A 
CuSO4 Copper Sulphate 
DAPI 4',6-Diamidin-2-phenylindol 
dATP Deoxyadenosine-5'- triphosphate 
DCs Dendritic cells 
dCTP Deoxycytidin-5'- Triphosphate 
DDB1 DNA damage-binding protein 1 
DDIT4 REDD-1; DNA Damage Inducible Transcript 4 
DENV Dengue virus 
Deptor DEP domain containing mTOR-interacting protein 
dGTP Deoxyguanosin-5'- triphosphate 
dH2O Distilled water 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid  
dNTP 2'-Deoxyribonucleoside-5'- triphosphate 
dpi Days post infection 
Dr. Doctor 
DTT Dithiothreitol 
ECDC  European Centre for Disease Prevention and Control 
Edm Edmonston 
EDTA Ethylenediaminetetraacetic acid 
eGFP Enhanced green fluorescent protein 
EM Electron microscopy 
env Envelop 
ER Endoplasmic reticulum 
ERAD ER-associated degradation 
ESCRT Endosomal sorting complexes required for transport 
et al. and others 
F Forward 
F MV Fusion protein 
FACS Fluorescence-activated cell sorting 
FCS Fetal calf serum 
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FIP Fusion Inhibitory Peptide 
FKBP12  FK506 binding protein of 12kDa 
FP Fusion peptide 
FRB FKBP12-rapamycin binding 
FSC Forward Scatter 
gag Group antigen 
GAP GTPase-activating proteins 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase  
Gly Glycine 
GPCR G protein-coupled receptors 
GRP78 78 kDa glucose-regulated protein  
GRP94 Heat shock protein 90kDa beta member 1 
GSK3b Glycogen synthase kinase-3b 
GTP Guanosine triphosphate  
GTP Guanosine triphosphate  
H MV Hemagglutinin protein 
HA Hemagglutinin of Influenza virus 
hA3G Human APOBEC3G 
HCl Hydrogen chloride 
HEK Human Embryonic Kidney cell 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV Human Immunodeficiency Virus 
HMM High molecular mass complex of A3G 
hpi Hours post infection 
HPLC High performance liquid chromatography 
HRA Heptad repeat A 
HRB Heptad repeat B 
HRP Horseradish peroxidase 
ICTV International Committee on Taxonomy of Viruses 
IFITIM Interferon-induced transmembrane protein 
IFN Interferon 
IgG Immunoglobulin G 
IgM immunoglobulin M 
IKKB IκB kinase 
Il-1α  Interleukin-1α 
Il-1β Interleukin-1β 
IP Immunoprecipitation 
IRE1  Inositol-requiring protein 1 
IRF-3  IFN regulatory factor-3 
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ISGs  Interferon-inducible genes 
JAK Janus kinase 
JEV Japanese encephalitis virus 
KAP1 KRAB-associated protein 1 
kb Kilobase pair 
KCl Potassium chloride 
kDa Kilodalton 
KDEL Lysin-aspartic acid-glutamic acid-leucine 
KDELR2 ER Lumen Protein Retaining Receptor 2 
KH2PO4 Monopotassium phosphate 
L MV Large protein 
LB Luria-Bertani  
LFA-1  Leucocyte function-associated antigen-1 
LMM Low molecular mass complex of A3g 
log Logarithm 
LOXL 1 Lysyl-Oxidase 
LTR Long terminal Repeat 
M Molar 
M-MLV Moloney Murine Leukemia Virus 
mA Milliampere 
mAb Monoclonal antibody 
MEM Minimum essential medium 
MgCl2 Magnesium chloride 
MIBE Measles Inclusion Body Encephalitis 
min Minute 
mLST8  Mammalian lethal with Sec13 protein 8 
MLV Murine leukemia virus 
mM Millimolar 
mm Millimetre 
MMTV Mouse mammary tumour virus  
MOI Multiplicity of infection 
MOPS 3-Morpholinopropanesulfonic acid 
MOSC Molybdenum Cofactor Sulfurase C-terminal Domain 
MOSC1 MOSC Domain-Containing Protein 1 
MOSC2 MOSC-Domain-Containing Protein 2 
mRNA Messenger RNA 
mTORC1 Mammalian Target of Rapamycin 1 
MuV Mumps virus 
MV Measles virus 
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MxB Myxovirus resistance gene B 
N Nucleoprotein 
N-Terminus Amino terminus 
N/A Not applicable 
Na2 EDTA EDTA disodium salt hydrate 
NaCl Sodium Chloride 
NaF Sodium fluoride 
NaHPO4 Sodium phosphate 
NaOH Sodium hydroxide 
NC membrane Nitrocellulose membrane 
NF kB Inducibility of κ-Immunoglobulin Enhancer-Binding Protein 
ng Nanogram 
NK cell Natural killer cell 
NLRs NOD-like receptors 
nm Nanometer 
NP-40 Nonidet P-40 
nt Nucleotide 
NTD N-terminal domain  
NTE Sodium-Tris-EDTA 
OD Optical density 
Oligo-dT Oligodeoxy-thymidine nucleotides 
OPD o-Phenylenediamine 
ORF Open reading frame 
P Phospho protein (MV) 
P-bodies RNA processing bodies 
PAGE Polyacrylamide gel electrophoresis 
PAMP Pathogen associated molecular patterns 
PAMPs  Pathogen associated molecular patterns 
PBL Peripheral blood lymphocytes 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate Buffered Saline 
PCR Polymerase chain reaction 
PCT P-protein C-terminal domain 
PEI Polyethyleneimine  
PERK  Protein kinase RNA-like endoplasmic reticulum kinase 
PFA Paraformaldehyde 
pfu Plaque forming unit 
pH power of hydrogen 
PHA Polyhydroxyalkanoates 
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Phe Phenylalanine 
PKR (ds)RNA-dependent protein kinase R 
pmol Picomole 
PNT P protein N-terminal domain 
pol Polymerase 
PP1 Protein phosphatase 1 
PPRs Pattern recognition receptors 
PPRV Peste’s Petits Ruminants Virus  
PRAS40  Proline-rich Akt substrate of 40 kDa 
PRDX1 Peroxiredoxin 1 
Prof. Professor 
PRRs Pattern recognition receptors 
PVRL-4  Polio virus receptor-like protein-4 
R Reverse 
RBC Red blood cells 
RdRp RNA dependent RNA polymerase 
REDD-1 Regulated in Development and DNA Damage Responses 1 
rev Reverse 
Rheb Ras homolog enriched in brain 
RIG-I Retinoic acid-inducible gene I 
RIPA  Radio-immuno precipitation assay 
RISC RNA-induced Silencing Complex 
RLRs RIG-I like receptors 
rMV Recombinant Measles Virus 
RNA Ribonucleic acid 
RNP Ribonucleoprotein 
ROC1 Regulator of cullins 1 
rpm Rotations per minute 
RPV Rinderpest virus 
RRE Rev Responsive Element 
RSV Respiratory Syncytial Virus 
RT Room Temperature 
RT-PCR Reverse Transcriptase polymerase chain reaction 
S6K1 Ribosomal protein S6 kinase beta-1 
SAMHD SAM domain and HD domain-containing protein 1 
SDS Sodium dodecyl sulphate 
SERNIC5 Serine incorporator 
SFKs Src family kinases 
shRNA Small hairpin RNA 
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siRNA Small interfering RNA 
SIV Simian Immunodeficiency Virus 
SLAM Signalling Lymphocytic Activation Molecule  
Sp1  Specificity protein 1 
Sp3  Specificity protein 3 
SPINK5 Serine Peptidase Inhibitor, Kazal type 5 
SPINK6 Serine Peptidase Inhibitor, Kazal type 6 
ss Single-stranded 
SSC Side scatter 
SSPE Subacute sclerosing pan encephalitis 
STAT  Signal transducer and activator of transcription (STAT) protein  
T Thymidine 
TAE Tris-Acetate-EDTA 
TAR Transactivation response element 
TCID50 Tissue Culture Infectious Dose 
TE Tris-EDTA 
TEMED Tetramethylethylenediamine 
TGFβ1 Transforming Growth Factor 
TH1 Th1 helper cell 
TLR Toll-like receptor 
TLRs Toll-like receptors 
TM Transmembrane domain 
TRIM5 Tripartite motif-containing protein 5 
TRIS Tris(hydroxymethyl)-aminomethan 
tRNA Transfer-RNA 
TSC2 Tuberous sclerosis complex 
TXNIP Thioredoxin-Interacting Protein 
U Uracil 
UPR Unfolded protein response 
USF1  Upstream regulatory factor 1 
UTR Untranslated region 
UV Ultraviolet 
V Voltage 
Vif Virion infectivity factor 
VLP  Virus-like particle 
vpr Viral Protein R 
vpu  Viral Protein U 
VSV Vesicular Stomatitis Virus 
WBCs White blood cells 
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WHO World Health Organization 
WT Wild Type 
x g Gravitational Constant 
ZAP Zinc-finger antiviral protein 
µg Micro gram 
µl Micro litre 
µM Micro molar 
µM Micro meter 
  
 =
    
147 
Appendices: List of publications and presentations 
  
B. List of publications and Presentations 
Research article 
1. APOBEC3G-regulated host factors interfere with measles virus replication: 
role of REDD1 and mTORC1 inhibition  
Vishakha Tiwarekar, Julia Wohlfahrt, Markus Fehrholz, Claus-Jürgen 
Scholz, Susanne Kneitz, Jürgen Schneider-Schaulies. Journal of Virology 
92: e00835-18. https://doi.org/10.1128/ JVI.00835-18. 
 
2. KDELR2 competes with measles virus hemagglutinin for cellular 
chaperones and reduces chaperone-mediated cell surface transport of the 
hemagglutinin  
Vishakha Tiwarekar, Markus Fehrholz, Jürgen Schneider-Schaulies. 
Viruses. 2019 Jan 4;11, 27. 
 
 
Poster presentations 
1. Analysis of Host factors in Measles virus replication. 
Vishakha Tiwarekar, Julia Wohlfahrt, Sabine Kendl, Markus Fehrholz, 
Jürgen Schneider-Schaulies. Eureka! 10th International GSLS Symposium, 
Rudolf-Virchow Center, University of Würzburg, Germany (2015). 
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Münster, Germany (2016). 
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Jürgen Schneider-Schaulies. Eureka! 11th International GSLS Symposium, 
Rudolf-Virchow Center, University of Würzburg, Germany (2016). 
4. Analysis of APOBEC3G-mediated inhibition of Measles virus replication. 
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Jürgen Schneider-Schaulies. 11th Annual meeting of Immunology training 
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Vishakha Tiwarekar, Sabine Kendl, Julia Wohlfahrt, Markus Fehrholz, 
Jürgen Schneider-Schaulies. 6th European Congress of Virology, Hamburg, 
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